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SHORT ABSTRACT 
 
Background 
Goal directed therapy, the utilisation of fluids and inotropes to optimise cardiovascular performance 
of tissue oxygen delivery during surgery, has been shown in small studies to reduce complications after 
major surgery. The OPTIMISE trial was conducted to see if this benefit of morbidity reduction seen with 
the use of goal directed therapy was replicated in a larger pragmatic trial. I hypothesised that there 
were potential barriers to the use of goal directed therapy under these conditions that may reduce the 
clinical effectiveness of this treatment approach. 
Methods 
This thesis is based on sub-studies of the OPTIMISE trial examining the difficulties in utilising goal 
directed therapy as a treatment that focused primarily on the administration of fluids via an algorithm 
and the effect of goal directed therapy on a specific complication. Acute kidney injury was chosen as 
an important postoperative complication that was directly affected by fluid administration. 
Results 
OPTIMISE did not demonstrate a statistically significant effect of a reduction in complications in a 
population of 732 high risk surgical patients receiving goal directed therapy. Compliance to the goal 
directed therapy algorithm was mostly good across seventeen hospital sites. The use of dynamic fluid 
markers was not shown to be beneficial as indicators of when to give fluid boluses in the perioperative 
period. Goal directed therapy did not protect against acute kidney injury in the high risk surgical 
population. There was no difference in the incidence of acute kidney injury in the goal directed therapy 
group and the usual care group as measured by standardised criteria and measured by a urinary 
biomarker. 
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Conclusions 
Goal directed therapy did not result in a significant reduction in complications in a high risk surgical 
population. However, there are some barriers to the use of goal directed therapy particularly the 
evidence base for the effectiveness of goal directed therapy and understanding the mechanisms, if 
any, by which goal directed therapy improves outcomes. Further work should focus on establishing 
supporting the current evidence base for goal directed therapy and seeking the mechanism by which 
this may improve outcomes. 
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SCIENTIFIC SUMMARY  
Background 
Major surgery initiates an inflammatory state that is not particularly well understood but if not 
appropriately managed can develop into complications that significantly impact the patient’s health. 
Alongside the immediate effects of complications arising from surgery, such as increased use of critical 
care resources and length of hospital stay, complications after surgery have also been associated with 
long term adverse effects including poorer quality of life and reduced survival. A predefined high risk 
surgical patient group accounts for a small amount of the surgery performed but for disproportionately 
large amount of post-operative morbidity and mortality. Targeting this group of patients with 
treatments designed to reduce morbidity and mortality has the  potential to significantly to improve 
patient outcomes. The use of inotropes and fluid boluses to optimise cardiac output and thus oxygen 
delivery has been shown in small studies and subsequent meta-analyses to reduce complications in 
the high-risk surgical patient group undergoing major gastrointestinal surgery. It is unclear how 
effective this therapy is in this surgical population outside the setting of small trials. My aim in this 
thesis was to establish the barriers to treatment of the high-risk patient group using goal directed 
therapy. 
 
Goal Directed Therapy 
This thesis uses data from the OPTIMISE trial. In this trial goal directed therapy did not lead to a 
statistically significant reduction in complications using a composite of all complications although there 
was a non-significant clinical effect noted in favour of goal directed therapy. The current evidence base 
suggests that goal directed therapy improves morbidity and mortality in an older high risk surgical 
population undergoing major gastrointestinal surgery. There was a reduction in the overall 
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complication rate in the patient group receiving goal directed therapy and when this data were 
combined with those from other trials of goal directed therapy. In an updated meta-analysis the 
findings did suggest a benefit for those patients receiving goal directed therapy. There are potential 
confounders in bigger trials designed to reflect clinical practice including compliance with the 
algorithm, simplification of the algorithm leading to reduced clinical effectiveness, inconsistent fluid 
choice and if goal directed therapy using fluid and inotropes has a discrete effect on reducing organ 
injury. I decided to investigate any benefit in prevention of acute kidney injury as the next most likely 
organ to have a beneficial effect from goal directed therapy  
 
Compliance 
Compliance with the algorithm in the trial was measured by research staff supervising the intervention. 
Self-assessment was undertaken on all aspects of the intervention and deviations from protocols were 
noted in protocol deviation forms. I evaluated the ability of different hospitals to follow our 
prespecified goal directed therapy algorithm. 
 
Dynamic predictors of fluid responsiveness 
Fluid excess is associated with poor outcomes after major surgery. The OPTIMISE algorithm used stroke 
volume as the haemodynamic parameter that fluid challenges were given against. This potentially 
could lead to excess fluid administration as a fluid challenge is required to establish stroke volume 
responsiveness even in euvolemic patients. Dynamic parameters such as pulse pressure variation and 
stroke volume variation had been shown to provide a useful predictor of fluid responsiveness under 
specific, well-controlled  conditions. I wished to evaluate the practical use of these parameters by 
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assessing their accuracy in predicting fluid responsiveness. Dynamic parameters were average to poor 
in their ability to predict fluid responsiveness in the OPTIMISE patient cohort.  
 
Acute Kidney Injury 
Previous work has suggested that goal directed therapy may have a beneficial effect on kidney injury. 
Acute kidney injury after major surgery is common and is associated with poorer outcomes. I wished 
to evaluate the effect goal directed therapy in preventing acute kidney injury after major surgery. 
Neutrophil Gelatinase-associated Lipocalin (NGAL) was chosen as a the most sensitive biomarker of 
acute kidney injury after major surgery. There was no difference in NGAL readings between those 
patients having goal directed therapy and those having usual care. This suggests that goal directed 
therapy does not protect against acute kidney injury after major surgery. 
 
Conclusion 
Goal directed therapy is a complex intervention that has previously been shown to be of benefit in a 
high-risk population undergoing major gastrointestinal surgery. The value of the goal directed 
algorithm used in the OPTIMISE trial has yet to be established and further trials are required. The 
compliance with the algorithm is high. However, there are barriers to the widespread adoption of goal 
directed therapy including establishing the most sensitive fluid responsiveness parameters, the best 
fluid to use and to establish at what level goal directed therapy is beneficial.  
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LAY SUMMARY  
 
Introduction 
Surgery is a large burden on our healthcare particularly as less well people undergo larger surgeries. 
These patients are at high risk of developing complications or even dying after surgery. Using 
intravenous fluids and drugs which augment the cardiovascular system, known as goal directed 
therapy, has been shown to be beneficial in patients at high risk having major gut surgery. It is unclear 
if the advantages in using this treatment are still observed when not under strict medical trial 
conditions. A large trial (OPTIMISE) aimed at answering this question showed the answer was not clear 
cut, though pooling all the studies of goal directed therapy still suggests there is benefit from this 
treatment for these patients. The purpose of this thesis was to address barriers to the introduction of 
Goal Directed Therapy. 
 
Goal Directed Therapy 
The OPTIMISE trial aimed to answer the question of the effectiveness of goal directed therapy in study 
conditions that would most faithfully reflect real life practice. It showed that there was potentially a 
clinical benefit but it did not reach the requirement to be statistically certain. The barriers to 
introducing this treatment revolve around the uncertainty of its effectiveness, the ability to deliver the 
treatment correctly, when we decide to give the fluid and if we have the correct fluid to give. It has 
not yet been established exactly how goal directed therapy exerts its effects and if it is on a specific 
organ in the body. Other studies have looked at the effect on the heart without finding benefit so I 
proposed to look at any potential benefit in the kidney. 
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Compliance 
Adherence to any complex treatment is hard when giving medical treatment due to the patient’s 
variation in response to injury and illness. However, consistency in medical care is important because 
variation in medical care is associated with poorer patient outcomes. For any treatment algorithm to 
be effective it must have a high compliance rate. I found that the goal directed therapy algorithm used 
in the OPTIMISE trial had an excellent compliance rate. 
 
Dynamic measures of fluid responsiveness 
A barrier to goal directed therapy is the potential to give too much fluid. If there are more accurate 
end points to guide the clinician as to when to give fluid the problem could be avoided. Pulse pressure 
variation and stroke volume variation are two endpoints that have been shown under certain 
conditions to accurately predict if the patient requires fluid. In the setting of a pragmatic trial neither 
pulse pressure variation or stroke volume variation were better than average at predicting if the 
patient needed fluid. 
 
Kidney Injury 
It is not currently clear where goal directed therapy exerts beneficial effects. Most studies have looked 
at the heart and the cardiovascular system to try to establish where goal directed therapy helps 
patients. These studies have not shown any benefit or harm to the heart from goal directed therapy. I 
wished to evaluate the effect of a goal directed therapy on the kidney using a specific marker of kidney 
injury. This did not show any beneficial effect from goal directed therapy in protecting the kidney from 
injury. 
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Conclusion 
There are significant barriers to the introduction of goal directed therapy. Although algorithms appear 
easy to follow we have yet to establish more accurate predictors for when to give fluid, which fluid to 
give and the mechanism by which goal directed therapy is likely to exert its effect. 
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CHAPTER 1 INTRODUCTION 
1.1 Background 
1.1.1 The Global Burden of Surgery 
Estimates of the number of surgical procedures performed around the world vary. One study 
suggests at least 300 million surgical procedures are undertaken each year, an increase from 
the estimated 230 million procedures in 2004.1 Access to surgical interventions varies 
between nations with an estimated 4,000 procedures undertaken per 100,00 population in 
the lowest income countries rising to 10,000 procedures per 100,000 population in the highest 
income countries.2 There is an increasing drive to increase access to surgery across the globe 
headlined by the global access to surgery campaign. This has highlighted the inequality of 
access to surgery throughout the world with an estimated 2 billion people being unable to 
access surgical services when required.3 However, access to surgery is not the only issue. 
Recent perioperative studies have also highlighted different degrees of risk for patients 
undergoing surgery in similarly resourced countries.4, 5 These studies suggest that in addition 
to improve access to surgery there is a need to make surgery safer. Reducing the risks that 
surgery poses to the patient involves understanding the consequences of surgery, identifying 
the risks posed to the specific individual and developing treatment algorithms that 
consistently allow for the best care possible. This is vital to improve surgical outcomes for all 
and particularly important as the surgical population ages (table 1.1).  
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Table 1.1 Number of Surgical Procedures 
Change in numbers of discharges for surgical procedures by age for the time periods 1994/95 and 2004/05 as 
reported from the 2005 US National Hospital Discharge Survey  
 
Number of procedures (in thousands) 
Age (years) 1994/95 2004/05 % change 
18 - 44 7311 7326 +2.1 
45 - 64 4111 5210 +26.7 
65 -74  3069 3036 -1.1 
75 and over 3479 4317 +24.7 
18 and over 17 969 19 889 +10.7 
 
 
1.1.2 The High Income Countries 
In the developed world, surgical morbidity and mortality has fallen during the last twenty 
years.6 This reflects significant improvements in preoperative, intraoperative and 
postoperative care as well as surgical and anaesthetic techniques. Overall the non-cardiac 
surgical population has seen the risk associated with surgery decrease significantly within the 
developed world but specific surgical populations continue to have a high risk for morbidity 
and mortality when undergoing surgery .7, 8 Objective scoring to identify these patient groups 
is available but currently there is no consistency in the specific score used or in the outcomes 
they attempt to predict. Attempts to gather this specific data on risk reduction at a national 
or international level are limited by clinical engagement and the resources required to 
accurately gather large data sets. Abbott et al undertook a study to clarify the amount and 
types of surgery that were undertaken in the United Kingdom.9 This study suggested that there 
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are around 11 million surgical procedures undertaken each year, though there was significant 
variation in the classification of the types of surgery. The ongoing Perioperative Quality 
Improvement Programme (PQIP) initiative is designed to investigate the risks and outcomes 
of patients undergoing pre-specified high risk surgical procedures in the United Kingdom, 
utilising quality improvement techniques to improve outcomes. Data that focuses on 
increasing the understanding of surgical outcomes improves clinical awareness of the key 
issues and allows for feedback to improve care. However, we still require to study any new 
interventions that may reduce the impact of adverse surgical outcomes. 
 
1.1.3 Cardiac surgery in the United Kingdom 
Significant improvements have been made in the postoperative outcomes for patients 
undergoing cardiac surgery. In the United Kingdom this has been associated with a dedicated 
programme, the National Adult Cardiac Surgery Audit (NACSA), that has identified these 
improvements throughout the perioperative journey for the cardiac patient. This programme 
has addressed cardiac surgery as a high risk procedure and aims to inform and optimise the 
patient in the preoperative period and use targeted interventions associated with improved 
outcomes both during and after surgery. Consistency in perioperative nursing and medical 
care is delivered in dedicated centres and a large range of outcomes are audited with the 
potential to initiate investigations of any centres that are outliers. This pathway approach has 
been replicated in the care of out of hospital cardiac arrests where timely treatment and 
appropriate post-intervention care has been associated with an improvement in survival as 
demonstrated by the Myocardial Ischaemia National Audit Project (MINAP). The 
demonstration of a successful pathway that lowers both morbidity and mortality in a high risk 
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cohort of surgical and medical patients has led to calls for this approach to be taken with other 
high risk patient groups. Replicating this success in patients undergoing non-cardiac surgery 
would be difficult. Cardiac surgery and treatment of myocardial infarctions in the United 
Kingdom are undertaken in dedicated units with a relatively homogenous recovery profile 
allowing for a consistency in care that is difficult to achieve out with these specialities. By 
necessity the pre-surgical screening for cardiac surgery focuses on cardio-respiratory fitness 
as a major determinant of surgical outcome and though such assessment is recommended 
prior to major non-cardiac surgery they are not always undertaken. Cardiac surgery aims to 
significantly improve the function of the stressed or failing heart and when surgery is 
successful this will improve outcomes after surgery. In the non-cardiac surgery patient surgery 
is not usually undertaken to improve the function of a specific organ but to address ongoing 
pathology. Any organ failure is associated with worse outcomes from surgery. Despite the 
differences between cardiac and non-cardiac surgery there are learning points that are 
applicable to the non-cardiac surgery patient group. Outcomes for surgery are reported 
nationally and those surgeons or units who are outliers are investigated to understand any 
issues.10 Standardised surgical and anaesthetic techniques are employed intraoperatively to 
reduce the impact of surgery on patients including cooling and cardioplegia. Postoperatively 
local unit standardised protocols are in place to ensure the consistency of care is high 
throughout the patient journey and patients are monitored closely for the first twenty-four 
hours after surgery either in a critical care or a postoperative anaesthetic care unit. Using 
collated data to improve outcomes has been studied in specific high risk non-cardiac surgical 
populations and these techniques can be used to identify vital parts of a complex pathway 
that improve patient care.11 
 28   
1.1.4 High Risk Non-Cardiac Surgery in the UK 
The large amount and variety of surgery undertaken in the United Kingdom means that 
surgical procedures are difficult to quantify and information regarding specific patient groups 
is difficult to identify.9 The Royal College of Surgeons has defined risk based on the type of 
surgery though the definition of a high risk surgical group remains difficult (table 1.2). Pearse 
et al identified a high-risk non-cardiac surgical population within the United Kingdom showing 
that these patients were older with significant co-morbidities undergoing major surgery.12 
Several studies have also identified high-risk patient groups with the common themes of older 
patients with more co-morbidities undergoing major surgical procedures.13, 14 There is an 
acknowledgement that there is a high risk surgical population but there is no consensus as to 
what constitutes or how to define a high risk surgical patient.15 The most common description 
is of a patient over a specified age (usually 50) with pre-defined co-morbidities undergoing 
organ surgery within a major body cavity. 
In the Pearse study the high risk population that was identified accounted for over eighty per 
cent of overall postoperative deaths but only twelve per cent of surgical procedures.  They 
also had a significantly longer length of hospital stay. This compares poorly with the mortality 
and length of hospital stay of patients undergoing major cardiac surgery described in the 
NACSA reports. It follows that by targeting a high-risk population in a similar manner to cardiac 
surgery patients, a significant reduction in mortality and length of hospital stay can be 
achieved. As this high risk surgical group undergoes more diverse surgical procedures than its 
cardiac counterpart, it is more difficult to implement a consistent care package and not 
feasible to have only one pathway. It is important to establish a proven evidence base of the  
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Table 1.2 Surgery Specific Estimates of Risk 
 Adapted from The Royal College of Surgeons of England/Department of Health3). © The Royal College of 
Surgeons of England. Taken from The Higher Risk Surgical Patient, 2011. Reproduced with permission. 
High risk (cardiac risk 
>5%)  
Intermediate risk (cardiac 
risk 1–5%)  
Low risk (cardiac risk 
<1%)  
Open aortic  Elective abdominal  Breast  
Major vascular  Carotid  Dental  
Peripheral vascular  Endovascular aneurysm  Thyroid  
Urgent body cavity  Head and neck  Ophthalmic  
  Major neurosurgery  Gynaecological  
  Arthroplasty  Reconstructive  
  Elective pulmonary  Minor orthopaedic  
  Major urology  Minor urology  
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complex components of any perioperative pathway for this high risk surgical group and 
measure them against outcomes shown to be beneficial to the patient including but not 
limited to complications, length of stay, patient reported outcomes and mortality. 
 
1.1.5 Perioperative complications 
The most common measurement of postoperative outcomes in published perioperative 
studies into the high-risk patient is 30-day mortality despite patient expectations likely to be 
greater than simply being alive one month after their surgery.16 Mortality outcomes do not 
capture the burden that postoperative complications place on the patient, the patient’s family 
or carers and the healthcare system in the short, medium and long term.17, 18 Complications 
are common after major surgery and are associated with an increased mortality and longer 
hospital stay. A study from 2005 demonstrated the long-term significance with patients who 
had developed complications after surgery having an increased ten-year mortality.19 Studying 
complications after surgery rather than mortality as a primary outcome allows trials to recruit 
a smaller number of patients to demonstrate the impact of a particular intervention in 
addition to identifying and addressing a surgical outcome that is relevant to the patient, the 
clinician and the hospital.  
Reporting of postoperative surgical complications has been more common as a secondary 
outcome measure but over time the importance of perioperative complications has become 
clear.19-21 Due to different definitions and lack of consistency in scoring severity the impact of 
any intervention of post-operative complications was difficult to assess outside small study 
settings. Widespread consensus of definitions over post-operative complications such as 
myocardial injury22(MI) definitions and the Acute Kidney Injury Network (AKIN) definition of 
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acute kidney injury23 (AKI) have allowed pooled meta-analyses to be far more accurate in 
assessing and reporting the sequalae of these complications. The Clavien-Dindo classification 
of postoperative complications has allowed for the consistent evaluation and reporting of 
complications after surgery allowing for a fuller assessment of their impact.24 A recent 
initiative lead by the British Journal of Anaesthesia (BJA) has proposed international working 
groups of experienced perioperative trialists to define perioperative complications for 
consensus use in perioperative studies25 and these are beginning to be published.26-28 The 
widespread adoption of such definitions within the literature would allow for comparisons 
between studies in subsequent meta-analysis and greatly increase the utilisation and value of 
shared data. 
 
1.2 Goal Directed Therapy 
1.2.1 Enhanced Recovery After Surgery 
There have been a large number of different interventions designed to improve outcomes in 
high-risk surgery.29 In the United Kingdom, these interventions have been grouped together 
in a pre-operative, perioperative and post-operative care bundle that covers all the patient’s 
hospital interactions called the Enhanced Recovery After Surgery (ERAS) programme.30 ERAS 
has been widely adopted in the United Kingdom with the introduction of the Enhanced 
Recovery Partnership Programme (ERPP) which introduced the concept at a national level. As 
a result the vast majority of hospitals have an ERAS programme, usually specific to a particular 
speciality, that groups together a consensus of what the local caregivers feel are the most 
effective interventions.31 These interventions include pre-operative carbohydrate drinks, early 
mobilisation, early removal of the nasogastric tube, early enteral feeding and an individual 
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post-operative pain plan utilising neuro-axial or regional blockade if appropriate.32 The use of 
the carbohydrate drinks is controversial as although they have been shown to improve 
outcomes33-35 after major surgery subsequent meta-analysis of these studies found them to 
be at risk of bias.36, 37 However, they are used to ameliorate the mandatory six hour fasting 
period prior to major surgery and have shown benefit in patient reported outcomes measures 
in this regard.38, 39 This fasting period along with the use of bowel preparation contributes to 
a fluid deficit that requires correction during the intraoperative period. Perioperatively fluid 
and inotrope therapy guided by cardiac output monitoring has been identified by several 
investigators as improving surgical outcomes.40-48 This intervention also known as goal 
directed therapy (GDT) is included in the vast majority of ERAS bundles of care. In an ERAS 
programme the ongoing postoperative care of the surgical patient is centred around a multi-
disciplinary approach. Pain control allowing the patient to breathe deeply, cough and mobilise 
is essential to a complication free recovery for the patient.49 Physiotherapy is key to the early 
mobilisation of the patient after surgery and a patient specific plans for movement should 
continue after the discharge of the patient home.50 Early enteral feeding, with expert 
nutritional input if required, to aid the patient over their relative catabolic state after surgery 
should also be supported up to and after discharge51, 52 alongside occupational therapy 
assessing the ability of the patient after surgery ensures support at the point of discharge.53, 
54 Underpinning this multidisciplinary approach is the psychological support of the patient 
with good communication from the health professionals maintaining the motivation of the 
patient in their recovery.55 The adoption of ERAS has not been universal and there is no 
consensus as to what ERAS entails.56, 57 It differs between the surgical specialties but can also 
differ between institutions for the same speciality.57 This lack of consistency in care opens up 
the possibility of a wide variation care to patients. It is suggested that it takes seventeen years 
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for medical research to become part of mainstream medical practice and it is likely that this is 
even longer for complex medical interventions such as an ERAS programme.58, 59 This is in part 
due to a resistance to change that is seen throughout medical practice but also due to the 
complexity of the interventions within the pathway. This complexity makes it difficult to 
obtain a consistent evidence base particularly due to the differences in the definition of ERAS 
and the different surgical populations in any randomised controlled trials that are undertaken. 
This can affect the accuracy of any subsequent meta-analysis undertaken.31, 60  One option to 
increase the utilisation of an ERAS programme is to undertake a large, prospective trial of a 
predefined ERAS programme though this would be not only difficult and costly, but may be 
hampered by the lack of clinical equipoise and be criticised over its differences from other 
ERAS protocols. The Enhanced Perioperative Care for High-risk patients (EPOCH) trial used a 
stepped wedge cluster randomised trial to evaluate a perioperative care bundle to patients 
undergoing emergency laparotomy.61 This design could be used to evaluate the introduction 
of a large scale ERAS programme more effectively although the EPOCH study found that lack 
of investment of time and money from the health care system was a major barrier. It is also 
possible to study the individual components of ERAS to determine which influence outcomes. 
The last approach raises the possibility that any positive influence a combination of 
interventions may have is missed by studying them in isolation. However, this approach is 
probably the most valid given the complexity of the perioperative pathway and the time cost 
and economic burden as well as the potential for patient harm of introducing an intervention 
into the pathway that is not improving care. 
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Figure 1.1 Schematic representation of ERAS 
 
 
The role of perioperative fluid therapy within the multiple aspects of Enhance Recovery that have 
been shown to benefit patients undergoing high risk gastrointestinal surgery. These represent a 
series of simple or complex interventions that combine to improve care.  
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1.2.2 Goal Directed Therapy 
There has been interest in GDT since the introduction of the pulmonary artery catheter (PAC) 
in the 1970s.62, 63 The PAC was the first device that allowed the objective measurement of 
haemodynamic variables that would allow the clinician to target an optimal cardiac output 
and therefore an optimal oxygen delivery.  Clowes et al noted increased survival in peritontic 
patients who were able to increase their cardiac output.64 Shoemaker and Bland investigated 
and initially defined the haemodynamic variables associated with increased survival in high-
risk and critically ill surgical patients.65, 66 Boyd et al demonstrated that targeted fluid and 
inotrope therapy towards the haemodynamic indices identified previously improved both 
morbidity and mortality within a high-risk surgical patient population.41 These indices were 
either the increase in cardiac output, the increase in cardiac index or an increase in oxygen 
delivery. GDT was also utilised in the critically ill population, though a study suggested that 
late intervention of GDT utilising specific haemodynamic targets may be harmful in these 
patients.67 More recent studies of GDT in several different high risk surgical patient groups 
were done which have demonstrated a benefit in morbidity though not in mortality.44, 46, 68, 69 
These studies were undertaken using minimally invasive cardiac output monitors after the 
controversy surrounding the pulmonary artery catheter that is discussed below. They also 
avoided the use of specific haemodynamic targets, trying to optimise the individuals cardiac 
output rather than attain prespecified goals. 
 
1.2.3 What is Goal Directed Therapy? 
There are many definitions of GDT. It can be described an intervention that aims to maximise 
oxygen delivery during a specific period most commonly after a physiological insult such as 
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sepsis or major surgery. Alternatively, GDT has been described as the optimisation of fluid 
volume during surgery or as the use of fluid and inotropic therapy to achieve pre-specified 
haemodynamic goals. In addition to the myriad of issues surrounding the definition of GDT 
there is also a lack of a consistency in the patient group, the length of time of the GDT 
intervention in the perioperative period and the process by which GDT is delivered.70, 71 
Perhaps the most complicated factor is the large number of different algorithms that have 
been used even in GDT trials of similar patient groups. The nomenclature is also diverse as 
GDT is studied under many different names including goal directed haemodynamic therapy, 
goal directed fluid therapy, fluid therapy, haemodynamic therapy, elevated oxygen delivery 
and optimisation of cardiac output or index. The concept of GDT is thought to be simple but it 
is a complex intervention that is defined in many different ways. This heterogeneity 
surrounding GDT makes it more difficult to establish a solid evidence base to confirm its 
overall effectiveness.70 The difficulty in comparing different versions of complex interventions 
is high and despite the high numbers of meta-analysis72-77 of GDT they do not provide 
conclusive answers partly due to the differences between the studies.78 Small studies have 
established the groups of patients in which GDT was efficacious such as major abdominal 
surgery46, 68, 69, certain orthopaedic procedures44, 79, 80 though not in vascular surgery.81-83 The 
heterogeneity of these studies also means the components of a GDT algorithm, the length of 
the intervention and the variables used to deliver GDT remain undetermined in spite of the 
large number of studies undertaken. 
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1.2.4 Timing of Goal Directed Therapy 
Timing of the intervention of GDT has been investigated and being shown to be important to 
perioperative outcomes.67, 84 Initial studies have shown a small benefit from preoperative GDT 
but as the theory of GDT moved away from predefined variables to optimisation of oxygen 
delivery during or immediately after an insult, intervention prior to surgery was no longer 
considered necessary. GDT has been shown to be effective in reducing complications without 
the preoperative optimisation of haemodynamic variables.43, 46, 85, 86 A core component of the 
ERAS philosophy means that even patients undergoing major surgery should be admitted on 
the day of their surgery. In addition, ERAS programmes include preoperative carbohydrate 
drinks which lessen the impact of the mandatory six hour fasting period prior to surgery. Both 
of these concepts have meant that preoperative GDT in elective patients has had no recent 
study conducted examining its influence on patient outcomes. The POM-O study looked at 
GDT exclusively in the immediate post-operative period using fluid with or without 
dobutamine to achieve an individualised haemodynamic target.87 The authors demonstrated 
no difference in outcomes between the intervention and control arm but confirmed the 
importance of achieving an individualised haemodynamic target to avoid postoperative 
complications. A study trialling a later intervention of GDT studied a heterogeneous critical 
care population with a GDT algorithm introduced after their admission to critical care showed 
harm in attempting to deliver increased oxygen delivery.67  
 
1.2.5 Surgical Populations that benefit from Goal Directed Therapy 
The definition of a high risk surgical population is difficult and varies widely with no definitive 
consensus. Both Shoemaker and Boyd reported successful trials of GDT and although the 
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inclusion criteria  was similar, the reported control group mortality outcome between the two 
studies was different highlighting the difficulty in defining high risk populations.40, 41 Pearse et 
al set out to characterise a high risk surgical population by examining data regarding surgical 
outcomes from the Intensive Care National Audit and Research Centre (ICNARC) and Caspe 
Healthcare Knowledge Systems (CHKS) databases.12 They defined high risk surgery as 
procedures that had a greater than five per cent mortality risk. They confirmed earlier findings 
that the high risk surgical patient group is older, has more co-morbidities and undergoes more 
complex surgery88, 89 but more significantly that the high risk surgical group accounts for the 
majority of the morbidity and mortality seen after surgery.12 These findings have been used 
by the vast majority of studies in GDT to define high risk surgery and to describe the surgical 
population they are investigating as objective scoring systems are not yet sufficiently accurate 
to identify the high risk patient.8 The improvement in mortality seen in the GDT groups in the 
Shoemaker and Boyd studies led to further studies attempting to demonstrate the effect of 
GDT on other surgical populations. Successful studies of GDT have been reported in major 
abdominal surgery,42, 46, 68, 69 cardiothoracic surgery90-92 and in major orthopaedic surgery.44, 93 
These groups initially appear to encompass a large diversity of surgical insults but have in 
common a large physiological stress response secondary to surgery. A systematic review 
concluded that there were no benefits of GDT in patients undergoing major vascular surgery.94 
Explanations for the lack of effect in this population include the nature of ischaemic 
reperfusion injury, the ongoing large changes in circulating volume which may be difficult to 
predict and manage even with cardiac output monitoring and the effect of a cross clamp 
providing no flow to part of the body for a period of time most of which are unique to major 
vascular surgery. There also appears to be no benefit in established critical illness.67 A 
systematic review suggested that those patients at low to medium risk either due to their own 
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co-morbidities or the nature of the surgery undertaken do not benefit from GDT71 and in one 
study there is a suggestion of harm95 though more recent studies have shown benefit to a low 
to medium risk surgical population from GDT.96, 97 From the studies and subsequent meta-
analysis trying to elicit which surgical group benefits from GDT, the main beneficiaries appear 
to be those patients undergoing high risk surgery with the exception of those patients 
undergoing major vascular surgery. The evidence is less clear for low to medium risk surgical 
patients but any benefit they may receive appears to have less impact than in the high risk 
surgical patient group.95, 97 
 
1.2.6 The Current Evidence Base for Goal Directed Therapy 
The current evidence base for goal directed therapy is dominated by a large number of small, 
single centre though well conducted trials that evaluate GDT in very specific populations. 
These smaller, focused studies have been essential in defining the usefulness and applicability 
of GDT in the context of surgery. Most studies of GDT recruit less than 200 patients, sometime 
less than 100 patients, in well-defined high risk patient groups such as older people with co-
morbidities undergoing major abdominal surgery or surgery for proximal head of femur 
fracture.43, 44, 46, 68 This confirms the efficacy of the intervention in these specific groups but 
does not allow us to evaluate its effectiveness or applicability to a wider surgical population. 
This is best demonstrated in a pragmatic, multicentre randomised controlled trial. A larger 
trial of GDT in major surgery has been undertaken but there was no specific GDT algorithm to 
compare against usual care,98 instead the authors set predefined goals which could be 
achieved at the discretion of the treating clinician. This study confirms the neutrality of the 
cardiac output monitoring technology indicating that it is the composition and delivery of the 
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algorithm that confers any potential benefit of the treatment in a specific population. This has 
led to a large number of meta-analysis using the aforementioned small single centre studies 
that have identified a reduction in morbidity and mortality in specific patient cohorts. This has 
potentially led to the overstating of the effectiveness of GDT by concentrating solely on its 
efficacy. A large, pragmatic trial is required to support the evidence base that GDT is an 
intervention that can play a useful role in surgery.99 The smaller exploratory trial has identified 
the high risk surgical groups that benefit from GDT but the composition of the ideal GDT 
algorithm and the biological mechanism by which GDT may be reducing complications after 
surgery remain unclear. 
 
1.3 Physiology of oxygen delivery 
 
The ability to increase oxygen delivery is a major determinant in the physiological recovery 
from any major insult including major surgery.40, 64, 100, 101 There are several physiological steps 
in delivering oxygen from the outside environment to the cell mitochondria best described in 
the oxygen cascade.102 Oxygen is taken from the surrounding environment through the 
bronchial tree of the lungs to the alveoli where it diffuses through the alveoli membrane into 
the pulmonary circulation. Oxygen is then attached to the haem on the haemoglobin molecule 
within the red blood cell with a small proportion dissolved into the plasma. The oxygenated 
red blood cell passes into the left side of the heart which pumps it through the arterial 
circulation to the microvascular circulation (Fig 1.2).  
The rate of delivery of oxygen to the microvascular circulation is determined by the cardiac 
output. This is given by the oxygen delivery equation with oxygen delivery equalling the 
cardiac output multiplied by the oxygen content of blood (Fig 1.3).  
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Figure 1.2 Perioperative Oxygen Cascade 
 
Representing the delivery pathway of oxygen through the body and the treatments that have been 
shown to or potentially  enhance its uptake and where these treatments have their primary effect 
 
The more efficient the oxygen delivery the better the patient’s ability to reduce or eliminate 
oxygen debt which is described as the difference between the oxygen extracted and the 
oxygen required to remain in cellular aerobic respiration (Fig 1.4).103 Oxygen delivery can be 
optimised at any stage in the oxygen cascade though in some areas we lack the technological 
or pharmaceutical advancements to have an effect.   
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Figure 1.3 Oxygen delivery equation 
𝑫𝑶𝟐 = 𝑪𝑶 × 𝑪𝒂𝑶𝟐 
DO2 = oxygen delivery, CO = cardiac output, CaCO2 = arterial oxygen content 
Oxygen is delivered via the microvascular circulation to the cells where it is utilised in the 
mitochondria as the end receiver in the electron transport chain in aerobic respiration. 
Currently the most effective way to improve oxygen delivery is to improve cardiac output 
during and after major surgery.72, 85 
 
Figure 1.4 Oxygen extraction equation 
 
𝑶𝒙𝒚𝒈𝒆𝒏 𝑬𝑹 =  
𝑪𝒂𝑶𝟐 − 𝑪𝒗𝑶𝟐
𝑪𝒂𝑶𝟐
 
 
Oxygen ER = oxygen extraction ratio, CaO2 = arterial oxygen content,   
CvO2 venous oxygen content 
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1.3.1 Increased inspired oxygen fractionation 
 
Increasing inspired oxygen fraction in the gas the patient is breathing has been postulated to 
improve surgical outcomes particularly the reduction of surgical site infection.104 The 
mechanism proposed is that the increased availability of oxygen at the alveolar/pulmonary 
vasculature will translate into an increased oxygen delivery to the microvascular circulation 
where wound tension oxygen has been shown to be an important determinant of wound 
infection.105 A study looking at abdominal surgery suggested a reduction in surgical site 
infections when comparing inspired oxygen fraction of 80% against 30%.106 The largest 
randomised trial directly studying differences in inspired fraction of oxygen failed to 
demonstrate any difference in its primary outcome.107 Interestingly this study reported an 
increased long term mortality and a reduction in cancer survival post-operatively in the group 
receiving higher inspired oxygen concentrations. The ENIGMA-II trial showed a reduction in 
infection in the group receiving higher oxygen concentrations, though this study was primarily 
looking at the difference between the use of Nitrous Oxide and oxygen rather than difference 
between oxygen concentrations, though some meta-analysis have included it.108 Meta-
analyses have differed in the conclusions regarding the use of hyperoxia. More recent studies 
have not shown any difference in the reduction of surgical site infections in abdominal 
surgery.109 Despite the lack of clear evidence the World Health Organisation (WHO) currently 
recommends increasing the oxygen fraction to reduce surgical site infections110 though doubts 
have been expressed over this advice.111 Exposure to high concentrations of oxygen can lead 
to the generation of oxygen free radicals, an increase in oxidative stress causing intracellular 
dysfunction can lead to poorer outcomes.112-114 The role of oxidative stress in surgery is not 
fully understood particularly in high risk surgery and an aging population.115-117 As a result, the 
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recommendation that the patient, be hyperoxemic during and after a major physiological 
insult such as major surgery is not universally accepted. 
 
1.3.2 Optimising ventilation 
Optimising ventilation describes changes in the respiratory rate, tidal volume and pulmonary 
end respiratory pressure (PEEP). Increasing respiratory rate or tidal volume does not increase 
oxygen availability at the alveolar/pulmonary circulation though using PEEP will increase the 
number of alveoli available for gas exchange by reducing atelectasis. The current Cochrane 
review suggest there is not enough quality evidence on which to determine if PEEP is useful in 
decreasing surgical complications118 though a more recent study has suggested an 
improvement in post-operative pulmonary complications after with major abdominal surgery 
with the use of PEEP set at >5cm H20119 contrasting with the PROVHILO study.120 Gas exchange 
in the lungs is also influenced by the flow of the pulmonary circulation through the lungs. 
Ventilation perfusion mismatch (V/Q) decreases the oxygen available to be taken up by 
pulmonary circulation though this is circumvented by the hypoxic pulmonary vasocontraction 
reflex. This reflex is dulled during anaesthesia and prevention of a significant shunt is 
important to ensure optimal oxygen delivery.121 There are no interventions outside of good 
routine care to prevent V/Q mismatch in the perioperative period. The positive pressure 
ventilation required during major surgery can potentially have an impact of surgical outcomes 
with recent studies have suggested benefit for a protective strategy during major surgery.122, 
123 Studies of patients undergoing long term ventilation on intensive care units have shown 
the benefits of a protective ventilation strategy limiting the tidal volume and inspiratory 
pressures.124, 125 Limiting the tidal volume and the use of PEEP has implications for the 
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usefulness of dynamic measures of fluid responsiveness and studies have altered the 
ventilatory strategy to accommodate this.126-128 
 
1.3.3 The Principles of Cardiac Output 
Cardiac output is determined by the equation cardiac output equals stroke volume multiplied 
by heart rate. This gives an output in litres/ minute (L/min) which can be used in conjunction 
with the patient’s body surface area (BSA) to give a cardiac index. Both cardiac output and 
cardiac index have been used to improves outcomes in high risk patients undergoing 
surgery.40, 41, 85 The stroke volume is determined by the difference between the volume of the 
left ventricle from the end of diastole to the end of systole (Fig 1.5) 
 
Figure 1.5 Stroke volume equation 
 
𝑺𝒕𝒓𝒐𝒌𝒆 𝒗𝒐𝒍𝒖𝒎𝒆 = 𝑬𝒏𝒅 𝑫𝒊𝒂𝒔𝒕𝒐𝒍𝒊𝒄 𝒗𝒐𝒍𝒖𝒎𝒆 − 𝑬𝒏𝒅 𝒔𝒚𝒔𝒕𝒐𝒍𝒊𝒄 𝒗𝒐𝒍𝒖𝒎𝒆 
 
Starling’s law states that the left ventricle will relax allowing an increase in stroke volume with 
further fluid administration. This increase in stroke volume gives an increase in cardiac output. 
Starling law also states that there is an optimal filling point and giving more fluid after this 
overstretches the left ventricle decreasing stroke volume and reducing cardiac output (Fig 
1.6). Heart rate is measured in beats per minute and an increase in heart rate will increase the 
cardiac output. 
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If the increase in heart rate is too high, the time allowed to fill the left ventricle is compromised 
resulting in a reduction in end diastolic volume and potentially cardiac output. In addition, the 
reduction in diastolic time reduces coronary flow time to the ventricle increasing the 
possibility of poor myocardial perfusion and resulting ischaemia. Therefore, current GDT 
interventions focus either solely on maximising the stroke volume or on maximising stroke 
volume with a limited degree of chronotropy. 
 
Figure 1.6 Schematic representation of cardiovascular change with a fluid challenge 
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Fluid administration improves right ventricular filling and subsequently cardiac output until the right 
atrial pressure reaches the flat part of the curve and no increase in cardiac output is seen with fluid 
challenges 
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1.3.4 Microvascular circulation 
The capillaries or microvascular circulation is where the direct exchange of oxygen and 
nutrients happens with the tissues.129 Oxygen diffuses across the gradient into the cells while 
carbon dioxide diffuses out. The main determinants of microvascular flow depend on an 
optimal circulating volume though in certain disease states this may be difficult to achieve.130 
A study looking at microvascular flow after GDT examining both fluid only and fluid and 
inotrope therapies against control, demonstrated a marked improvement in microvascular 
flow in the patients receiving GDT.131 Alteration in microvascular flow can be seen after a 
serious physiological insult including major surgery and sepsis.132 Changes in microvascular 
flow have been used to assess oxygen delivery but most studies have focused on the 
microcirculatory flow in severe sepsis and septic shock.133 There have been many attempts to 
discover therapies that improve microvascular flow after sepsis but the combination therapy 
of inotropes, vasopressors and fluid therapy appears to be the only effective intervention.134 
The utility of microvascular flow remains in monitoring the response of the microvascular 
circulation to physiological insults such as major surgery. Microvascular flow can be measured 
in a number of different ways but due to the difficulty of interpretation and the time taken to 
do so they have not been used to measure the response to fluid and inotropic therapy outside 
of a trial setting. The improvement of oxygen delivery within and from the microvascular 
circulation is likely to be important to improved outcomes for high risk patients after major 
surgery but currently there are no proven therapeutic interventions outside of GDT available 
to achieve this. 
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1.3.5 Cellular use of oxygen 
Oxygen is used as the recipient of the final electron of the electron  transport chain within the 
Krebs cycle during aerobic respiration.135 The original principle of GDT is to minimise the 
extent of oxygen debt that is accumulated during any major insult including major surgery by 
improving oxygen delivery to the tissues. Mitochondrial dysfunction rather than oxygen level 
has been postulated as a different reason for the poor utilisation of oxygen after sepsis.136, 137 
There are no current agents commercially available that improve the utilisation of oxygen at 
cellular level in acute illness. Animal studies have shown some treatments can improve 
mitochondrial use of oxygen after sepsis but this has not been replicated in human studies.138 
The majority of studies examining the role in mitochondria in GDT and oxygen delivery have 
been in septic patients where mitochondrial dysfunction is a known consequence and of 
severe sepsis and septic shock. The COSMOS study will examine the role of oxidative stress 
and mitochondrial dysfunction after major surgery though there seems no biologically 
plausible mechanism by which GDT would improve this utilisation. 
 
1.4 Clinical measures of cardiovascular performance 
1.4.1 Clinical measures 
The initial measurement of cardiovascular performance involves clinical measurements. Most 
commonly these are composed of heart rate, blood pressure, capillary refill peripheral, core 
temperature and urine output. They are quick and easy to do and a number have been 
grouped together to identify the failing patient in an in-hospital setting. In the United Kingdom 
these are part of routine ward measurements usually called the medical early warning system 
(MEWS) or variants thereof.139, 140 Heart rate, blood pressure and temperature are routine 
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measurements for all patients undergoing any major surgery but they are not sensitive or 
specific enough to use in titrating fluid therapy. Compensatory physiological mechanisms 
allow most patients undergoing major elective surgery to maintain adequate blood flow to 
the vital organs despite significant pressure on the cardiovascular system.141 It is not until 
major fluid shifts happen that large changes related to cardiovascular performance are seen 
in these patients and at this stage the patient is potentially significantly under resuscitated.142 
They are also poor markers of fluid overload sometimes maintaining normal or even low 
values in the presence of significant overload. Heat rate and blood pressure are altered by 
other variables present during surgery such as pain stimulation, plane of anaesthesia and 
blood vessel clamping or compression. Temperature can be measured peripherally during 
anaesthesia but is not routinely performed and is influenced by many other factors included 
peripheral vasodilatation related to anaesthesia, warming techniques and inflammatory 
states particularly systemic inflammatory response (SIR). Urine output is similarly influenced 
by factors other than filling status. The physiological renal response to any traumatic insult 
such as surgery is to retain fluid though this in itself is controlled by a number of interacting 
hormonal and neurological systems that mean interpreting hourly urine output during and 
immediately after surgery is very difficult.143 The inconsistency of urine output ensures that 
population measurements cannot be applied to the individual during this period. This ensures 
that urine output is a useful trend to follow but does not perform well as a singular 
measurement of filling status. The use of clinical measurements are important in the overall 
management of the patient but due to the large number of factors that influence them and 
the compensatory physiological mechanisms they are not suitable to use to guide fluid therapy 
in the high risk surgical patient. 
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1.4.2 Biomarkers of cardiovascular performance 
A biomarker that could accurately predict fluid responsiveness would require to be available 
in real time, track changes in filling status quickly and accurately, be easy to interpret and 
cheap to measure with consistent results. No such biomarker is available, though traditionally 
biochemistry available from blood gas analysis has been used.  
The most studied measurable biomarker to aid fluid therapy is mixed or central venous 
saturations. Mixed venous saturations are measured from the tip of a pulmonary artery 
catheter lying in the pulmonary artery and central venous saturations from the end of a central 
venous catheter lying in the right atrium or superior vena cava. Both have been used as 
surrogate marker of overall oxygen delivery. Reduction in mixed and central venous 
saturations is associated with poorer outcomes after major abdominal surgery144, 145 and early 
studies treating low central venous saturations with fluid in severe sepsis had shown improved 
outcomes.84 However this treatment was not shown to be beneficial in subsequent severe 
sepsis studies146 and has not been demonstrated to be beneficial in major surgery.145 Mixed 
oxygen central saturations and central venous saturations are important measures in patients 
undergoing major surgery but are not specific enough to accurately titrate ongoing fluid 
therapy to the hypovolaemic patient undergoing major surgery. 
Lactic acid is produced by the body in times of energy requirement and under stress its 
production and that of its conjugate, lactate can exceed its clearance.147 Lactate is easily and 
commonly measured by both arterial and venous blood gas samples and is one of the more 
common biomarkers used to interpret a patient’s filling status. Hypovolaemia causing a 
reduction in oxygen delivery leading to overall hypoperfusion will result in anaerobic 
respiration, increasing lactate production and a subsequent rise in serum lactate. It should be 
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noted that lactate production is influenced by many other factors than organ hypoperfusion 
including ischemia, exercise and liver failure.148 It is not always possible to identify the source 
of the lactate production and then definitively attribute it to a global hypoperfusion state 
secondary to hypovolaemia. Values differ significantly between arterial, central venous and 
peripheral venous samples making the consistent interpretation of these values more difficult. 
There has been an increase in interest in hyperlactatemia as a biomarker signal in the 
resuscitation of people in septic shock. It has been included in international sepsis 
guidelines149 and a number of studies have identified lactate clearance as a specific aim 
associated with improved outcomes in these patients.146, 150-152 Lactate remains too crude a 
tool to utilise to guide intraoperative fluid therapy and there are no studies using lactate as 
an endpoint for fluid therapy after major surgery though reduction in lactate has been used 
as an end point in studying GDT. 
Similarly, to lactate, the acid base balance has been suggested as a guide for perioperative 
fluid therapy. Acid base balance describes the tight regulation of physiological pH in the 
human body between 7.35-7.45. An increase in free hydrogen ions will result in a metabolic 
base deficit that can be detected through arterial or central venous gas sampling. Although 
changes in acid base in response to hypovolaemia are quicker than those seen with lactate 
they can still lag behind patient requirements. The measurement of the acid base also reflects 
a number of interacting physiological systems and so may not accurately reflect or track filling 
status. It is also influenced by renal function and the chloride concentration of fluid that is 
being used, which can make it difficult to accurately interpret the patient’s fluid status from 
the  acid base balance.153 There are very few studies using acid base as a primary endpoint for 
fluid resuscitation154, 155 and it is not incorporated in clinical guidelines.  
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The change in biomarkers is too slow to allow accurate decision making for immediate 
decisions regarding fluid therapy though they have a role in the longer term management of 
the patient. In addition to the interest in lactate clearance, biomarkers of cardiovascular 
performance have been shown to correlate with outcomes after major surgery. Measurement 
of serial troponins after major surgery have shown that a small rise in this biomarker in the 
absence of clinical symptoms is associated with a worse outcome.13 This study has highlighted 
the importance of biomarkers as a prognostic and diagnostic tool after major surgery and as 
safety marker for GDT which is discussed in further detail later. 
 
1.5 Haemodynamic variables 
It is unclear which haemodynamic variable or which combination are the best endpoints to 
use in the delivery of GDT. Studies have used a number of different endpoints to direct fluid 
therapy including central venous pressure (CVP), cardiac output and cardiac index.40, 41, 84 
These measures are described as static measures of filling status as they do not give a cyclic 
variation that can be used to target fluid or inotrope therapy. As a result absolute 
haemodynamic targets were developed but studies demonstrated no difference or poorer 
outcomes when these were used 67, 156 and other static values such as stroke volume (SV) or 
flow time corrected (FTc) have been incorporated into the GDT algorithms.43, 44, 157 More 
recent studies investigating GDT have included dynamic parameters such as the variation of 
stroke volume and pulse pressure during the mechanical ventilatory cycle.152, 158 Pulse 
pressure variation, stroke volume variation and systolic pressure variation can be derived from 
minimally and non-invasive cardiac output monitors. 
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1.5.1 Central venous pressure 
Central venous pressure (CVP) was initially used as a surrogate for filling status. The principle 
was that a low CVP reflects a low left ventricle end diastolic filling pressure reflecting an under 
filled patient. However there has been growing evidence since the 1970s that CVP is not a 
predictor of fluid responsiveness and a systematic review concluded that it should not be used 
to assess the patient’s volume status.159 CVP does reflect right atrial pressure but as a static 
measure it does not take into account ventricular compliance. After any major insult, including 
major surgery, CVP can reflect right ventricular end diastolic pressure but this does not 
accurately reflect where the left ventricle is in relation to the Starling curve. Rivers et al used 
CVP in their algorithm to guide GDT in early sepsis in the emergency department84 though the 
evidence in GDT trials in major surgery is that CVP does not correlate with fluid responsiveness 
and should not be used in decisions regarding fluid therapy.159 
 
1.5.2 Stroke volume 
Stroke volume is one of the most commonly used cardiovascular endpoint in GDT algorithms 
to determine if the patient is fluid responsive. Studies have used a prespecified stroke volume 
increase to guide fluid therapy in perioperative patients undergoing major surgery.46, 68, 69, 131 
Stroke volume is defined as the volume of blood that has the been expelled from the left 
ventricle during one contraction. In health this usually consists of around two thirds of the 
resting end diastolic left ventricular volume. The stroke volume rise in response to fluid is 
described by the Starling curve with the response to fluid predicted by the filling status of the 
patient on the curve.160 GDT measures the response to a known fluid challenge and use the 
Starling curve to assess if the patient’s filling status is on the optimal flat part of the curve. If 
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on the fluid responsive part of the curve, stoke volume will have a transient but significant rise 
to the fluid challenge indicating the patient requires further filling. If on the non-responsive 
part of the curve there will be no or only a very small rise in response to a fluid challenge, 
indicating the patient is adequately filled and no further filling is required at that point.  
 
1.5.3 Pulmonary artery occlusion pressure 
Pulmonary artery occlusion pressure (POAP) or pulmonary artery capillary wedge pressure 
(PCWP) is the pressure measured when an inflated balloon is wedged in a small pulmonary 
arterial branch. It provides an estimated left atrial pressure and thus provide an accurate 
reflection of left sided filling pressures.161 Although this can be measured in all the high risk 
patient groups involving major surgery, burns, trauma and critical care patients it requires the 
insertion of a PAC with all the associated risks. However, the physiology of positive pressure 
ventilation changes intrathoracic pressures which subsequently significantly changes the 
measurement of pulmonary artery occlusion pressure. This means that pulmonary artery 
occlusion pressure more accurately reflects intrathoracic pressure changes rather than 
relative hypovolaemia as measured by left atrial filling pressures. As a consequence of the 
requirement for a PAC to be inserted the most recent trials of pulmonary artery occlusion 
pressure have been undertaken in cardiac surgery where the insertion of PAC remains more 
common. Pulmonary artery occlusion pressure in GDT has been most commonly used in 
combination with other PAC derived variables in patient groups undergoing cardiac surgery or 
in patients with severe sepsis or septic shock. A pulmonary artery occlusion pressure of 
greater than 20mmHg was thought to indicate pulmonary oedema and was used in the criteria 
to distinguish pulmonary oedema from acute respiratory distress syndrome (ARDS). A number 
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of GDT studies have incorporated pulmonary artery occlusion pressure into their algorithms 
suggesting fluid to keep the it between a pressure of 12-14mmHg which is suggestive of an 
optimally filled patient. Due to the lack of use of PAC in major abdominal surgery, there are 
very few recent trials using as pulmonary artery occlusion pressure as part of a GDT algorithm 
and it now rarely used as a variable with which to target fluid or inotropic therapy. It has not 
been found to be useful in predicting fluid responsiveness in this patient groups.162  
 
1.5.4 Cardiac output 
Cardiac output, or more commonly the  more specific derivative cardiac index, has been used 
as a therapeutic endpoint for GDT. The first trials of GDT by Shoemaker and Boyd aimed to 
elevate these variables to supranormal levels.40, 41 These are no longer used as standard 
endpoints for GDT but are still measured as surrogate variables in some studies to 
demonstrate the effectiveness of the GDT algorithm increasing cardiac output and therefore 
oxygen delivery.87 Cardiac index which is the cardiac output divided by the body surface area 
(BSA) has been used in a number of different GDT trials as it gives a more patient specific 
target.47, 163 Most GDT algorithms initially relied on just fluid therapy to improve cardiac output 
and the use of inotropic support was not considered until the patient was fully resuscitated. 
A meta-analysis has shown the potential for the improvement of morbidity in high risk patients 
with the use of a low dose inotrope164 with a study showing improved cardiac output and 
microvascular flow using this approach.131 The use of trend cardiac output monitoring because 
of its practicality in the intraoperative and immediate postoperative period has also led to the 
reduction of cardiac output and cardiac index in GDT protocols. These remain useful tools for 
monitoring the effectiveness of the delivery of oxygen in GDT algorithms87 but should not be 
used as primary endpoints due to the potential harm to the patient.67, 156 
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1.5.5 Systolic aortic flow time 
Systolic aortic flow time is a haemodynamic variable that is measured exclusively by the 
oesophageal doppler and is the time between the opening of the aortic valve to the closing of 
the aortic valve. The corrected flow time (FTc), which is the flow time corrected to a heart rate 
of 60 beats per minute, has been used as a haemodynamic variable to be optimised in most 
doppler based GDT algorithms.43, 44, 69 The FTc has been validated in a number of studies of 
GDT in surgery and in the intensive care unit. The inappropriate use of FTc as a marker of left 
ventricular preload in favour of other haemodynamic indices has been suggested.165 The use 
of vasopressors particularly noradrenaline can influence FTc and this can affect its suitability 
in high risk surgical patients. A corrected flow time of less than 0.35 seconds suggests a fluid 
challenge is required and the result of this is monitored. If FTc is between 0.35s and 0.4s after 
the challenge then the stroke volume is assessed with an increase of stroke volume of more 
than 10% indicating a further fluid challenge. Variations of this protocol have been used in 
studies but the majority use an initial FTc reading with stroke volume analysis to guide fluid 
and inotropic therapy.43, 44, 69 FTc combined with stroke volume or stroke volume variation has 
been shown to be effective and the main limitation of its use is patient tolerance in the post-
operative setting of the oesophageal doppler.157 
 
1.5.6 Right and left ventricular end diastolic area index  
The right end diastolic area is calculated by the using thermodilution to calculate the right 
ventricular ejection fraction (RVEF) and using the stroke volume to determine the right 
ventricular end-systolic and end-diastolic volumes and areas (RVEDA).166 This is the indexed 
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to the patient’s demographics to calculate RVEDAI which has not been shown to predict fluid 
responsiveness. A similar variable the left ventricular end diastolic area (LVEDA) and the 
derived index LVEDAI can be calculated using transoesophageal echocardiography during 
mechanical ventilation and one study did suggest it could predict fluid responsiveness.167 
However further studies have demonstrated its limitation in this respect.168 Due to the 
difficulty in the use of the different monitoring modalities that would be required to use either 
variable in a GDT algorithm there have not been any GDT studies using these parameters in 
major abdominal surgery though LVEDAI is used in the ROSE resuscitation protocol for fluid 
management in the brain injured patient.169  
 
1.6 Dynamic measures of fluid responsiveness 
 
There has been a great deal of interest in the development of an accurate dynamic measure 
of fluid responsiveness since the 2000s.170 The advantage of dynamic prediction is that it 
should allow a prediction of successful fluid challenge before a fluid challenge is performed. 
This contrasts with the use of static predictors of fluid status such as cardiac output and stroke 
volume which require a fluid challenge to be performed in order to assess fluid status. By using 
these static indicators we expose the patient to at least one and possibly more superfluous 
fluid challenges which at best confer no benefit and at worst could be harmful.171 The 
development of an accurate dynamic fluid responsiveness trigger would allow this measure 
to be included in GDT algorithms and potentially save the patient from unnecessary fluid 
challenges. Much of the work has been focused on looking at variable that change with 
intrathoracic pressure during the respiratory cycle.74 In an anaesthetised patient the increase 
in intrathoracic pressure during inspiration decrease venous return resulting in a change in 
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stroke volume. The change in stoke volume is directly related to the filling status of the 
patient. This is seen using the Frank-Starling curve when hypovolemic patients are 
mechanically ventilated the greater the change in the stroke volume.160, 172 Conversely when 
the patient are adequately filled there is a much smaller variation in stroke volume. These 
variations in stroke volume that are related to the respiratory cycle, can be measured by 
systolic pressure variation (SPV), pulse pressure variation (PPV) and stroke volume variation 
(SVV). 
 
1.6.1 Pulse pressure variation 
Pulse pressure variation (PPV) describes a dynamic measure of fluid responsiveness given by 
pulse pressure max minus pulse pressure min divided by pulse pressure mean (Fig 1.7). It is 
most commonly used as a dynamic measure of fluid responsiveness in the cardiac output 
monitoring systems that use pulse contour and pulse power analysis. It has been validated in 
individual studies and used in studies of GDT as targeted endpoint.47, 158 These studies have 
been small, single centre studies of GDT and its practical use has yet to be demonstrated in a 
large trial of GDT. Similarly the studies evaluating its usefulness have been small single, centre 
studies under specific conditions and the effectiveness of the variable in guiding a GDT 
algorithm in a larger, pragmatic study has not yet been evaluated.173  
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Figure 1.7 Pulse pressure variation equation 
 
𝑷𝑷𝑽 =  
𝑷𝑷 𝒎𝒂𝒙 − 𝑷𝑷𝒎𝒊𝒏 
𝑷𝑷 𝑴𝒆𝒂𝒏
 
PPV = Pulse pressure variation, PP max = maximum value of pulse pressure in measured cycled 
PP min =  minimum variation of pulse pressure in measured  cycle, . PP mean = mean value of 
pulse pressure 
 
The accuracy of PPV depends on a number of conditions being met. It is noted to be inaccurate 
when the patient is spontaneously breathing, when the patient is ventilated at less than 7-8 
ml/ kg, arrhythmias and in the presence of vasoactive medications. Two meta-analysis in 2009 
and 2013 found PPV to have a good predictive value.74, 174 Despite this further work to evaluate 
its sensitivity and specificity outside of the ideal conditions is required, alongside its 
effectiveness in a large trial of GDT are needed prior to the widespread adoption of PPV in 
GDT algorithms. 
 
1.6.2 Stroke volume variation 
Stroke volume variation (SVV) is the calculation of the variation in the stroke volume 
throughout the respiratory cycle. It is calculated by the maximum stroke volume minus the 
minimum stroke volume divided by the mean stroke volume (Fig 1.8). Like all dynamic 
haemodynamic variables based on the respiratory cycle the accuracy of SVV depends on a 
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number of set conditions. It has been used in a number of GDT studies that have shown an 
improvement in measured outcomes in the treatment group. 
 
Figure 1.8  Stroke volume variation equation 
 
𝑺𝑽𝑽 =
 𝑺𝑽𝒎𝒂𝒙 − 𝑺𝑽𝒎𝒊𝒏
𝑺𝑽 𝒎𝒆𝒂𝒏
 
SVV = stroke volume variation, SV max = maximum value of stroke volume over a measured 
cycle, SV min = minimum value of stroke volume over a measured cycle, SV mean = mean value 
of stroke volume over a measured cycle  
Similarly to PVV, these have been small, single centred studies that demonstrated the efficacy 
of SVV not the effectiveness of SVV in a large pragmatic trial.96, 152, 163 The studies validating 
the use of SVV as a good predictor of fluid responsiveness have also been small studies 
allowing the variable to be studied under ideal conditions. Subsequent meta-analysis in 2009 
and 2013 suggested SVV was an accurate haemodynamic variable to predict fluid 
responsiveness.74, 174 It is still not clear how this variable would perform as part of an GDT 
algorithm in a large study that would replicate the conditions this algorithm would have to 
perform in.   
1.6.3 Systolic pressure variation 
Changes in the systolic pressure associated with the respiratory cycle were termed systolic 
pressure variation (SPV) and large changes in SPV were associated with hypovolaemia.175 This 
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change was demonstrated in a study that showed SPV to be an accurate predictor of fluid 
responsiveness in patients undergoing surgery. PPV and SVV have supplanted SPV as the 
haemodynamic variable of choice in GDT as studies suggested there was no benefit in using 
SPV.176, 177 The main focus of research into SPV since has examined the role of non-invasive 
SPV. Non-invasive SPV as measured by amplitude difference in plethysmography trace has 
been used to assess fluid responsiveness in mechanically ventilated patients.178-180 In addition 
to the conditions required for PPV and SVV to work the non-invasive SPV is reliant on 
peripheral vasomotor tone to be consistent and changes in it can cause adverse readings. This 
limits its performance in anything other than the cardiovascularly stable patients. The non-
invasive SPV shows some promise as a monitoring entity for GDT but further studies are 
required to assess its applicability.181  
 
1.6.4 Summary 
GDT requires a haemodynamic variable that can be targeted in order to deliver a fluid and 
inotropic therapy to improve outcomes. Initially the use of supranormal therapeutic targets 
was the gold standard for GDT but with the advent of less invasive monitoring and the 
reduction in risk of complications from the monitor, alternative targets have been sought. 
These targets have been shown to have been effective and in the evidence base a number of 
different variables have been validated as legitimate predictors of fluid responsiveness and 
shown to improve outcomes when optimised in a large number of studies. The majority of 
studies have used stroke volume either singularly or in combination with flow time, pulse 
pressure variation and stroke volume variation with only a few retaining the original approach 
of targeting cardiac index or oxygen delivery directly. As clinicians start to use less and less 
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invasive cardiac output monitoring, a pragmatic trial with the aim of trialling the algorithm in 
a situation akin to clinical practice requires the algorithm to reflect day to day clinical practice. 
Stroke volume is the most consistently used variable in the literature for GDT using minimally 
or non-invasive cardiac output monitoring with the further advantage of being more familiar 
to clinicians than PPV or SVV and has been used in larger trials of GDT. FTc is limited in its use 
in the post-operative period due to the potential intolerance if the monitor. PPV and SVV have 
shown a great deal of promise and this warrants further investigation to their accuracy in a 
larger trial setting. 
 
1.7 Goal Directed Therapy Algorithms 
 
GDT is the use of fluid and inotropes to achieve predetermined haemodynamic goals. The 
initial goals of a stipulated cardiac output and cardiac index have been supplanted by more 
individual fluid therapy targets.182 While there is consensus on the goals to be reached how to 
achieve these goals is still the subject of debate. In the literature there have been many 
different protocols used in the many different trials into the efficacy of GDT.74 Those that have 
routinely failed to achieve the goals set have either been done in the wrong time frame or 
have used inotropic therapy to reach these goals after the patient has been appropriately 
resuscitated67, 156 though some more recent studies have not shown a difference in 
outcome.73, 87 The introduction of GDT to the surgical population has likely been limited by the 
lack of a consensus on the best way of delivering GDT.183 Meta-analyses comparing fluid only 
regimens to fluid and inotropes have shown little difference in the outcomes both suggesting 
benefit from the patient. However, the patient is less likely to reach the haemodynamic goals 
suggested by Shoemaker with fluid alone and Lobo et al demonstrated a better out come with 
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fluid and inotropes than just with fluids alone.184 The increased resources that are required to 
ensure the safe delivery of GDT gives rise to the suggestion that a better quality of care is given 
to the intervention group thereby accounting for the poorer outcomes in the control group. 
This is another reason for the slow implementation of GDT. 
 
1.7.1 Fluid controversy 
During the past 100 years, intravenous (i.v.) fluid therapy has become an integral part of 
perioperative care, and yet the question of the ‘ideal’ fluid remains elusive. For both the 
intensive care physician and the anaesthetist, i.v. fluid resuscitation is considered a core skill, 
which we expect to deliver safely and effectively. Despite this, the evidence base for fluid 
therapy remains a hotly debated topic.185 There many reasons fuelling these debates and an 
objective summary of the current knowledge on this topic is useful when considering barriers 
to GDT. I have not covered the use of blood products or the use of i.v. fluids for specialised 
indications, such as traumatic brain injury. This is outside the scope of use in GDT as these 
fluids are given for and in the treatment of specific pathologies or for the prevention for 
specific injuries that are not commonly seen in the patient groups who have been shown to 
benefit from GDT. The use of blood products has been shown to be injurious to patients 
undergoing major surgery and is best avoided if possible.186, 187 Most institutional and national 
guidelines have specific transfusion triggers at which to give packed red cells or other blood 
products. These targets are deliberately set low as a result and so blood and blood products 
should not be considered resuscitation or maintenance fluid but rather only to be given in pre-
specified circumstances. 
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1.7.2 History of fluid therapy 
In 1831, William O'Shaughnessy wrote to The Lancet to report some fascinating and 
remarkably detailed observations on the blood drawn from cholera sufferers.188 His account 
included a detailed description of reduction in water content, low bicarbonate concentrations, 
and uraemia ‘… where suppression of urine has been a marked symptom’. A few months later, 
Thomas Latta achieved some success with the i.v. administration of a solution of saline and 
sodium bicarbonate to moribund cholera victims in Sunderland. In another detailed letter 
to The Lancet, he provided a fascinating account of the clinical response to fluid therapy.189 
We can trace the history of fluid therapy as modern medicine itself has evolved. Hartmann 
used a modified Ringer's solution to rehydrate children suffering from gastroenteritis in the 
1930s, and by World War II the benefits of i.v. fluid in the treatment of haemorrhagic shock 
were widely acknowledged.190 Four million bottles of i.v. fluid solutions were purchased by the 
US Army during this period.191 The improvement in outcome associated with the use of fluid 
therapy during surgery for combat casualties was subsequently reported during the Korean 
War.192 Improvement in patient outcomes remains the driving factor in fluid therapy research, 
which continues to highlight the importance of choosing the optimal type and dose of fluid for 
each individual patient. 
 
1.7.2.1 Theoretical properties of the ideal fluid 
The concept of the ‘ideal’ fluid is a popular topic for anaesthesia teaching and examinations. 
The acute illness will determine the nature of the fluid lost, from whole blood to almost pure 
water. Thus, the ideal fluid will also vary from patient to patient, a fact not well understood 
by doctors who seek a one-size-fits-all formulation for fluid therapy. The ideal resuscitation 
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fluid should remain within the intravascular space for several hours. The chemical composition 
should be similar to that of extracellular fluid, and any constituents should be readily 
metabolised and excreted by the body. The fluid must be safe, sterile, and not prone to cause 
allergic reactions, organ toxicity, or other side-effects. From a practical perspective, we may 
also want the fluid to be easy to transport and store, easy to administer, and modestly priced. 
The reader will appreciate that no such fluid yet exists. 
 
1.7.2.2 Crystalloid solutions 
Crystalloids have traditionally been categorised as hypertonic, isotonic, and hypotonic 
solutions to contrast their composition with that of plasma. Most hypertonic solutions in 
common use have a slightly higher osmotic load than plasma, with the exception of hypertonic 
saline solutions used in neurocritical care to control elevated intracranial pressure. 
Hartmann's and similar balanced solutions are widely used in anaesthesia and critical care, 
although saline 0.9% is also popular in many countries. The choice of saline 0.9% is debated 
by many because the high concentrations of sodium and chloride (154 mmol litre−1) lead to 
salt overload and hyperchloraemic acidosis.193, 194 This may also occur less frequently with any 
solution containing supraphysiological doses of electrolytes, including several popular colloid 
solutions. At present there is only circumstantial evidence that this phenomenon leads to 
permanent harm.153 
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1.7.2.3 Colloids 
Many different i.v. colloid solutions, with a diverse range of properties, have been developed 
for clinical practice though most are no longer used in clinical practice. Human albumin 
solution, hydroxyethyl starch, and succinylated gelatins are the only types of colloid solutions 
still in widespread use, and their clinical value is hotly debated. The CHEST and 6S trials have 
provided very high-quality data on the effects of hydroxyethyl starch in critically ill patients.195, 
196 Both trials included two active treatment arms comparing starch solutions with 
crystalloids, it being unethical to withhold fluid resuscitation as a ‘control’ therapy. Taken 
together, the findings of these trials suggest that starch solutions are associated with an excess 
rate of acute kidney injury requiring renal replacement therapy, which may lead to a higher 
mortality rate.197 In the USA, hydroxyethyl starch solutions are no longer licensed for use in 
critically ill patients and those with renal dysfunction, whereas they have been completely 
withdrawn in the UK. The European Medicines Agency has permitted ongoing use of these 
agents to treat haemorrhage in surgical patients and victims of major trauma. A systematic 
review did not identify any excess mortality associated with hydroxyethyl starch solutions in 
surgical patients, but did not suggest benefit either.198 Multicentre trials are planned to 
confirm the safety of these solutions to treat haemorrhage in surgical and trauma patients, 
but many clinicians are sceptical of this strategy. Succinylated gelatins are not available in all 
countries because of data suggesting a high incidence of anaphylaxis.199 However, in one 
recent major trial of GDT there were no reported instances of anaphylaxis despite widespread 
use of these solutions within the trial.200 We are not aware of any recent major studies 
specifically evaluating gelatin solutions,201 but given the general concern about harm from 
colloid solutions, there may be limited equipoise for the pragmatic trials needed to confirm 
safety and effectiveness. 
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The use of albumin is better supported by published clinical trial evidence. The SAFE trial 
confirmed that albumin 4% was equivalent to normal saline in terms of safety and clinical 
outcomes amongst critically ill patients, and the ALBIOS trial demonstrated no difference in 
survival rates amongst patients suffering from severe sepsis and septic shock.202 The updated 
Cochrane systematic review of trials of albumin solution still includes a very heterogeneous 
selection of trials, many of which are small and methodologically poor.203 This review includes 
trials from the 1970s with potentially significant bias, and consequently, we would not 
recommend basing clinical practice on its findings. 
 
1.7.2.4 Restrictive versus liberal fluid management formulae 
The stress response to surgery, trauma, or critical illness will result in salt and water 
retention.143 Such patients should therefore receive lower doses of maintenance fluid during 
the period of this response. Anecdotal evidence suggests that most patients receive more fluid 
than they need. A ‘restrictive’ approach to fluid therapy is therefore an attractive concept. 
There is an extensive literature comparing restrictive and liberal fluid regimens during and 
after surgery, but with inconsistent findings.182 Much of this apparent contradiction can be 
explained by differences in the fluid algorithms used. Regimens described as restrictive in one 
trial will meet the definition of liberal in another. Most algorithms were developed from 
expert opinion and not experimental observation, but the opinions of experts may be 
prejudicial and often vary widely. The major limitation of current restrictive fluid algorithms is 
that they combine fluid maintenance and resuscitation into a single algorithm based on body 
mass. The prescription of maintenance fluid is very simple and should indeed be determined 
by body mass. However, the optimal dose of resuscitation fluid will have a weak relationship 
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with body mass and should primarily be determined by physiology. Nonetheless, the concept 
of a restrictive approach to fluid therapy is valuable, and UK guidelines on postoperative fluid 
maintenance therapy promote this approach.204 
 
1.7.2.5 Closed-loop fluid administration 
An interesting emerging technology in this field is the ‘closed-loop’ automated fluid 
management system, which uses computer software to interpret haemodynamic physiology 
on a second-by-second basis to determine the optimal rate of fluid administration.205 Such 
technologies have passed the proof-of-concept stage and are now being tested in clinical 
trials. Patients may receive comparable amounts of fluid when driven by a closed-loop system, 
whilst spending more time in the optimal haemodynamic target zone.206 This is a promising 
development but comes with the caveats that should accompany all innovative technology. 
The evidence base requires to be established in small explanatory and efficacy trials to allow 
rigorous safety testing before being subject to a large pragmatic trial to allow an assessment 
of the effectiveness of this concept in clinical practice. 
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Table 1.3 Fluid Therapy Guidance 
Based on the National Institute for Health and Care Excellence guidelines and statement from the 
International Fluid Optimization group. *No definitive haemodynamic end point has been identified. 
Most algorithms state either cardiac output or stroke volume end points, although dynamic parameters, 
such as pulse pressure variation, have been used 
 
 
Type of Fluid Maintenance dose Resuscitation dose Reported  
side-effects 
 Intraoperative Postoperative Intraoperative Postoperative 
 
 
 
 
Saline 0.9% 
 
 
 
1ml kg-1 h-1 
 
 
1ml kg-1 h-1 
200 -300 ml bolus 
 
Titrate to 
haemodynamic 
endpoint* 
200 -300 ml bolus 
 
Titrate to 
haemodynamic 
endpoint 
 
 
 
Hyperchloraemic 
metabolic acidosis 
 
Hypernatraemia 
 
 
‘Balanced’ 
solutions 
 
 
1ml kg-1 h-1 
 
 
1ml kg-1 h-1 
200 -300 ml bolus 
 
Titrate to 
haemodynamic 
endpoint 
 
200 -300 ml bolus 
 
Titrate to 
haemodynamic 
endpoint 
 
 
 
Hypernatraemia 
 
 
Hypotonic 
solutions 
 
 
 
1ml kg-1 h-1 
 
 
1ml kg-1 h-1 
 
 
Not recommended  
 
 
Not recommended  
 
 
Hyponatraemia 
 
 
Gelatin-based 
colloids 
 
 
 
Not 
recommended 
 
 
Not 
recommended 
200 -300 ml bolus 
 
Titrate to 
haemodynamic 
endpoint 
 
200 -300 ml bolus 
 
Titrate to 
haemodynamic 
endpoint 
 
Anaphylaxis 
 
Others related to 
carrier fluid 
 
 
 
Starch-based 
colloids 
 
 
 
Not 
recommended 
 
 
Not 
recommended 
200 -300 ml bolus 
 
Titrate to 
haemodynamic 
endpoint 
 
200 -300 ml bolus 
 
Titrate to 
haemodynamic 
endpoint 
 
Nephrotoxicity. 
Coagulopathy. 
Others related to 
carrier fluid 
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1.7.2.6 Challenges of fluid research 
Some commentators debate the value of large multicentre trials, which frequently fail to 
confirm the clinical effectiveness of study treatments. This may be because of the numerous 
challenges of designing and completing a trial to provide high-quality data. Clinical trials of 
fluid therapy are very heterogeneous because they are designed to answer different questions 
in different patient populations. Trials use a variety of clinical outcome measures, from safety 
end points and explanatory mechanisms through to patient-centred outcomes, such as 
morbidity and mortality. It is often difficult to identify a simple well-defined population who 
may benefit from the fluid treatment in an easily measurable way. The indications for fluid, 
and its dose, are almost always subjective, making the trial intervention hard to standardise 
and adding further variability. This is a particular problem when so many randomised trials of 
i.v. fluid therapy have been conducted in only one hospital, where clinical practice may not 
fully reflect wider international standards. These differences can make comparison of studies 
difficult. In many instances, however, randomised trials have failed because the researchers 
failed to pose a relevant question or design a trial appropriately to answer it, or both. Our 
understanding of the purpose of large trials may also be poor. The purpose of clinical 
effectiveness (or pragmatic) trials is to balance the benefits of a treatment that has shown 
promise in smaller efficacy (or explanatory) trials with the practicalities of widespread use in 
the clinical environment. It is therefore very important that we do not progress to large clinical 
effectiveness trials until efficacy trials have established a sound biological basis for our 
treatment strategy in a given patient population. Clinical effectiveness trials must focus on a 
small number of clinical outcomes that may realistically be modified by the study treatment 
and are of direct relevance to patients. Clinical effectiveness trials are not designed to extend 
knowledge into new areas but to enhance the acuity of clinical evidence on an existing 
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question. Well-conceived and well-designed clinical effectiveness trials improve patient care 
regardless of findings; they prove the value of some treatments, demonstrate the marginal 
benefit and hence lack of utility of others, and confirm the importance of harms that were 
previously thought insignificant. The findings of successful multicentre trials may deliver more 
value than excitement. 
 
1.7.3 The uncertainty about the use of inotropes in GDT algorithms 
In initial trials of GDT, the use of inotropes was required to achieve the pre-specified 
haemodynamic targets in the algorithm but when those targets were shown to be potentially 
harmful many GDT algorithms used fluids only, aiming to optimise fluid therapy to improve 
outcomes.41 There is evidence both for and against inotrope use though a meta-analysis in 
2008 suggested that the use of a fixed low dose of the inotrope dopexamine was beneficial.164 
Many studies have thought this to be a class effect of the beta agonism and have used other 
inotropes such as dobutamine and adrenaline in their GDT algorithms.207 Adrenaline has fallen 
out of use in GDT algorithms as one RCT used a double blind infusion of dopexamine versus 
adrenaline in their treatment arm with the dopexamine treated patients showing improved 
outcomes.42 The use of high dose inotropy was not associated with any benefit and was 
thought to be potentially associated with harm and is no longer used in GDT algorithms.67, 164 
Further studies examining GDT have shown benefits related to the use of an inotrope in terms 
of oxygen delivery and reduction of inflammation and the benefit of using the inotrope may 
not just be in the increase in cardiac output.208 
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1.8 Compliance 
1.8.1 Compliance 
A major barrier to the introduction of GDT is the lack of agreement as to what constitutes goal 
directed therapy, when it should be delivered and who it should be applied to. This lack of 
consistency means that the literature covering goal directed therapy does not have a defined 
protocol, patient group or delivery time or method.207 Comparing the literature and drawing 
conclusions about the benefits or harms of GDT becomes very difficult. Sandham et al is often 
quoted as the largest study of GDT but it did not have a predefined intervention based on 
cardiovascular variables rather suggestions of fluid loading, inotropic and vasopressor therapy 
to achieve pre-specified indices.98 This paper highlights a major issue on large pragmatic trials 
of complex interventions that have to allow a certain degree of clinical discretion, as a protocol 
that attempted to cover every scenario would be very large and difficult to follow. Most 
pragmatic trials attempt to mirror a ‘real life’ situation where there are a clear standards of 
care set out that are simple and every physician will be comfortable in delivering. This leaves 
large pragmatic randomised controlled trials open to criticism as the best way to measure the 
effectiveness of complex interventions as they can fail to measure all variables that may 
contribute to the success or failure of the treatment.209, 210 In the Sandham trial the lack of a 
clear protocol and target of a specific cardiovascular variable left too many variables for 
individual clinicians to aim for, resulting in a trial of many GDT protocols rather than one GDT 
protocol. There is a requirement to study the effectiveness of a GDT protocol that can be 
compared against usual care (i.e. a protocol that does not involve the specific targeting of 
cardiovascular variables) to see if there is an improvement in patient outcomes.211 If an agreed 
GDT algorithm can be established and be shown to improve patient outcomes then it becomes 
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feasible to compare one GDT algorithm against another GDT algorithm to establish the 
superior algorithm. However, until we have established that GDT is an effective therapy for 
high risk surgical patients there is little point in testing one algorithm against another.  
 
1.8.2 Compliance to algorithms 
The lack of consistency in the GDT algorithm used is another barrier to the introduction of 
GDT, as it has the potential to lead to poor compliance to any GDT algorithm.211 Compliance 
to any algorithm or pathway decreases the more complex it becomes.212 GDT is a complex 
intervention and it is not possible just to simplify the algorithm. Measurement of compliance 
is important to establish if the algorithm proposed is intuitive and easy to follow as this should 
reflect whether it can be successfully adopted on a wider scale.213, 214 The likely compliance to 
trial algorithms in clinical practice is difficult to estimate from the trial setting. For the duration 
of the trial, governance is set up to strive for 100% compliance rates which is difficult enough 
in the trial setting and near impossible in clinical practice.215 Therefore, any trial should record 
the reasons for non-compliance within the study and extend this if possible to the potential 
study group as to the reason they were not included. If large groups of patients refuse this 
may be because of the of unpalatable nature of the intervention, if there is an increased rate 
of clinician refusal this may reflect the difficulty in delivering the intervention, similarly if the 
patient is not randomised due to a lack of staffing or equipment resource. The reasons given 
will inform any retrospective study of compliance in clinical practice and inform future trials 
of complex interventions about how likely the complex intervention studied will translate well 
into clinical practice. There is very little published literature on the expected compliance rate 
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in clinical practice for a complex intervention but a lack of compliance within in a trial setting 
suggests it would be difficult to deliver effectively in clinical practice.215 
 
1.8.3 Potential Harm of Goal Directed Therapy 
Further concerns are raised over the risk of injury to the patient from the protocol itself. By 
increasing myocardial workload to achieve these haemodynamic goals does GDT risk inducing 
myocardial ischaemia especially in those known to be at risk of myocardial injury. Gattoni et 
al demonstrated no benefit to the critically ill patient when pursing the haemodynamic goals 
after organ injury was established.156 Hayes at el demonstrated an adverse outcome when 
using high levels of dobutamine when pursuing these goals.67 Lobo et al showed a reduction 
in cardiovascular complications when using a GDT including inotropes than when using fluid 
alone.184 A meta-analysis of GDT using both inotropes and fluids demonstrated benefit only 
when using either dobutamine or dopexamine and only when the inotrope is used at low dose 
<1mcg/kg/min.164 Challand et al showed that there was potential harm to fitter younger 
patients undergoing major abdominal surgery who received GDT though a more recent study 
has shown benefit in the low to medium risk surgical patient group undergoing major 
abdominal surgery.95, 97 Trials attempting to replicate the findings of the original Rivers trial of 
early goal directed therapy in severe sepsis and septic shock did not demonstrate any 
difference in outcomes.216, 217 Any therapeutic intervention has the potential to cause harm to 
the individual patient and it is important any study identifies and measures the potential harm 
that can be caused. As GDT is a complex intervention there is the potential for harm to be 
caused not only by the intervention but in failure to follow the intervention algorithm and this 
also requires to be quantified.   
 75   
1.9 Mechanism of Goal Directed Therapy  
1.9.1 Mechanism of action 
GDT has also suffered from the uncertainty over its mechanism of action. Recently Jhanji et al 
demonstrated the superior microvascular flow seen in the GDT group that used both fluid and 
inotropes.131 They also demonstrated significantly better tissue oxygenation in the GDT group. 
This improved perfusion theoretically should reduce the risk to individual organs, although 
this study was not powered to show this. Meta-analysis have shown suggested GDT can 
reduce the rate of AKI, infective complications and gastric and cardiac complications within 
the high risk surgical group.86, 218-220 Avoiding organ dysfunction is clearly important in aiding 
the high-risk surgical patient due to their vulnerability and the worsening prognosis when 
organ failure is established. The consensus agreements as to what constitutes organ 
dysfunction are recent and previous differing definitions may influence meta-analyses of small 
studies that are comparing different degrees of organ dysfunction under the assumption they 
are the same. Previous definitions usually relied on a clinical diagnosis which can be very 
subjective and this has led to the use of biomarkers as an objective marker of organ 
dysfunction. Any biomarkers proposed must reflect organ dysfunction that can be seen after 
major surgery though there is not an established specific biomarker to measure every form of 
organ dysfunction. These relevant biomarkers have been measured in the studies utilising GDT 
not only to establish that there is no adverse effect from GDT but also to investigate any 
potential benefit it may offer.  
Biomarkers are now the most commonly investigated way to measure the influence of GDT 
on organ damage or injury. The most significant clinical concern surrounding GDT is the 
potential to induce myocardial damage due to fluid overload and subsequent heart failure or 
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secondary to the tachycardia seen when using inotropes that are also chronotropes. This is a 
well-documented concern in GDT literature alongside the concern over lack of understanding 
of a plausible biological mechanism by which GDT exerts its effect. Biomarker proven benefit 
or harm from a large pragmatic GDT trial will inform any further work studying the mechanism 
by which GDT is seen to improve outcomes. Meta-analyses of GDT studies suggest benefit by 
reducing specific complications namely cardiovascular complications, infective complications, 
acute kidney injury and gastrointestinal complications. 
 
1.9.2 Effects on Cardiac Complications 
CnT (troponin) is a biomarker released in the event of acute myocardial injury though elevated 
levels can be seen in certain chronic conditions.  It is specific and sensitive enough to be used, 
in conjunction with other investigations, in the diagnosis of acute myocardial injury.22 If 
detected in the post-operative period it has been demonstrated to be a prognostic indicator 
for a poor outcome. However, the study investigating the utility of troponin after surgery 
found that patients with raised troponin were not dying exclusively from myocardial related 
injury but rather showed an increase in all-cause mortality.13 Previous studies investigating 
biomarkers after the delivery of a GDT intervention have not shown troponin to be raised in 
the group receiving GDT in comparison to the control group.221 In a sub-study of the OPTIMISE 
trial there was no difference in troponin between those patients who received the 
intervention and those who did not suggesting there is no induced cardiac injury when using 
the OPTIMSE GDT algorithm.222 Similarly, previous studies have seen rises when investigating 
other markers of cardiac injury that could be seen in a failing myocardium including Nt-BNP 
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(brain naturetic peptide) but again this was not demonstrated in the OPTIMISE cardiac 
biomarker sub study.223 
1.9.3 Effects on Kidney Complications 
Meta-analyses of GDT after major surgery suggest a reduction in acute kidney injury (AKI). 
Biomarkers are routinely used to measure kidney injury after major surgery. The most 
common is creatinine which is readily available and is commonly measured as a routine blood 
result. It now forms part of the globally accepted definition of AKI23 which has aided the 
investigation of this perioperative complication. It is associated with increased length of stay 
and long term morbidity and is thought to be a significant contributor to the development of 
chronic kidney disease. A more recent study have not shown any reduction in kidney injury 
from GDT algorithms.224 This study did not show any difference in the amount of fluids 
between the two groups suggesting any previous noted difference may be due to control 
group care rather than a benefit conferred by GDT. The assessment of perioperative AKI by 
more sensitive biomarkers and the effect of GDT on these biomarkers of renal injury awaits 
further investigation. A number of different biomarkers have been identified and are 
discussed in chapter two but the KIDGO criteria remains the consensus choice to identify 
kidney injury. 
 
1.9.4 Effects on Infective Complications 
Meta-analysis of GDT studies have demonstrated a reduction in infective complications.86 Pro-
calcitonin has been used in the intensive care setting to help distinguish between 
inflammation caused by sepsis and inflammation from other causes.225, 226 Only one study has 
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shown any benefit of procalcitonin in detecting early sepsis after non-cardiac surgery and 
larger studies are awaited to demonstrate the usefulness of this finding.227 
Inflammatory markers have been measured in studies comparing GDT groups to the control 
group to ascertain if there is any difference in the inflammatory markers.131 Several markers 
have been measured including Il-1beta, Il-6, and Il-8, Il-10 C-RP and TNF alpha. Noblet et al 
demonstrated a reduction in the pro-inflammatory marker Il-6 in the GDT group but no other 
study has demonstrated any difference between the groups in any of the other biomarkers 
measured.69 The assessment of the reduction of infective complications with GDT after major 
surgery has been shown in small studies but a large pragmatic study looking at the effects of 
GDT is yet to be done. 
 
1.9.5 Effects on Gastrointestinal Complications 
Gastrointestinal complications have also been demonstrated to have been reduced by GDT.220 
One of the early papers that demonstrated the potential methods by which GDT may work 
examined the effects on gut mucosal pH.90 This suggests a biologically plausible mechanism 
by which GDT may protect gut function and integrity. However, in major abdominal surgery 
any impairment of gut function may be related to intraoperative injury, independent of fluid 
therapy given. The return of gut function is frequently measured by first flatus or bowel 
movement which are subjective measurements. Ileus may again reflect gut dysfunction but 
can be difficult to define and there are no available biomarkers to assess return to full 
function. Similarly, to the other postoperative complications that may be improved by GDT 
large scale trials are yet to be undertaken. 
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1.10 Conclusion 
 
There have been many barriers to the implementation of GDT. As with any new therapy it 
initially had a resistance from the established practice but the barriers appear to go beyond 
that. The use of PAC has never been routine out with cardiac surgery and the controversy 
surrounding its benefit to the patient ensured that GDT could never be effectively used bar by 
a number of highly trained proponents within randomised trials. The introduction of less 
controversial, less invasive monitors has allowed the further investigation of GDT in the non-
cardiac surgical patient. The validation of these monitors has been established but there is still 
debate over which haemodynamic variable is the best to target. The type of fluid used in GDT 
has recently been under scrutiny due to the revelations about Boldt’s work in this field and 
the identification of the risk of renal injury from hetastarches. The risk to the patient from GDT 
is a frequently raised concern by clinicians particularly cardiovascular problems. Some studies 
have shown increase risk of morbidity and mortality while using GDT though meta-analyses 
focusing on non-cardiac high-risk surgery have demonstrated reduced mortality or no 
difference in the groups and a reduction in complications. The improvement in microvascular 
flow delivered by GDT has been demonstrated though there appears to be no difference in 
the biomarkers or organ damage outside the cardiac surgical population. Although we seem 
to be clear that GDT reduces complications in the high-risk non-cardiac surgical population 
and improves microvascular flow there remain many questions as to its effectiveness outside 
of a small trial setting, the goals that should be measured and attained, the algorithm best 
used to achieve these goals and the assessment of potential  harm to the patient.  
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Research Aims 
1. To investigate in a pragmatic RCT to evaluate the effectiveness of GDT in a high risk 
non-cardiac surgical population 
2. To investigate the compliance to a GDT algorithm in a pragmatic trial setting 
3. To investigate the sensitivity and specificity of dynamic haemodynamic variables in a 
pragmatic trial setting 
4. To investigate the role of GDT in the prevention of biomarker sensitive AKI  
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CHAPTER TWO  METHODS  
2.1 Methodology 
 
Investigating GDT is difficult due to its many facets. It is a succession of observations and 
interventions all of which influence the potential outcomes. GDT is not a standardised therapy 
and this further increases the degree of difficulty in investigating any barriers in its 
introduction. Consequently, I decided to investigate the barriers to using GDT using the data 
available from the OPTIMISE trial which was the largest randomised controlled trial using a 
singular GDT algorithm. 
The OPTIMISE trial, as the largest investigation of a GDT algorithm in the high risk surgical 
patient generated large data sets that could be examined to try to determine the applicability 
of an algorithm, the applicability of dynamic measures of fluid responsiveness and the effect 
on kidney function during or after major surgery. These studies were pre planned analysis of 
data sets that would be collected during the study. 
 
2.1.1 Goal Directed Therapy as a complex Intervention 
Complex interventions were first acknowledged in a Medical research council paper in 2000 
which went on to describe and define what made an intervention complex.228 This was further 
reviewed in 2008 to update the evidence base and inform researchers based on the 
experience of the past eight years.229 A complex intervention can be defined superficially as 
an intervention with several interacting components all of which are required in order to 
achieve the desired outcome. However, the levels of complexity are difficult to define ranging 
from the number of individual actions to the complexity of a single action. Interventions span 
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across a range of behaviours and systems adding further depth to the complexity that has to 
be understood and tested. Understanding the complexity of the intervention allows for 
successful testing and planning of studies that evaluate such interventions. In complex 
interventions it is important to fully investigate all components and outcomes from the 
intervention as there may be unintended benefits or consequences that were not foreseen at 
the initiation of a trial or study.214 
Recommendations for the methodology behind trial of complex intervention allows for the 
study to examine a primary outcome but also gather data on a number of secondary outcomes 
that are thought to be relevant. There are a number of ways to gather information on complex 
interventions. Ultimately randomisation of the intervention versus a standard control is 
preferable but is not always practicable in trials of a complex intervention.230, 231 This may be 
due to large scale implementation or that the intervention is applicable to a large number of 
the population immediately. In these circumstances observational study design can be used 
but the implications of the findings are limited. Randomised clinical trials are preferred for the 
evaluation though the design of these may vary depending on the most practicable way of 
investigating the intervention. 
GDT is a complex intervention as defined by the MRC and therefore has many factors in its 
delivery that may affect the outcome for the patient. The complexity arises from the 
interpretation of cardiovascular variables and the decision-making process to assess the 
specific intervention required to suit the patient.  
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Figure 2.1  Hierarchy of Evidence  
 
The hierarchy of evidence pyramid showing the weakest to the strongest evidence that is used in 
evidence based medicine 
 
2.1.2 How to study a complex intervention? 
The complexity of the intervention makes it difficult to study the impact of the intervention 
and raises the questions of the individual impact of the components of the intervention. Two 
ways to study complex interventions have been suggested.232 The first is to break down the 
complex intervention into its components and study them individually. This has the advantage 
of identifying any benefits of harms caused by the components but may miss the marginal 
gains effect of combining all of the components leading to the conclusion that they do not 
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benefit the patient. The second is to study the intervention as a whole utilising an inclusive 
approach. The advantages and disadvantages of the previous approach are reversed though 
similar. The second approach is usually favoured as the individual components would not be 
included in a complex intervention unless they are known to be safe though they may not 
have been proved beneficial. The second approach also allows for the intervention to be 
tested in a practical setting. It can examine the logistics involved in the set-up, the ability to 
deliver the intervention, and the effects and pressures it may introduce or relieve in a given 
healthcare system. The introduction of carbohydrate drinks within an ERAS programme is a 
good example. There is a plausible explanation as to why these drinks would be beneficial to 
the patient but as a singular intervention they do not appear to improve outcomes.233 
However they are associated with improved outcomes as part of an ERAS programme.234 
Complex interventions such as GDT are best trialled in large, pragmatic trials that have the 
scope to examine a range of identified outcomes of the specified trial population. This helps 
eliminate the potential bias of meta-analysis that consist of small, single centred trials that 
underpin the evidence base. In addition they can provide a useful practical bridge to a more 
widespread adoption of the intervention in clinical practice not only in the evidence base but 
by informing service and quality improvement programmes required to introduce such 
interventions.229  
 
2.1.3 Observational study 
The observational study can be used to evaluate a complex intervention though as it is not a 
randomised allocation the interpretation of the results is limited compared to a RCT. 
Observational studies are very practicable and easier to perform than RCTs and are usually 
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less expensive. In these studies, the independent variable is out with the control of the 
research group. The most commonly used observational study for complex interventions is 
the cohort study where the comparison is between two similar groups who have either 
received or not received the intervention.230 Cohort studies rank in the middle of the hierarchy 
of evidence and therefore are useful tools to change practice but these results should be , if 
possible, confirmed in RCTs. In the case of a cohort study of GDT it would be feasible to follow 
up patients based in whether they did or did not have the intervention and a number of 
dependent variables such as mortality or a defined morbidity. However it is likely there would 
have been a large amount of selection bias and it may not have been clear if the intervention 
was available to all who were included in the study.235 Even if other variables had been 
standardised (staff availability, algorithm) this approach only allows an association of benefit 
or harm to be drawn from the study not that GDT was the cause of the measured outcome. In 
the methodology for studying GDT observational studies would not have been appropriate to 
assess the effectiveness of GDT. 
 
2.1.4 Retrospective evaluation 
Recently some complex interventions have been evaluated with a retrospective evaluation 
technique where the impact has been measured through the use of large data sets and 
comparison to previous matched groups. Large data sets or ‘big data’ has gained a lot of 
traction in the medical literature especially in the evaluation of complex interventions and 
health systems.236 These data sets take advantage of the increasing use of electronic health 
records to tease out population data sets that identify improvements in care with complex 
interventions. Retrospective evaluation is a very important tool to examine changes in any 
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population but similarly to other observational studies can only infer not confirm the reasons 
for any changes observed.235 This makes the retrospective evaluation important particularly 
for hypothesis generating and for the governance and impact evaluations of new interventions 
or changes when they are rolled out at a regional, national or even international level. 
However, this particular method is not appropriate to evaluate the efficacy or effectiveness 
of a complex intervention as it can only provide retrospective observational data without 
randomisation. This does not account for significant bias that would be encountered nor 
control for, or measure the confounding factors associated. In the case of GDT as a complex 
intervention it would be very difficult to define GDT as a single therapy and measure the 
compliance to all aspects of the complex intervention. Although GDT has an evidence bas that 
shows it is safe and efficacious and has already been adopted at some centres throughout the 
country it would be very difficult to draw any conclusions regarding the effectiveness of GDT 
from an approach that uses retrospective evaluation. 
 
2.1.5 The Randomised controlled trial 
The randomised control trial (RCT) is considered a high quality level of evidence that is the 
foundation on which to confirm or change medical practice. RCTs are near the top of the 
evidence based medicine hierarchy pyramid and a very important factor in evaluating the best 
practice for our patients. The combination of RCTs in a robust meta-analysis is the pinnacle of 
the hierarchy pyramid and forms the most compelling argument to implement their outcome. 
However the meta-analysis is only as strong as the RCTs they contain and therefore the 
individual RCT must be robustly designed to answer the particular study question.237 As with 
observational studies there are many different variations in the designs of RCTs and they can 
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be categorised into several different types depending on the explored outcome. RCTs can be 
designed to explore the efficacy or the effectiveness of an intervention. As previously stated, 
the evidence base for GDT rested on a number of small single centre studies that prove the 
efficacy of the intervention. This demonstrated that GDT works in very specific conditions 
usually in a very specific patient group in the hands of highly invested physicians.42, 44, 46, 68, 69, 
90 These explanatory trials are very important in establishing the principle of GDT but still 
leaves unanswered questions over the effectiveness GDT and the ability to replicate these 
results on a regional, national or international basis. The answer to the effectiveness of GDT 
is important as it will influence local and national guidelines in the treatment of high risk non-
cardiac surgery. There are no large randomised controlled pragmatic trials looking at the role 
of GDT in non-cardiac surgery. Previous large trials have not had a specific algorithm to 
compare the ability of a cardiac output monitor to guide GDT.98 These large pragmatic trials 
required to be designed carefully to allow physicians to explore the utility of interventions that 
are efficacious in small trials and evaluate their effectiveness. 
 
2.1.5.1 The Pragmatic clinical trial 
The pragmatic clinical trial is a term used to describe a specific type of RCT. Their specific 
purpose is to bridge the gap between the highly specialised explanatory RCTs, to translate that 
knowledge into a practicable and actionable evidence base for clinicians.238 The number of 
pragmatic RCTS has been growing through the last three decades  as evidence suggested very 
few RCTs were changing medical practice.239 Explanatory RCTs are most commonly done in 
highly specific circumstances and therefore the commonly seen drop in effectiveness when 
the intervention is used in everyday practice is used as a reason not to implement any 
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change.240, 241 Pragmatic RCTs should fulfil a number of criteria.239 They should be designed to 
demonstrate the effectiveness or not, of the particular intervention allowing the intervention 
to be introduced into everyday care. The design should not only consider the specifics of the 
intervention, but the practicality and logistics of introducing the intervention and the 
economic and personnel  burden that will have on the organisation or organisations that have 
to introduce it. This collaboration with patients, physicians, medical management and policy 
makers should ensure that the intervention is deliverable if desired, and also that it is an 
intervention that is useful, wanted, understood and financially viable within the health care 
system.242 The explanatory and pragmatic trial are not entirely separate entities but rather 
encompass a scale of what an RCT can deliver.243 The design of any RCT investigating a complex 
intervention such as GDT is vital to ensure its success. There are a number of different RCT  
designs that can be employed to evaluate a complex intervention. 
 
2.1.5.2 RCTs to examine complex Interventions 
The vast majority of RCTs can be described as individual RCTs as they compare two treatments 
between similar groups of patients. The main principle of an individual RCT is to try to match 
the groups aiming to minimise the chance of any confounding factors causing a false finding. 
This approach has been criticised by those undertaking pragmatic RCTs. The criticism relates 
to the very tightly controlled nature of both groups allowing circumstances to arise which are 
not applicable to ‘real world’ scenarios244. This can lead to the introduction of interventions 
into common practice which are actually not effective and potentially harmful to patients. This 
criticism is particularly pertinent to complex interventions which can be shown to work under 
highly specific circumstances but not be achievable at all in normal conditions. In order to 
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address this there are suggested different designs of RCTs with which it may be appropriate 
in investigate complex interventions.245  
 
2.1.5.3 Individual RCTs 
Despite the criticism around individual RCTs it remains the gold standard tool to investigate 
complex interventions. A robust trial design specifically including the elements described in 
the pragmatic trial design allows for a significant majority of the confounding factors to be 
accounted for and assessed in the conclusion of the trial. The methodology used allows the 
acknowledgment of the many variables that may be encountered while trying to deliver a 
complex intervention in the health care system. Some have argued that this makes the trial 
conclusions more applicable in the ‘real world’ scenarios in which they will be expected to be 
effective.244 However, the less control over variables or confounders the more likely an error 
is to occur. An alternative to tightly controlling the tested population to reduce the risk of type 
one or type two error is to increase the sample size as any other way of reducing the risk of 
one error increases the risk of the other error occurring and for any given test. This why most 
pragmatic individual RCTs require large numbers to be recruited making them more 
expensive.209 
 
2.1.5.4 Cluster RCTs 
Cluster RCTs  are increasingly being used to trial complex interventions.246 Previously cluster 
RCTs were most commonly used in examining interventions at an institutional or societal 
level however it can be used to study complex interventions at an individual patient level.247 
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This RCT methodology has some advantages over individual RCTs specifically when the 
complexity of the intervention may mean that not all individuals are not receiving the same 
treatment. This is particularly important in studies utilising algorithms to determine the best 
treatment choices for the patient. They can also prevent contamination between the groups 
in the case of GDT a physician deciding that they like or dislike the algorithm and then 
overtly or even subconsciously employing or not employing it in the opposite group.248 The 
major drawback of using cluster RCTs is the complexity of the statistical design of the study. 
Comparisons between individuals or institutions are difficult to assess usually requiring 
hierarchical linear models to test the hypothesis.241 Typically these types of RCTs require 
more patients to achieve a similar statistical power. A cluster RCT of GDT would be more 
difficult and expensive to undertake then an individual RCT of GDT and would not give a 
more conclusive answer. In addition due the complexity of the trial proposed and the 
potential refusal of individual clinicians and patients it may be more difficult to draw 
definitive conclusions regarding the effectiveness of GDT.249 
 
2.1.5.5 Stepped Wedge RCTs 
The stepped wedge RCT is similar to the cluster RCT and only differs in that the intervention 
is commonly introduced in a timed manner.250 This type of trial is usually undertaken when 
training resources or infrastructure are insufficient to introduce the intervention 
simultaneously. The disadvantage of this design is that time is another confounding factor in 
assessing the impact of the intervention. While the influence of time has to be accounted for 
in both pre and post-trial analysis initially there was no consistency in how to do this in these 
types of trials.251 More recently there has been a general consensus published on how this 
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should be done increasing the utility of the stepped wedge RCT.250 In a complex intervention 
aimed at and delivered by an individual such as GDT the ‘wave’ nature of the introduction on 
the intervention has the potential to bias the rest of the study groups involved.252 It would 
also suffer from the same potential confounders and bias in other types of cluster RCTs and 
although these trial designs are being increasingly used it would not deliver a conclusive 
answer about the effectiveness of GDT. 
 
2.1.6 Preference/Randomised consent 
The preference RCT or randomised consent design is a methodology designed to overcome 
the bias of an individual’s preference. In this scenario either a patient or clinician has decided 
which treatment arm of the trial they would prefer to be in and therefore are unable to be 
randomised as they would not accept the alternative. Missing out on a number of eligible 
patients has the potential to bias the results and therefore the preference RCT has been used 
in the investigation of complex interventions. By including these patients alongside those 
patients who have agreed to be non-preferentially randomised this should add to the study 
potentially giving four groups those randomised into the treatment arm, those who prefer the 
treatment arm, those who are randomised into the control arm and those who prefer the 
control arm (figure2.2). However, the data and outcomes of those not randomised should be 
treated as observational study data and strong conclusions should only be drawn from the 
data of the groups who were randomised. This means it functions as an individual RCT though 
the observational data capture may go some way to informing the overall conclusions of the 
study. It is unlikely that there will be true equipoise for every patient and clinician in any RCT 
let alone in a complex intervention and this would probably be the case for any trial of GDT.253 
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An observational study which would not be conclusive in addressing the question of the 
effectiveness of GDT would not be a cost-effective way to study the intervention. An individual 
RCT should note the reason for an eligible patient not being included in the trial. 
 
Figure 2.2 Preference RCT flow chart 
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The preference RCT flow chart in which patients are still included in the randomisation if they express 
a preference for which treatment are they are to be in. Those not expressing a preference are 
randomised. 
 
2.1.7 N of 1 designs 
The N of 1 design trial is used to evaluate complex interventions using a single patient. They 
can be randomised into determining which order this patient undergoes the intervention or 
the control. They were introduced to overcome difficulties in gathering and interpreting large 
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data sets associated with group comparisons.254 They most commonly use the withdrawal 
technique in which the patient’s baseline is measured the treatment is then introduced and 
then withdrawn. The presence or absence of the disease during the treatment phase is then 
used to draw conclusions over the efficacy of the treatment.255 The single patient nature of an 
N of 1 trial design would not allow conclusions to be drawn on the effectiveness of GDT in a 
specific surgical population.254 
 
2.1.8 Conclusion 
The individual pragmatic RCT is the best way to measure the effectiveness of GDT. It allows 
for standardised definitions of GDT, of the patient group and of their treatment during the 
trial period. The large sample size reduces the risk of statistical error and the recording of 
potential confounding factors ensures that any statistical anomalies can be acknowledged in 
the conclusions. It avoids the difficulties and larger numbers associated with cluster RCTS and 
the potential increased costs of a preference treatment RCT. 
 
2.2 OPTIMISE trial 
The OPTIMISE trial was the largest study of GDT in a specified a homogenous high risk surgical 
population.200 I became involved in the OPTIMISE trial after the Delphi consensus of the best 
GDT algorithm but prior to the start of recruitment. I was involved in the conduct of the trial 
at the Royal London Hospital which recruited 189 patients. In this capacity I organised the rota 
of research nurses in the screening of eligible patients and the recruitment of patients in the 
pre-operative assessment clinic, the electronic randomisation of patients. I was the point of 
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contact for the study within the anaesthetic department of the hospital. The equipoise within 
the department was very variable and I presented the study at a number of different audit 
days and departmental meetings to explain the rationale behind it. During the trial the Royal 
London Hospital merged with another local trust, Newham General Hospital, and I was able 
to help set up another trial site which recruited a further 35 patients into the study. For this 
role I recruited an anaesthetic consultant to be the principal investigator, helped fill in the 
IRAS forms and open the site for recruitment and organised the junior anaesthetic staff into a 
rota to ensure the protocol could be delivered to the patients recruited to the trial. I took part 
in several trial phone conferences and designed a dopexamine aid that allowed a quick and 
easy rate calculation for the delivery of dopexamine in its various doses. In addition to 
delivering the intervention myself I was responsible for the follow up of the patient on the 
critical care unit and then the ward as well as the phone calls to the patient or their families 
and general practitioners if required. The phone calls required to be completed in a timely 
fashion and required a rolling timetable to maximise chances of a successful follow up phone 
call. This data was collated on a 30 day follow up sheet which was presented to a consultant 
blinded to the patient’s allocation for them to determine if any of the criteria to diagnose a 
complication had been met and how serious the complication was on the Clavien-Dindo 
scale.24 This data then had to be faithfully transcribed into the CRF and onto the electronic 
database. I was responsible for the governance of this system at the Royal London and 
Newham sites.  
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2.3 Principles of direct cardiac output measurement 
The Fick principle was initially used to measure cardiac output demonstrated by Klein and then 
refined by Cournand.256 It is considered the gold standard to measure cardiac output but due 
to the difficulty sampling blood at the appropriate points it has largely been replaced by other 
methods. The ability, accuracy and precision of these methods is important to establish as 
doubt over the monitor used in a GDT algorithm could be a significant barrier to the 
introduction of GDT. 
 
Figure 2.1  Demonstration of Fick Principle and equation 
 
The Fick principle which allows the calculation of flow based on oxygen concentration difference and 
the rate of oxygen consumption 
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2.3.1 Pulmonary artery catheters 
The pulmonary artery catheter (PAC) was developed in the 1970s and its use increased 
throughout the 1970s and into the 1980s.62 The PAC consisted of a catheter that was designed 
to be inserted via a large vein usually the internal jugular, subclavian or femoral vein. The 
initial part of the catheter stayed in the venous system but a further catheter could be 
advanced through the right atrium and tricuspid valve into the right ventricle and allow the 
measurement of right ventricular pressure. The catheter could be further advanced through 
the pulmonary valve and then ‘floated’ by means of an inflated balloon at the tip into a 
‘wedge’ position in the pulmonary vasculature. This allowed the pulmonary occlusion pressure 
or ‘wedge’ pressure to be measured.  
The introduction of a thermistor allowed the measurement of cardiac output by the 
thermodilution technique (TDT).63 This technique consists of the injection of a known quantity 
and temperature of water at the CVP tip into the right atrium and then the measurement of 
the change if temperature at the thermistor at the tip of the pulmonary vasculature catheter. 
It is important to inject at the same point during the respiratory cycle due to the variations 
seen in cardiac output in inspiration and expiration. From these changes in temperature a 
thermodilution profile is obtained. This is averaged over a number of attempts and the cardiac 
output is calculated from the measurements. The PAC can directly measure a large number of 
haemodynamic variables including cardiac output and pulmonary artery pressure and can 
indirectly measure some others including systemic vascular resistance (SVR) and oxygen 
delivery (DO2). As it directly measures cardiac output it is less affected than other monitors in 
low output states and in the presence of arrhythmias.  
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Figure 2.2 Insertion of a pulmomary artery catheter through the right side of the heart 
 
 
ECG = electrocardiograph, PAP = pulmonary artery pressure, PAWP = pulmonary artery wedge 
pressure 
 
The PAC was the first monitor that would allow objective measurement of a number of 
different haemodynamic variables that would be able to be manipulated by the clinician. It 
was with the pulmonary artery catheter that observation was made that the patients with 
severe abdominal sepsis who could increase their cardiac output in response to a septic insult 
had a much lower mortality. It was from this first observation that studies were performed 
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that appeared to identify haemodynamic goals that, if attained, suggested the patient was 
more likely to survive. These were used in trials of goal directed therapy and showed 
improvement in both mortality and morbidity in a high risk surgical patient groups.40, 41   
 
Figure 2.3 Measurement of cardiac output using indicator dilution method 
 
A known amount of a stable indicator is injected into the body and measured at a point distant from 
the injection site creating a concentration curve. The area under the curve is then used to calculate the 
cardiac output. 
 
There was debate over the safety of the PAC monitors at the introduction of GDT however the 
only monitor available that was able to measure the required haemodynamic variables was 
the PAC. This monitor has been validated but has significant risks associated with the insertion 
and maintenance of the invasive lines required.257 Some felt that the associated risks of the 
PAC did not outweigh the potential benefits including GDT in a significant proportion of the 
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surgical population. It was not a monitor in routine use and required at least critical care level 
2 and usually critical care level 3 for post-operative care. Connors et al conducted a trial 
suggesting that the PAC caused harm to the critically patients in which it was used.258 More 
recent studies by Sandham et al and the PAC-Man trial demonstrated that there was no 
difference in outcomes in those surgical and critically ill patients who received a PAC and those 
who did not.98, 259 The PAC changed the way that fluid was given in surgical patients and gave 
objectively assessed haemodynamic goals to be achieved for patients undergoing major 
surgery. However, there were still significant risks associated with the insertion of the PAC and 
less invasive methods would be preferable to measure cardiac output and associated 
haemodynamic variables.  
 
2.3.2 Less invasive cardiac output monitoring 
The advent of less invasive cardiac output monitors (utilising Doppler flow, bioimpedence and 
pulse pressure analysis amongst others) allowed further investigation of GDT by avoiding the 
argument of the potential harm caused by the PAC. Doppler flow, bioimpedence and pulse 
pressure analysis have been validated as ways of measuring the cardiac output.260 This 
validation allowed for the randomised controlled trials that measured the efficacy of GDT. 
Despite this validation, the accuracy of these monitors has been questioned in relation to the 
objective haemodynamic variables measured by the PAC261 though the PAC has been recently 
questioned as the gold standard with which to compare less invasive cardiac output 
monitors.262 
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2.3.3 Measuring cardiac output using the Doppler effect 
The Doppler effect describes the change in frequency of sound waves as an object changes 
position first observed by Christian Doppler in 1845. The Doppler effect is most used in 
medicine in the measurement of flow, particularly echocardiography. Echocardiography was 
first used medically to diagnose mitral valve disease and although not adopted immediately 
techniques were developed to measure blood flow using the Doppler effect though images of 
the heart were first seen via ultrasound in the 1970s and transoesophageal echography (TOE) 
was also established.263-265 TOE is not used widely outside of cardiothoracic surgery in the 
measurement of flow and is currently most commonly utilised for assessing heart valve 
placement. There has only been one study of GDT in non-cardiac surgery using TOE as the 
cardiac output monitor showing a reduction in perioperative fluid administration.266 This is 
likely due to the non-routine use of TOE in non-cardiac surgery and the lack of required 
expertise of non- cardiac anaesthetists in using the TOE. The insertion of a TOE is associated 
with morbidity and even mortality from potential damage and rupture of the oesophagus so 
there should be some caution regarding its use.267 The development of the oesophageal 
Doppler cardiac output monitor uses the same principles as the TOE but does not provide a 
visualisation of the heart as the TOE does. It is a much smaller probe and so reduces the risk 
of oesophageal injury with insertion. It consists of a straight probe with an angular surface the 
emits a four megahertz (MHz) continuous wave. The probe is placed in the mid-oesophagus 
principle is to focus the Doppler beam on the descending aorta and measure the velocity of 
blood through it. The probe has a receiver within it and based on the Doppler principle of 
altered frequency proportional to the change in velocity and is therefore able to calculate the 
speed of blood as it travels down the descending aorta in systole. Using a nomogram it is 
possible to derive an accurate stroke volume for the patient by inputting the appropriate 
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demographics. The nomogram calculates the diameter of the descending aorta and an 
assumption about the proportion of the stroke volume that enters the descending aorta. The 
stroke volume, cardiac output and cardiac index can then be calculated. The oesophageal 
Doppler also measures the flow time, that is the time from the opening to the closing of the 
aortic valve, and the corrected Flow Time (FTc) which is the flow time adjusted for a heart rate 
of 60 bpm. The ejection time multiplied by the average velocity gives stoke distance which 
when multiplied by the aortic constant (the aortic cross-sectional area) gives the stroke 
volume. As the derived measurement is stroke volume the other dynamic variable that is 
measured is SVV rather than PPV.268 The newer versions of the Deltex ODM have a secondary 
pulse contour analysis function that allows the derivation of stroke volume and cardiac output 
by calibrating the original Doppler reading against the arterial waveform. They do not use a 
non-invasive measure of the arterial waveform via a finger cuff to measure haemodynamic 
variables. 
 
2.3.4 Measuring cardiac output via pulse contour analysis 
Pulse contour analysis to derive cardiac output is based on the observation by Erlanger and 
Hooker that arterial pulse pressure is proportional to cardiac output. A number of proprietary 
algorithms use the measurement of the arterial pulse contour to measure stroke volume and 
derive the cardiac output from this. Calibration is most commonly undertaken using the 
transpulmonary thermodilution technique which requires the insertion of a CVP line.269 In the 
PAC this is measured in by a thermistor placed beyond the right ventricle in the pulmonary 
vasculature. For less invasive devices the temperature is measured by an arterial line placed 
in a large artery usually the femoral artery. A graph of arterial waveform versus time is 
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constructed and by calculating the area under the curve the stroke volume is calculated using 
the Stewart-Hamilton equation.270 
 
Figure 2.4 Stewart Hamilton Equation 
𝑀 = 𝑄 ∫ 𝐶(𝑡)𝑑𝑡 
M = Indicator injected into the right atrium, Q = Flow (assumed to be constant), C = concentration,  
 dt = specific point in time 
 
The PiCCO and Edwards Volumeview systems use pulse contour analysis based on the initial 
readings of the thermodilution technique. The PiCCO requires three calibrations after which 
it can be used for a specified period of time  if real time analysis of the cardiac output of other 
haemodynamic variables is required for treatment and when any other therapy such as 
vasopressors that is introduced that may affect cardiovascular performance.271 The main 
advantage of using cardiac output monitors that use thermodilution is the additional 
parameters they can calculate including extravascular lung water (EVLI). In the intra-operative 
and immediate postoperative settings these parameters are not used and are not required in 
any GDT algorithms. The Edwards FloTrac system uses an uncalibrated pulse contour analysis 
algorithm. 
This relies on a proprietary nomogram using the patients age, height, gender and uses a 
conversion factor to estimate vascular tone itself derived from a multivariate polynomial 
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function. This function takes into account aortic compliance, the standard deviation (SD) of 
blood pressure and the form of the pressure curve in its calculation.  
 
Figure 2.5 Schematic representation of pulse contour analysis and equation  
 
 
𝑆𝑉 =
∫ dP ∕ dt
𝑍
 
Calculation of stroke volume using pulse contour analysis. SV = stroke volume, dP = change in 
pressure, dt = time from the end of diastole to end of systole, Z = impendence of aorta 
 
 
The FloTrac algorithm was initially used in the Vigelio monitor but this monitor was withdrawn 
due to inaccuracy.272, 273 It was replaced by the Edwards EV1000 monitor (also used by the 
Pulse Contour Analysis
SV estimated from systolic portion of waveform.
Importance of recognition of dicrotic notch.
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Volume view system) which uses an updated FloTrac algorithm to calculate the 
haemodynamic variables.274 The new monitor also uses a non-invasive technology using a 
finger cuff to derive an arterial waveform to which the algorithm can be applied. Similarly, to 
the more invasive direct arterial line trace it requires a ‘zero’ calibration at the level of the 
atria. Two fingers cuffs are usually used in order to avoid ischaemia in a single digit of the 
patient. 
 
2.3.5 Measuring cardiac output via pulse power analysis 
The LiDCO systems (PLUS and rapide) use pulse power analysis to measure haemodynamic 
variables that are used in GDT algorithms.275, 276 This analysis techniques differs from pulse 
contour analysis in that it uses the law of conservation of mass rather than the geometric 
shape and the assumption that net power has a linear relationship with net flow to deliver 
continuous cardiac output monitoring. The use of pulse power analysis has some advantages 
over the use of pulse contour analysis. The morphology of the waveform is less important as 
it does not rely on the geometry of the waveform in its calculations so should be less affected 
by over or under dampening. The pulse power analysis takes into account the power of the 
beat throughout the whole cycle not just the systolic contour and as a result should be less 
affected by the morphology of the waveform.277 The LiDCO plus system uses a specialised 
lithium dilution technique to assess cardiac output. A small amount of lithium (0.002-
0.004mmol/kg) is injected and measured using a lithium ion sensitive monitor sited in the 
arterial line.278 This is performed by the use of a lithium preamble membrane which calculates 
the plasma voltage using the Nernst equation correcting for plasma sodium. This allows a 
concentration versus time curve to be plotted and the area under the curve (AUC) is used to 
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derive the haemodynamic variables. This level of lithium is very low and not going to lead to 
toxicity unless a large number of measurements are performed. The interaction of high dose 
aminosteriod muscle relaxants with lithium can limit the use of this technique particularly  
intra-operatively and care must be taken to avoid calibration when a high dose of muscle 
relaxant has been administered.277 The LiDCO rapide uses an uncalibrated version of the pulse 
power technology to determine haemodynamic variables. This allows the LiDCO rapide to be 
used in the intra-operative period avoiding any interaction with muscle relaxants but means 
that it should be used to establish trends of haemodynamic variables rather than absolute 
numbers.279 
 
Figure 2.6 Lithium Dilution curve and equation used to estimate cardiac output 
 
𝐶𝑂 =  
𝐷𝑜𝑠𝑒 𝑜𝑓 𝑙𝑖𝑡ℎ𝑖𝑢𝑚 𝑐ℎ𝑜𝑙𝑟𝑖𝑑𝑒 (𝑚𝑚𝑜𝑙)  ×  60
𝐴𝑟𝑒𝑎 𝑢𝑛𝑑𝑒𝑟 𝑡ℎ𝑒 𝑐𝑢𝑟𝑣𝑒 × (1 − 𝑃𝐶𝑉)
 
CO = cardiac output, PCV = packed cell volume 
Using trends rather than absolute numbers has been used in algorithms of GDT that in studies 
have shown better outcomes for patients. The LiDCO system now also incorporates a 
completely non-invasive finger cuff that establishes an arterial waveform and can derive 
haemodynamic variables using the LiDCO algorithm. 
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Figure 2.7 Lithium dilution curve measurement via LiDCO nomogram 
 
  
The lithium dilution curve as used in the LiDCO nomogram for one of the three tests required to calibrate 
the monitor. The recirculation point can be seen and the extrapolation of the curve is used to calculate 
the cardiac output 
 
2.3.6 Measuring cardiac output via Bioimpedence 
The use of impedance or impedance cardiography (ICG) to monitor the cardiovascular system 
has been established since the 1940s. A large amount of the development of ICG was done 
outside of the surgical setting including in space exploration and high altitude mountaineering 
as it does not require invasive monitoring. In ICG four pairs of electrodes are placed at the 
neck and the diaphragm essentiality outlining the thorax. A small current is passed through 
the chest parallel to the spine with ICG and as the current seeks the path of least resistance 
through the chest will measure the baseline impedance to this current.280 This impedance will 
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change with each heartbeat as the amount of blood in the aorta and the alignment of the 
erythrocytes changes during systole and diastole. 
These changes are calculated against the baseline changes measured initially and from this 
haemodynamic variables are derived.281 The haemodynamic variables that can be measured 
using this technique include stroke volume, cardiac output, cardiac index and a velocity index 
allowing the use of this technology in GDT. Recent studies have shown poor correlation to 
other monitoring methods including Doppler measurements and thermodilution.282, 283 In 
addition, there is relatively poor signal to noise ratio and the required placement of the 
electrodes is sometimes not possible due to the need for surgical access. Bioreactance has 
been proposed as an alternative to bioimpedance measurement for GDT. A current is applied 
but the phase difference is analysed rather than the change in current and this difference is 
proportional to the stoke volume.  
This has the advantage of not requiring such specific electrode placement and is reported as 
having a better signal to noise ratio.284 This study using bioreactance in a colorectal surgical 
population found it to have a good correlation with the oesophageal Doppler but a subsequent 
larger study using the same GDT algorithm in the same population did not show any difference 
in outcomes between the doppler group and the bioreactance group.285 A novel design of 
monitor using bioimpedance via tracheal tube monitoring in a cardiac surgery population also 
failed to show an improvement in surgical outcomes or length of stay. 
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Figure 2.8 Bioimpedance equation 
𝑍 = 𝑅 + 𝑖𝑋 
Z = thoracic impedance, R = resistance jX = phase shifted reactance 
 
2.3.7 Limitations of Less Invasive Cardiac Output Monitors 
Trials using these less invasive monitors GDT in the perioperative and immediate post-
operative period have demonstrated the benefit in reduced complications but not in 
mortality.46, 68, 69, 152 Some clinicians felt this may reflect the relatively small benefit of GDT but 
other authors feel this may be attributed to the improved care of the control group within 
these trials.286 This has led to the inclusion of cardiac output monitoring within NICE 
guidelines. There does not appear to be any difference in study outcomes in GDT algorithms 
that use monitors which are calibrated to measure absolute values and those monitors which 
measure trend values only.  
A further impediment to the use of post PAC group of haemodynamic monitors is the 
limitations in their use during the perioperative and post-operative period. Doppler 
monitoring is semi-invasive and the requirement of the stiff probe in the oesophagus is often 
not tolerated in the post-operative setting. The introduction of a new, nasal probe may 
improve this issue though there are no large studies using this technique for GDT in the 
postoperative period. The pulse pressure analysis monitor (LiDCO) uses lithium to initially 
measure the cardiac output has limited use in patients in whom aminosteriod based muscle 
relaxants are being used. In the trend monitors authors have noted the potential for a 
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compounded mistake and clinicians using these devices require to be aware that the 
haemodynamic variables given by the monitor are not likely to give accurate true values and 
it is the trends which are of more value.283 
The ideal cardiac output monitor would consist of a small portable, non-invasive device that 
did not require calibration and would directly measure all haemodynamic indices that the PAC 
measures. A device fulfilling the above requirements is not available at the time of writing. 
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2.4 Cardiac output monitoring 
2.4.1 Cardiac output Monitors 
In order to deliver GDT effectively the goal must be clearly defined alongside the requirements 
that the goal is easily measured, with reliable repeatable measures able to be performed. 
These requirements necessitate the use of a cardiac output monitor. Cardiac output monitors 
have been defined and described in the previous chapter. However, in order to trial the 
effectiveness of GDT the most appropriate cardiac output monitor should be used. This 
monitor should be as minimally invasive as possible, be available in both the intra-operative 
and post-operative setting, be easily used by the operator as well the requirements described 
above. There is no cardiac output monitor that fully fulfils this criteria so it is necessary to 
select the most suitable monitor that allows the investigation of the effectiveness of GDT. 
 
2.4.2 Comparing cardiac output monitors 
In the literature there remains no universal accepted description of measurement of cardiac 
output.287 The PAC was used in initial trials of GDT as described in the previous chapter and as 
it continues to be considered the most accurate it has remained as the gold standard with 
which to test the accuracy of other cardiac output monitors that are being proposed for 
widespread use.288 There requires to be a degree of accuracy in the readings between the PAC 
and the monitor that is being tested. There have been a number of papers highlighting the 
lack of agreement as to what constitutes an acceptable degree of error and authors have 
proposed different definitions as to what should be the industry standard.289 Bland and 
Altman initially described the bias and limits of agreement that should be used when cardiac 
output monitoring devices.288, 290 Subsequent reviews by have also commented on the lack of 
agreement of acceptable error when introducing new cardiac output monitors.291 The review 
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by Cecconi and Rhodes describes the bias and limit of agreements as the accuracy and 
precision of cardiac output monitors respectively and comments on the proposed agreements 
of +/- 30% to the gold standard.292 These potential inaccuracies become less important as GDT 
no longer requires specific haemodynamic targets but instead monitors a change in the 
specified variable.  
The alternative way to select the most appropriate cardiac output monitor is to examine the 
evidence base to assess which monitors have been used in successful trials of GDT. Although 
association is not correlation it suggests that the use of these monitors is beneficial in 
optimising the patient’s fluids status and oxygen delivery which is the goal of GDT. Those 
monitors that have been shown to be successful in delivering GDT are discussed below. 
The PAC has been associated with the improvement of outcomes after major surgery in those 
patients receiving GDT and remains the gold standard for accuracy and precision of monitoring 
cardiac output.85 However it is associated with specific harms related to the insertion of the 
monitor and potential high cost of monitoring the patient in a suitable area with trained staff 
post-operatively.257 In part due to the initial trial that suggested harm associated with the PAC 
and the new minimally invasive cardiac output monitors the use of PAC has dropped 
significantly and as such it is no longer part of routine care in most high risk surgical patient 
groups.258 Therefore it would not be an appropriate monitor to assess the effectiveness of 
GDT in a pragmatic trial design. The PAC can measure SVV though not PPV and for this reason 
it would not have been suitable to use as a monitor to examine dynamic measure of fluid 
responsiveness. 
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2.4.3 Calibrated Cardiac Output Monitors 
There are two other readily available cardiac output monitors that require calibration that 
were used widely during the OPTIMISE trial. The PiCCO uses both TPTD technique and pulse 
contour analysis to give continuous readings of cardiac output amongst other haemodynamic 
variables.293 It is more invasive than other minimally invasive cardiac output monitors 
requiring the insertion of a CVP line and a proprietary arterial line usually in the femoral artery 
or alternatively in the axillary, brachial or radial artery. They can accurately measure stroke 
volume and cardiac output as well as PPV and SVV and can be used in both the intraoperative 
and postoperative settings.294, 295  
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Figure 2.8  Schematic representation of the PICCO monitor 
 
 
The use of the PiCCO monitor requires the insertion of a CVP line and a proprietary arterial line in the 
femoral artery 
 
It can also evaluate extra vascular lung water. However the use of a CVP line is not always 
required in major surgery and is not required for most GDT protocols. There is a lack of 
evidence for the use of the PiCCO monitor in the fluid therapy for the surgical patient  possibly 
due to the complexity of lines required. The LiDCO plus uses lithium dilution to calibrate the 
stoke volume and then calculates cardiac output amongst other haemodynamic variables 
including PPV and SVV.277 It requires the insertion of an arterial line with three calibrations 
using lithium. Further calibrations are required at various time points but have to be spaced 
out to avoid the potential lithium toxicity. Aminosteriods muscle relaxants mimic lithium so 
48
PICCO
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using the LiDCO plus would limit their use in patients included in the trial. The use of the LiDCO 
plus in an effectiveness trial of GDT has the potential to expose the patient to lithium toxicity 
and limit the use of certain muscle relaxants which may limit the usefulness of this monitor277. 
However the monitor has been used in successfully in a major study of GDT in surgical patients 
overcoming these problems.46 
 
2.4.4 Non-calibrated Cardiac Output Monitors 
There are a number of available cardiac output monitors that do not require calibration 
available that have been shown to improve outcomes in GDT studies. The most commonly 
used monitor is the oesophageal doppler and has been shown in several studies of intra-
operative GDT to improve outcomes.157 It has the advantage of being easy to insert and well 
tolerated during the intra-operative period. It measures stroke volume and calculates 
cardiac output alongside specific other cardiac monitors. It is unique in the role of minimally 
invasive cardiac output monitors in that it does not require a catheter within an arterial 
circulation of the patient. However it can migrate during operations and it is difficult to 
ascertain if it is back to its optimal placement. It is also affected by certain surgical 
interventions particularly diathermy. It is placed in the mid to lower oesophagus and 
therefore those patients undergoing oesophagectomies cannot be included in any study. It is 
also poorly tolerated in the awake patient limiting its usefulness to provide a GDT algorithm 
postoperatively.296 It is this last that limits the usefulness of the oesophageal doppler for a 
perioperative GDT algorithm. 
The LiDCO rapide is a non-calibrated version of the LiDCO plus taking the arterial waveform 
and using a nomogram consisting of the patient’s demographics to derive a stoke volume as 
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well as cardiac output and PPV and SVV. It avoids the issues regarding lithium calibration but 
as it does not  directly measure the haemodynamic variables it is only used as a trend monitor 
and the values it gives should not be treated as absolutes.297 This is less important in the 
context of GDT no longer requiring specific haemodynamic targets though special attention 
has to be paid to the arterial waveform trace that is being used by the monitor. An 
overdamped trace can lead to significantly different measures of stroke volume potentially 
leading to incorrect application of the GDT algorithm. The main disadvantage of this monitor 
is the requirement for an arterial line though most patients requiring high risk surgery will 
have an arterial line placed as standard. 
The Edwards Vigileo monitor is also an uncalibrated cardiac output monitor that used a 
peripheral pulse waveform analysis to derive a stroke volume and other haemodynamic 
variables using a nomogram. It also required an arterial waveform but the algorithm required 
repeated re-evaluations due to inaccuracy. Despite this a further study suggested that it was 
too inaccurate for clinical use and it was withdrawn from the market and replaced by the 
Edwards EV1000 non-calibrated cardiac output monitor.298 
The use of echocardiography to measure cardiac output during surgery has not been used in 
any major trials of GDT in non-cardiac surgery. This is related to the potential injury and 
difficulty of inserting a TOE probe in addition to the requirement of specific expertise to 
interpret the results.299 Similarly to the oesophageal Doppler the TOE would not have been 
tolerated by the awake post-operative patient leading to the potential exclusion of many 
patients. The TTE probe would suffer from similar difficulties in accessing expertise that is not 
normally available in theatres and would be difficult to place without impeding the surgical 
access to the patient.300 
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Other cardiac output monitor technologies such as NiCCO where CO2 is measured as a 
surrogate for cardiac output were not appropriate as it does not derive a stroke volume 
measurement that would allow the response of fluid challenge to be measured. This 
technology uses the Fick principle to estimate cardiac output but has been shown to be 
unreliable in predicting cardiac indices.301, 302 
Bioimpedence does give a measure of stoke volume but has not been used in any major trials 
of GDT that have demonstrated an improvement in outcome.303 The major study on which 
bioimpedence has been used targeted haemodynamic variables rather than optimising stroke 
volume so the lack of significant outcome may be related to the protocol rather than the 
influence of the cardiac output monitor. It is not a widely used technology and this lack of 
familiarity may have prevented some trial centres randomising patients to the study. 
Alongside some of the other methods of minimally invasive cardiac output monitoring there 
have been some reviews which question its validity.283  
Figure 2.9  Placement of Bioimpedance leads for cardiac output monitoring 
 
The placement of bioimpedance leads on adults and on children. The placement if the leads can be 
difficult in thoracic and upper gastrointestinal surgery 
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2.4.5 Trending analysis in Cardiac Output Monitors 
The increase particularly in use of uncalibrated cardiac output monitors has seen some 
advocate the use of trends rather than absolute values when using these monitors to guide 
therapy. Analysis of the haemodynamic trends has been used in studies to guide fluid 
therapy but there is limited evidence about the trending ability of these monitors.47 This was 
shown in 2010 by Critchley et al who demonstrated there was a wide variety of methods 
used to assess trend analysis prior to this.304 One of the methods was to use the Bland-
Altman analysis but this analysis assumes that the comparison points are unrelated which is 
not the case in trending analysis. A concordance analysis (taking paired readings from the 
reference and studied techniques) emphasises the direction of change rather than the size of 
any change which is a significant limitation. A further paper by the same authors 
demonstrated the use of a polar plot technique to demonstrate the difference and this 
seems to have been adopted as the base method for comparison.305 Despite this there 
remain remarkably few studies that investigate trending analysis in cardiac output monitors. 
A meta-analysis on the interchangeability of echocardiogram and transpulmonary 
thermodilution found only one study that examined trending ability of these monitors and 
identified concordance in directional change of cardiac output but not in the magnitude of 
the change.306 Similarly a recent study on non-invasive cardiac output monitoring 
technologies concluded that there was no enough evidence to perform a meta-analysis to 
assess trending analysis in these technologies as there were only ten eligible studies with 
very limited information provided.291 The ability of cardiac output monitors to accurate track 
trending changes has not been demonstrated equivocally. There is a lack of evidence despite 
general agreement on the paucity of evidence and an agreed way on how to evaluate these 
monitors. The rise in the use of trending analysis to assess the patient fluid status and guide 
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fluid therapy without a firm foundation for their use potentially leads to wider variation in 
the application of goal directed therapy. 
 
2.5 OPTIMISE data collection 
Data collection for the OPTIMISE trial was on both paper and electronic case report form (CRF). 
The information was recorded on the paper CRF before being transferred to the electronic 
CRF which fed into a central database. All complications recorded required to be supported 
by 100% source data verification. All recruiting centres had at least two monitoring visits 
during the study at which the source data was checked alongside protocol deviations, fidelity 
to the protocol and trial governance. All health professionals involved in delivering the 
intervention were introduced to the intervention at the site initiation visit. The cardiac output 
monitor, the LiDCO Rapide that was to be used was also introduced at the site initiation visit. 
A practical demonstration was then carried out with the set-up, the timing of the introduction 
of the algorithm and frequently encountered problems all discussed. Frequent contact was 
maintained with all sites during the study and any issues raised were discussed and lessons 
learned were disseminated at the trial steering committee meetings.  
 
2.6 Fluid responsiveness 
In conjunction with the other authors I wrote a pre-planned analysis of dynamic measure of 
fluid responsiveness using the LiDCO Rapide. The pragmatic design of the OPTIMISE trial 
allowed the study design to as closely as possible reflect the real time situation the 
perioperative physician may be experiencing when deciding to use dynamic measures to guide 
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patient’s fluid therapy. Successful trials in the literature had identified a number of pre 
specified conditions that had to be met for the dynamic measures to be accurate. These 
variables include the patient to be paralysed and to be mechanically ventilated at least 
8mls/kg.174 These factors were built into the protocol but other confounders such as 
dysrhythmia and pneumoperitoneum could only be recorded and used in a sensitivity analysis 
at the end of the study. In addition the largest study of fluid responsiveness examined a fluid 
challenge of 500mls and only recorded data on the first fluid challenge given.173 This would be 
not be possible as the fluid bolus in the OPTIMISE trial was stipulated at 250mls. The 250ml 
challenge was felt to more accurately reflect the size of fluid challenge that a patient may 
receive during major surgery. These conditions may potentially differ from a clinical scenario 
in which these criteria may not be present or even possible when the physician is considering 
further fluid therapy. It is important to test the ability of these parameters to function in as 
wide a range as possible of clinical scenarios that may be encountered, though it is also 
important to ensure reasonable conditions are in place that allow the parameter to be most 
effective. This attempt was reflected in the protocol to set reasonable parameters that would, 
in the majority of cases, be safe and achievable from the point of view of the clinician treating 
the patient. If they were not this was recorded on the CRF.   
A separate data collection form was designed for the sub-study examining fluid 
responsiveness. An algorithm was given to the two sites participating in the sub-study in order 
to standardise how the fluid bolus was given. The time that the fluid bolus was given was 
specifically marked on the cardiac output monitor along with the type of fluid given. Any 
vasopressor or inotrope infusions were recorded on the case report form. Any bolus of 
vasopressor given within five minutes of the fluid bolus was also recorded. An anonymised 
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version of the electronic record of the case taken from the cardiac output monitor was 
downloaded onto a password protected USB stick. These were then examined with a specific 
computer programme and stroke volume, SVV and PPV were noted at one minute prior to the 
bolus of fluid and at five minutes after the bolus had been completed. There are a number of 
different variables that may affect the ability of stroke volume, SVV and PPV to predict fluid 
responsiveness. The variables that were recorded were inotropic and vasopressor infusions, 
bolus of vasopressor, pneumoperitoneum, type of fluid, cardiac rhythm and mechanical 
ventilation. SVV and PPV are considered to be accurate when being mechanically ventilated 
at 8mls/kg which was also accounted for in the protocol. This data was collected by the health 
professional who was delivering the GDT intervention. 
 
2.7 Biomarker Analysis 
The importance of early intervention to treat AKI after major surgery is currently being 
established. The evidence demonstrating a link between AKI and the development of chronic 
kidney disease is growing. Currently AKI is diagnosed with KDGIO criteria, using rises in serum 
creatinine and reduction in urine output to determine the severity of the injury.23 Previous 
studies have noted the fluctuations in creatinine production after major surgery that are 
independent of the development of AKI. This can be due to many cause including patients 
muscle mass, fluid received during the perioperative period and time after surgery the 
creatinine is measured. Similarly the physiological response to surgery varies amongst 
individuals so urine output can be a poor predictor of the development of an AKI after major 
surgery.143 This has led to the investigation of biomarkers to diagnose AKI. The most 
investigated molecules are kidney injury molecule one (KIM-1)307 and neutrophil gelatinase-
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associated lipocalin (NGAL)308 but other more recent biomarkers have been examined 
including interleukin -18 (IL-18), liver-type fatty acid-binding protein (L-FABP), 
Angiotensinogen, tissue inhibitor of metalloproteinases 2 (TIMP-2) and insulin like growth 
factor binding protein 7 (IGFBP7).309 It is important to note that there is no recognised 
biomarker that is released specifically by the injured renal cell in a similar manner to troponin 
release by the injured myocardial cell. All the biomarkers mentioned are manufactured by the 
injured renal cell as part of the physiological process of injury. Therefore their presence or 
absence depends, at least partly, on the cell’s and the body’s response to the injury. In addition 
the biomarkers all have slightly different peak times during the development of AKI. The ideal 
biomarker would be a preformed protein exclusively housed in the renal cell and released 
when injured, though as previously stated no molecule has yet been identified. In this scenario 
the biomarker requires to be able to identify both early and late AKI during the perioperative 
period. It requires an agreed sensitivity and specificity alongside an evidence base 
demonstrating its ability to identify AKI after major surgery. It is notable that individual or a 
combination of, biomarkers are commercially approved in different countries with NGAL being 
available in Europe, a combination of TIMP-2 and IGFBP7 being used in the USA and LFABP 
being approved in Japan.  
 
2.7.1 Neutrophil Gelatinase-Associated Lipocalin  
NGAL is produced both in the kidney and in other organs at very low levels with its expression 
being significantly increased in response to kidney injury.310 Urinary NGAL is found in urinary 
samples at 3 hours post kidney injury with plasma NGAL usually being measured from six hours 
onwards. Although plasma NGAL rises in responses to other organ injuries as well as in 
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addition to kidney injury studies show that both plasma and urinary NGAL can diagnose and 
predict AKI.311 The ability of this biomarker to predict AKI improves as the AKI becomes more 
severe (using AKIN classification) and when the AKI is termed persistent (lasting longer than 
48 hours) rather than transient. Different studies suggest a relatively wide range of optimal 
cut off points depending in the severity and type of AKI that is to be identified and these range 
from 50 to 400 ng/m.l307, 312 A more recent study has suggested an optimal cut off of 78ng/ml 
for urinary NGAL and 150ng/ml for plasma NGAL though a study looking at optimal cut-off in 
postoperative studies suggested a slightly higher threshold.313 This may be related to the 
different patient group, pre-existing renal disease or the physiological insult and response. 
NGAL will rise in response to AKI so can be used to monitor both early and late AKI. Both 
plasma and urinary NGAL have been studied in a postoperative patient group but these groups 
have been quite specific, examining AKI after cardiac surgery with cardiopulmonary bypass or 
paediatric surgery. In both of these setting NGAL Urinary NGAL requires a urine sample so is 
of no or limited use patients who were anuric and oliguric prior to surgery. Both plasma and 
urinary NGAL are suitable biomarkers to measure AKI after major surgery but are currently 
slightly limited in their use due to the lack of an agreed cut-off point though this is becoming 
clearer in more severe kidney injury. A recent update supports the use of these biomarkers 
but notes the limitations with a wide range of optimal cut-offs and the discrepancy of the AKI 
definition amongst the evidence base.314 
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Figure 2.10  Abbott Architecture i1000 platform for measuring urinary NGAL 
 
Most acute kidney injury biomarkers required to be tested on a laboratory machine similar to this 
though near patient testing for AKI is being used  
2.7.2 Kidney Injury Molecule – 1  
Kidney Injury Molecule –  1 (KIM-1) is a type one transmembrane protein which is increased 
in the presence of renal injury.315 It is upregulated early in renal injury and reflects acute 
tubular necrosis in the proximal renal tubule.316 It has been shown to predict AKI after cardiac 
surgery involving cardiac pulmonary bypass and a meta-analysis found it had good predictive 
value for AKI.317 However the same meta-analysis acknowledged the heterogeneity of the 
studies in which KIM-1 had been studied and recommended larger trials before 
recommending it as a renal injury biomarker. They authors also found that KIM-1 appeared to 
perform better in children and young adults and suggested that poorer performance was seen 
in patients with significant co-morbidities.317 This potentially limits KIM-1 as a biomarker with 
which to test renal injury after major abdominal surgery in a high risk population. 
2.7.3 Interleukin-18  
IL-18 is a member on the interleukin one (IL-1) family that is expressed throughout the body 
in macrophages but is also found on the proximal tubular cells of the kidneys.316 An initial 
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study evaluating its use in predicting and diagnosing AKI after cardiopulmonary bypass 
suggested that IL-18 was a good at predicting and diagnosing AKI but further studies have had 
more mixed results.318 A more recent meta-analysis has shown that it remains a fair to good 
at predicting AKI in certain populations such as paediatrics and early AKI it is poor in diagnosing 
AKI.319 IL-18 can be raised not only in acute tubular necrosis (ATN) but also in urinary tract 
infections (UTI) and other kidney diseases and its production can be increased in other organ 
pathologies. The cost relative to performance in comparison to creatinine is poor and 
therefore it is unlikely to be used as a biomarker of AKI and is unsuitable to measure the effect 
of GDT on AKI.319 
2.7.4 Cystatin-C 
Cystatin-C is a type 2 cystinase protein inhibitor which is found throughout the body. It’s a low 
molecular weight protein that is removed from the body by glomerular filtration. As kidney 
function decreases urinary levels of Cystatin-C rise and blood levels accumulate and there is a 
proposal for Cystatin-C to replace creatinine as the reference biomarker of kidney function.320 
The importance of Cystatin-C in measuring renal function is not just in chronic kidney disease 
but in AKI. Cystatin-C has shown good predictive and diagnostic value in paediatric and in 
cardiac surgery populations but there remains a lack of evidence regarding its ability to predict 
AKI in the major non-cardiac surgical population.321 Although the change in Cystatin-C is 
quicker than that of creatinine due to its shorter half-life it still is slower than other biomarkers 
to rise with recommendations that is should not be measured until 24 hours after the 
proposed AKI event.322 Its value likely remains as the best biomarker for estimating GFR and 
as a reference by which other biomarkers can currently be measured. Due to its relatively slow 
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rise and the potential miss of early AKI it was not considered suitable to evaluate the effect of 
GDT on AKI.  
 
2.7.5 Liver Fatty Acid Binding Protein  
LFABP is part of a family on nine associated fatty acid binding proteins of which two, LFABP 
and heart type fatty acid binding protein (HFABP), have been found to be expressed in the 
kidney after injury.323 HFABP studies have focused on its ability to predict myocardial necrosis, 
though more recently studies trialling it as an AKI predictor have been undertaken. More 
studies have been done on the role of LFABP. LFABP has been studied in predominantly in 
paediatric cardiac populations with some work on adult cardiac populations and a limited 
amount of research looking at non-cardiac surgery particularly open abdominal repair of aortic 
aneurysms (AAA).324, 325 It has been shown to be a fair predictor of AKI in the critically ill 
population and can predict even very late AKI. In the studies examining its ability to predict 
AKI after open AAA repairs it was shown to be a good predictor of AKI though the numbers in 
the studies were small.326 LFABP appears to be a good predictor of AKI but remains untested 
in major abdominal surgery. The rise of this biomarker is early (around six hours) in the 
postoperative period we would have been unable to ensure that this rise would be captured 
due to the timing of sample collection in the OPTIMISE trial. 
 
2.7.6 Angiotensinogen 
Angiotensinogen is the precursor of angiotensin 2 part of the renal angiotensin aldosterone 
system (RAAS)  a hormonal pathway that is a positive feedback loop regulating renal blood 
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flow. Activation of RAAS is associated with kidney injury as the angiotensin 2 molecule has 
been associated with increased expression of inflammatory cytokines. Angiotensinogen is the 
more stable molecule in urine and is therefore easier to measure consistently.327 The role of 
upregulated RAAS is well demonstrated in many animal model studies but fewer patient 
studies. In post cardiac surgery patients urinary angiotensinogen/creatinine ratios had good 
accordance with stage of AKI as defined by the AKIN criteria.328 In addition this biomarker test 
was strongly predictive of those patients with stage one AKIN who would go onto to 
subsequently develop stage three AKIN. A smaller study looking at ITU patients had similar 
findings but found the biomarker less good at predicting early AKI in this population.329 
Angiotensinogen as a urinary biomarker for AKI after non-cardiac surgery does not have a 
suitable evidence base to allow it to be used in the sub-study. In addition it is unclear what 
the effects of drugs designed to block RAAS such as angiotensin converting enzyme inhibitors 
(ACEi) or angiotensin II receptor blockers (ARB II) would have on the production urinary 
angiotensinogen. This was not protocoled or measured during the OPTIMISE trial so would 
make interpretation of this biomarker difficult.  
 
2.7.7 Tissue inhibitor of Metalloproteinase 2 (TIMP-2) and Insulin-like Growth Factor binding 
protein 7 (IGFBP7) 
TIMP-2 and IGFBP7 are two markers of G1 cell cycle arrest and were first demonstrated as 
markers of kidney injury in the SAPPHIRE study.330 They have been validated as independent 
markers of kidney injury and are also commercially licenced in the USA as a combination to 
predict and diagnose kidney injury, after validation in a secondary study performed by the 
SAPPHIRE investigators. Further analysis of the SAPPHIRE study allowed the investigators to 
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identify a post-operative surgical cohort in whom the combination of these two biomarkers 
was good at predicting stage two and three AKI. TIMP-2 is a marker of early cell injury and is 
expressed in the kidney in response to cellular damage. Its role in kidney injury is unclear but 
like other biomarkers of AKI it is not a preformed protein therefore it likely has a mechanistic 
influence on the development of AKI. This role has not yet been identified as studies have 
demonstrated both protective and injurious effects of the molecule in how it influences cell 
function after injury . Similarly IGFBP7 is a marker of early cell injury and its overall effect on 
kidney injury is not yet clear. A study done on critically ill patients showed that it was a better 
predictor than NGAL for persistent AKI.331 A commercial kidney injury test that is a 
combination of these two biomarkers is being widely adopted in cardiac surgery for routine 
use. However evidence in the non-cardiac surgery population remains small.332, 333 There is 
also dispute over the optimal cut-off points for the test in this population due to the lack of 
trials. This combination of biomarkers is relatively new and with the sparsity of evidence I felt 
that we should we not use them in our study regarding the effect of GDT on AKI. 
 
2.7.8 Conclusion 
There is no ideal biomarker currently available with which to test the effect of GDT on the 
development of AKI. The majority of biomarkers that are measurable are produced in 
response to the injury rather than released as an effect of renal cell damage in the same way 
troponins are with myocardial injury. This has required an evaluation of these biomarkers to 
assess which is best fitted to the purpose of identifying AKI in the non-cardiac surgical patient 
and related to the timing of samples that were available from the OPTIMISE study. The most 
promising biomarker is the TIMP-2/IGFBP7 test though it requires trials on the non-cardiac 
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surgical population and was very new when we planned this study. NGAL was chosen as the 
biomarker with the best evidence base to predict and diagnose AKI after surgery. Urinary 
NGAL was chosen over plasma NGAL as this appears to rise more specifically to renal cell 
insults. Urinary NGAL:creatinine ratio was also calculated to ensure that the relative hydration 
of the patient, which may be a confounder in GDT, was accounted for in the analysis of AKI. 
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CHAPTER THREE  Trial of Goal Directed Therapy 
 
Effect of a perioperative, cardiac output-guided haemodynamic therapy 
algorithm on outcomes following major gastrointestinal surgery: a randomised 
clinical trial 
 
3.1 Introduction  
 
Estimates suggest that over 300 million patients , increased from 230 million in the previous 
decade, undergo surgery worldwide each year with mortality reported between 1 and 4%.1, 
2, 4 The requirement for access to ‘safe surgery and anaesthesia’ is being acknowledged by 
large scale commissions such as the Lancet commission, which suggests a large number of 
patients will not have access to safe surgery over the coming decade. It has been shown that 
complications and deaths are most frequent among high-risk patients, consisting of an older, 
sicker cohort of patients most commonly undergoing major gastrointestinal or vascular 
surgery12. The patients who develop complications, and survive, have been shown to have 
reduced functional independence and longer-term survival.19, 334, 335 Large variations in 
reported perioperative mortality indicate that there is potential to improve this by 
establishing good perioperative care.4, 336 Given the high volumes of surgery, even a low rate 
of avoidable harm will be associated with a large number of preventable deaths. 
 
It is generally accepted that i.v. fluid and inotropic drugs have an important effect on patient 
outcome, in particular following major gastrointestinal surgery. Yet, they are commonly 
prescribed on subjective criteria leading to wide variation in clinical practice.337 One possible 
solution is the use of cardiac output monitoring to guide i.v. fluid and inotropic drug therapy 
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as part of a haemodynamic therapy algorithm. This treatment has been shown to modify 
inflammatory pathways, improve tissue perfusion and oxygenation,131, 208 and possibly 
improve clinical outcomes.41-43, 46, 85, 164, 338 The current evidence base is of a number of small, 
efficacy trials that are unable to establish the widespread applicability of this approach in 
high-risk patients As a result, GDT has not been widely adopted into clinical practice. More 
recent studies of GDT have been adapted to utilise less invasive forms of cardiac output 
monitoring and lower doses of inotropic therapy for shorter periods.46 These refinements 
have improved the feasibility, safety and costs and while these studies continue to 
demonstrate clinical efficacy, clinical effectiveness remains unconfirmed. Despite this, use of 
haemodynamic therapy algorithms has been recommended in a report commissioned by the 
Centers for Medicare and Medicaid Services in the USA,339 and by the National Institute for 
Health and Care Excellence (NICE) in the UK,340 based on the findings of a number of small, 
efficacy trials which suggest improved clinical outcomes. A recent Cochrane review, however, 
has suggested that the treatment benefit may be more marginal than previously believed.338 
The mortality benefit has become less apparent in more recent trials with lower control 
group mortality.85  
 
In this context, we developed a perioperative, cardiac output-guided, haemodynamic 
therapy algorithm for the administration of i.v. fluid and inotropic therapy, supported by 
solid clinical and mechanistic evidence. Our objective was to evaluate the clinical 
effectiveness of this algorithm in a large, pragmatic, multi-centre randomised controlled 
trial in high risk patients undergoing major gastrointestinal surgery.  
 131   
3.2 Methods 
3.2.1 Trial Design 
OPTIMISE was a multi-centre, randomised controlled trial conducted in seventeen acute 
hospitals in the National Health Service in the United Kingdom. Adult patients, aged 50 years 
or over undergoing major abdominal surgery involving the gastrointestinal tract of expected 
duration greater than 90 minutes, were eligible for recruitment provided they satisfied one 
of the following high-risk criteria: aged 65 years or over; presence of a defined risk factor for 
cardiac or respiratory disease; renal impairment (serum creatinine ≥1.5 mg dl-1); diabetes 
mellitus; or emergency surgery. Exclusion criteria included refusal of consent, pregnancy, 
acute pulmonary edema (within prior seven days), acute myocardial ischemia (within prior 
30 days) and patients undergoing surgery for palliative treatment only. Investigators were 
asked not to randomise patients where the clinician intended to use cardiac output 
monitoring for clinical reasons. OPTIMISE was approved by the East London & City Research 
Ethics Committee (09/H0703/23) and the Medical and Healthcare products Regulatory 
Agency and registered with Controlled Trials (ISRCTN04386758). Written informed consent 
was obtained from all patients prior to surgery. Site visits were performed by the chief 
investigator (Professor Rupert Pearse) and trial manager (Aoife Ahern) for training and for 
source data verification.  
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Figure 3.1 Flow diagram of OPTIMISE patients 
 
 
3.2.2 Randomisation and procedures to minimise bias 
Randomisation was performed through a dedicated, secure, web-based system. Participants 
were allocated to treatment groups using a computer-generated, dynamic procedure 
(minimisation) with a random component. Participants were allocated, with an 80% 
probability, to the group that minimised between group differences in trial site, urgency of 
surgery and surgical procedure category among all participants recruited to date. This was a 
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pragmatic effectiveness trial and it was not possible to blind all investigators to study group 
allocation. To minimise bias, investigators were instructed not to reveal study group 
allocation unnecessarily. Patients were followed up by another investigator who, wherever 
possible, was unaware of allocation. Investigators performing follow-up self-assessed the 
extent to which they remained blinded. Outcomes were verified according to pre-defined 
criteria by the principal investigator or designee at each site, who was always blinded to 
allocation. The decision to admit a trial patient to critical care was made by clinical staff and 
recorded prior to randomisation and surgery, allowing comparison with actual location of 
post-operative care. 
 
3.3 Clinical management 
 
The intervention period commenced with induction of anesthesia and continued until six 
hours following completion of surgery. 
 
3.3.1 All patients 
Perioperative care for all patients was loosely defined to avoid extremes of clinical practice 
and practice misalignment.341All patients received standard measures to maintain 
oxygenation (SpO2 94%), hemoglobin (>80 gl-1), core temperature (37 C) and heart rate 
(<100 beats min-1). 5% dextrose was administered at 1 ml kg-1 hr-1 to satisfy maintenance 
fluid requirements. Additional fluid was administered at the discretion of the treating 
clinician guided by pulse rate, arterial pressure, urine output, core-peripheral temperature 
gradient, serum lactate and base excess. Mean arterial pressure was maintained between 60 
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and 100 mmHg using an alpha adrenoceptor agonist or vasodilator, as required. Post-
operative analgesia was provided by epidural infusion (bupivacaine and fentanyl) or intra-
venous infusion (morphine or fentanyl). With the exception of the interventions below, all 
other treatment decisions were at the discretion of, and taken by, senior clinicians. 
 
3.3.2 Haemodynamic therapy algorithm group patients 
Intervention group patients received i.v. fluid and inotropes according to a cardiac output-
guided, haemodynamic therapy algorithm (appendix 2). The algorithm was developed for 
OPTIMISE by an expert group. It was designed to be delivered in the operating room/post-
anesthetic care unit by both medical and nursing staff, ensuring that admission for critical 
care was not necessary for compliance. A cardiac output monitor was chosen which could be 
used in conscious (extubated) patients (LiDCO rapid, LiDCO Ltd, UK). This technology has 
been extensively evaluated and in clinical use for more than ten years.342 The GDT algorithm 
was supported by solid clinical and mechanistic evidence and had a good cardiovascular 
safety profile.41-43, 46, 85, 131, 164, 208, 221, 338, 343, 344 I.v. colloid solution was administered in 250ml 
boluses in order to achieve and maintain a maximal value of stroke volume; no attempt was 
made to standardise choice of colloid. Dopexamine was administered at a fixed, low dose of 
0.5 g kg-1 min-1 either through a peripheral or a central venous catheter (Cephalon Ltd, 
Welwyn Garden City, UK). The choice and dose of inotrope was based on the findings of a 
previous meta-regression analysis.164 The dose of dopexamine was reduced if the heart rate 
increased to 120% of baseline or 100 beats min-1 (whichever was greater) for more than 30 
minutes despite adequate anesthesia and analgesia. If the heart rate did not decrease 
despite dose reduction, then the infusion was discontinued.  
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3.3.3 Usual care group patients 
These patients received usual perioperative care although the use of a dynamic central 
venous pressure target was recommended. Cardiac output monitoring was not used in the 
usual care group unless specifically requested by clinical staff because of patient 
deterioration.  
 
3.4 Trial endpoints 
The primary effect estimate was the relative risk of a composite of pre-defined moderate or 
major post-operative complications and mortality at 30 days following surgery (appendix 
one). Secondary outcomes were: Post-Operative Morbidity Survey (POMS) defined morbidity 
on day 7;345 infectious complications, critical care free days (number of days alive and not in 
critical care) and all cause mortality at 30 days following surgery; all cause mortality at 180 
days following surgery; and acute hospital length of stay. Level of post-operative critical care 
was categorised according to standard criteria. Patients were followed for 30 days by visit 
and through local computerised records while in hospital. All patients were contacted at 30 
days either by telephone for those who had left hospital or by visit for those who had not. 
Where necessary, investigators contacted community physicians or other hospitals, by 
telephone and in writing, for outstanding information describing the primary outcome. All 
cause mortality at 180 days was assessed through the Office for National Statistics. Data 
entry was performed through a dedicated, secure, web-based system. Automated validation 
checks included plausibility ranges and cross checks between data fields. Further data checks 
were performed centrally and through source data verification. 
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3.5 Statistical Analysis 
 
Assuming a type I error rate of 5%, 345 patients per group (690 total) were required to detect, 
with 90% power, a reduction in the composite of pre-defined moderate or major post-
operative complications and mortality at 30 days following surgery from 50% in the usual care 
group to 37.5% in the haemodynamic therapy algorithm group (absolute risk reduction 12.5%; 
relative risk reduction 25%).46 Allowing for a 3% one-way, cross-over rate due to use of cardiac 
output monitoring in the usual care group, this was increased to 367 per group (734 total). A 
planned interim analysis was performed at halfway. Pre-defined stopping guidelines 
permitted early termination of the trial for harm but not effectiveness. 
Analyses were performed according to an a priori statistical analysis plan including all 
patients on an intention to treat basis. Categorical data were compared using Fisher’s exact 
test. Differences in critical care free days and acute hospital length of stay were tested using 
the Wilcoxon rank-sum test. Kaplan-Meier curves were plotted for all cause mortality up to 
180 days following surgery. Adjustment for baseline data was made using a logistic regression 
model including age, gender, urgency of surgery, surgical procedure category, ASA grade, 
planned location following surgery, renal impairment, diabetes mellitus, risk factors for 
cardiac or respiratory disease and random effect of site. Baseline variables were selected for 
inclusion in the adjusted analysis according to anticipated relationship with outcome, 
including all variables used in the minimisation algorithm. Results for primary and secondary 
outcomes are reported as relative risks (RR) with 95% confidence intervals (CI). Results for 
the primary outcome are additionally reported as absolute risk reduction (ARR) with 95% CI. 
Results of the logistic regression model are reported as adjusted odds ratios (OR) with 95% 
CI, with unadjusted OR for comparison. 
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Pre-specified secondary analyses were: a modified intention to treat analysis excluding 
patients who did not undergo surgery; a compliance-adjusted analysis in which patients 
whose treatment did not comply with allocation were assumed to have the same outcome 
as if they had been assigned to the alternative treatment group;346 and scenario-based 
sensitivity analyses for missing primary outcomes (a best cases analysis assuming all missing 
outcomes in the intervention group were favorable and all missing outcomes in the usual 
care group were unfavorable and a worst case analysis assuming the reverse). Pre-specified 
sub-group analyses were performed: by urgency of surgery; by surgical procedure category; 
and by timing of recruitment (comparing the first ten patients recruited at each site with 
those recruited subsequently (sites recruiting fewer than ten patients were excluded). 
Continuous variables are presented as mean (SD) where normally distributed or median 
(quartiles) where not. Categorical variables are presented as n (%). Analyses were performed 
using Stata SE version 10.1. Significance was set at p<0.05 (two-tailed). 
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3.6 Results 
 
A total of 734 patients were enrolled between June 2010 and November 2012; 368 patients 
were allocated to the cardiac output-guided, haemodynamic therapy algorithm, and 366 to 
usual care. In the usual care group, one patient was randomised in error and excluded from 
the study. Baseline patient characteristics were similar between the groups (Table 3.1). Most 
patient types were well represented with the exception of those having emergency surgery 
(25 patients) and those having urological or gynecological surgery involving the gut (nine 
patients). Clinical care outside the trial intervention was also similar (Table 3.2), including 
admission for critical care. Overall volumes of intra-venous fluid (colloid and crystalloid 
combined) administered during the intervention period were similar (intervention 4190 ml 
versus usual care 4024 ml). For usual care group patients, more intra-venous fluid was 
administered during surgery, while for intervention group patients similar volumes were 
administered during surgery and during the six hours following surgery. Intervention group 
patients received more colloid and less crystalloid than usual care group patients. With the 
exception of dopexamine, use of vasopressor and inotropic agents was similar between the 
groups.  
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Table 3.1 Baseline Patient Characteristics 
All data presented as n (%) 
* Eligibility criterion 
† Minimisation criterion 
‡ Patients may have more than one risk factor 
 
 Cardiac output-guided 
haemodynamic therapy 
algorithm 
(n=368) 
Usual care 
(n=365) 
Age (years) 71.3 (8.4) 72.2 (8.6) 
Age* 
50-64 years 68 (18.5) 57 (15.6) 
≥ 65 years 300 (81.5) 308 (84.4) 
Sex 
Male 237 (64.4) 229 (62.7) 
Female 131 (35.6) 136 (37.3) 
Urgency of surgery*† 
Elective 356 (96.7) 352 (96.4) 
Emergency 12 (3.3) 13 (3.6) 
Baseline risk factors*‡ 
Renal impairment 26 (7.1) 12 (3.3) 
Diabetes mellitus 57 (15.5) 65 (17.8) 
Pre-defined risk factor for cardiac or respiratory 
disease 
117 (31.8) 118 (32.3) 
Planned surgical procedure category† 
Upper gastrointestinal 110 (29·9) 114 (31·2) 
Lower gastrointestinal 167 (45·4) 163 (44·7) 
Small bowel +/- pancreas 86 (23·4) 84 (23·0) 
Urological or gynecological surgery involving gut 5 (1·4) 4 (1·1) 
ASA grade 
1 21 (5.7) 24 (6.6) 
2 200 (54.5) 174 (48.1) 
3 143 (39.0) 155 (42.8) 
4 3 (0.8) 9 (2.5) 
Planned location following surgery 
Critical care unit (level 3) 275 (74.7) 276 (75.6) 
Critical care unit (level 2) 33 (9.0) 33 (9.0) 
Post-surgical recovery unit 4 (1.1) 7 (1.9) 
Ward 56 (15.2) 49 (13.4) 
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Table 3.2 Clinical management of patients during intervention period  
(during surgery and six hours following surgery) Data presented as mean (SD) or n (%) 
* Two patients (one in each group) missing data on anaesthetic technique 
† Two patients (both usual care) missing data on fluids both during surgery and during six hours following surgery; one patient 
(haemodynamic therapy algorithm) missing data on fluids during six hours following surgery; one patient (haemodynamic 
therapy algorithm) missing data on fluids during surgery; one patient (usual care) missing data on crystalloid during six hours 
following surgery; one patient (haemodynamic therapy algorithm) missing data on blood products during six hours following 
surgery 
§Two patients (one in each group) missing data on vasopressor or inotrope agents both bolus and infusion; one patient (usual 
care) missing data on vasopressor or inotrope infusion 
 Cardiac output-guided 
haemodynamic therapy 
 algorithm 
 (n=367) 
Usual care 
(n=362) 
Duration of surgery (minutes) 270 (200-350) 260 (195-360) 
Anesthetic technique* 
General anesthetic only 107 (29.2) 105 (29.1) 
General anesthetic plus epidural 259 (70.8) 256 (70.9) 
Intravenous crystalloid (ml)† 
During surgery 1518 (1410) 2420 (1382) 
During six hours following surgery 565 (254) 670 (367) 
Intravenous colloid (ml)† 
During surgery 1465 (913) 708 (695) 
During six hours following surgery 642 (498) 226 (361) 
Blood products (ml)† 
During surgery 141 (723) 95 (542) 
During six hours following surgery 80 (555) 10 (66) 
Bolus vasopressor or inotrope agent used during 
intervention period§ 
301 (82.2) 270 (74.8) 
Infusion of vasopressor or inotrope (other than 
dopexamine) used during intervention period§ 
103 (28.1) 108 (30.0) 
Actual location of care following surgery 
Critical care unit (level 3) 258 (70.3) 246 (68.0) 
Critical care unit (level 2) 42 (11.4) 40 (11.0) 
Post-surgical recovery unit 10 (2.7) 9 (2.5) 
Ward 57 (15.5) 67 (18.5) 
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The primary outcome, a composite of pre-defined moderate or major post-operative 
complications and mortality at 30 days following surgery, was met by 36.6% (134 of 366) of 
patients in the intervention group and by 43.4% (158 of 364) of patients in the usual care 
group (RR 0.84 [0.71-1.01], ARR 6.8% [−0.3% to 13.9%]; p=0.07) (Table 3.3). Following 
adjustment for baseline risk factors, the observed treatment effect remained non-significant 
with an adjusted OR of 0.73 [0.53-1.00]; p=0.05 (unadjusted OR 0.75 [0.56-1.01]; p=0.07). 
The pre-specified, modified, intention to treat analysis, in which three patients (all in the 
usual care group) who did not undergo surgery were excluded, had little effect on the 
primary outcome (RR 0.84 [0.70-1.00]; p=0.06). In the pre-specified, compliance-adjusted 
analysis conducted using established methodology,346 the observed treatment effect was 
strengthened when the 65 patients whose care was non-compliant were assumed to 
experience the same outcome as if they had been allocated to the alternative group (RR 0.80 
[0.61-0.99]; p=0.037). Scenario-based sensitivity analyses demonstrated that the very small 
number of patients with missing primary outcome data had minimal influence on treatment 
effect (RR 0.84 [0.70-1.00] to 0.85 [0.71-1.02]). 
Five patients in the intervention group experienced serious adverse cardiac events within 24 
hours of the end of the intervention period (two tachycardia, two myocardial infarction and 
one arrhythmia) compared with none in the usual care group (p=0.062). At 30 days following 
surgery, however, the incidence of cardiovascular events was similar between the groups 
(Table 3.3). There were no significant differences for any of the secondary outcomes: POMS 
defined morbidity on day 7; infectious complications, critical care free days and all cause 
mortality at 30 days following surgery; all cause mortality at 180 days following surgery; and 
duration of acute hospital length of stay (Table 3.4, Figure 3.2). No interaction was found for  
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Table 3.3 Results for primary outcome  
All data presented as n (%) 
*Six patients (three haemodynamic therapy algorithm, three usual care) missing data on self-assessment of blinding of 
outcome assessment 
†Includes three patients (two haemodynamic therapy algorithm, one usual care) who died within 30 days 
 
 Cardiac output-guided 
haemodynamic therapy 
algorithm 
(n=366) 
Usual care  
(n=364) 
Relative risk 
(95% CI) 
p-
value 
Composite 
Pre-defined moderate or major post-operative 
complications and mortality at 30 days 
following surgery 
134 (36.6) 158 (43.4) 
0.84 
 (0.71-1.01) 
0.07 
Individual elements 
Mortality 12 (3.3) 11 (3.0)   
Pulmonary embolism 4 (1.1) 1 (0.3)   
Myocardial ischemia or infarction 10 (2.7) 8 (2.2)   
Arrhythmia 39 (10.7) 40 (11.0)   
Cardiac or respiratory arrest 16 (4.4) 14 (3.8)   
Limb or digital ischemia 2 (0.5) 1 (0.3)   
Cardiogenic pulmonary edema 1 (0.3) 2 (0.5)   
Acute respiratory distress syndrome 3 (0.8) 4 (1.1)   
Gastrointestinal bleed 13 (3.6) 8 (2.2)   
Bowel infarction 2 (0.5) 5 (1.4)   
Anastomotic breakdown 12 (3.3) 16 (4.4)   
Paralytic ileus 20 (5.5) 27 (7.4)   
Acute psychosis 3 (0.8) 8 (2.2)   
Stroke 1 (0.3) 0 (0)   
Acute kidney injury 17 (4.6) 17 (4.7)   
Infection, source uncertain 11 (3.0) 9 (2.5)   
Urinary tract infection 9 (2.5) 9 (2.5)   
Surgical site infection 22 (6.0) 39 (10.7)   
Organ/space infection 20 (5.5) 36 (9.9)   
Bloodstream infection 6 (1.6) 15 (4.1)   
Nosocomial pneumonia 36 (9.8) 39 (10.7)   
Post-operative hemorrhage 6 (1.6) 4 (1.1)   
Self-assessment of blinding for outcome assessment* 
Assessor suitably blinded 342 (94.2) 349 (96.7)   
Assessor may have known allocation 9 (2.5) 6 (1.7)   
Assessor knew allocation† 12 (3.3) 6 (1.7)   
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Table 3.4 Results for secondary outcomes 
Odds ratios for all cause mortality at 30 days following surgery: unadjusted 1.09 (0.48-2.45); adjusted 1.20 (0.51-2.82); 
p=0.68 
Odds ratios for all cause mortality at 180 days following surgery: unadjusted 0.63 (0.39-1.04); adjusted 0.61 (0.36-1.04); 
p=0.071 
Data presented as median (quartiles) or n (%) 
*For patients alive and in hospital on day 7 following start of surgery 
 
 Cardiac output-
guided, 
haemodynamic 
therapy algorithm 
Usual care Relative 
risk 
(95% CI) 
p- 
value 
Post-Operative Morbidity 
Survey defined morbidity 
at 7 days following 
surgery* 
182 (66.2) 
(n=275) 
195 (67.9) 
(n=287) 
0.97 
(0.87-
1.09) 
0.72 
Infectious complications 
at 30 days following 
surgery 
87 (23.8) 
(n=366) 
108 (29.7) 
(n=364) 
0.80 
(0.63-
1.02) 
0.08 
Critical care free days at 
30 days following surgery 
27 (26-29) 
(n=366) 
28 (25-29) 
(n=364) 
-- 0.98 
All cause mortality at 30 
days following surgery 
12 (3.3) 
(n=366) 
11 (3.0) 
(n=364) 
1.08 
(0.48-
2.43) 
1.00 
All cause mortality at 180 
days following surgery 
28 (7.7) 
(n=363) 
42 (11.6) 
(n=361) 
0.66 
(0.42-
1.05) 
0.08 
Duration of post-
operative hospital stay 
10 (7-14) 
(n=359) 
11 (7-17) 
(n=356) 
-- 0.05 
Survivors 
10 (7-14) 
(n=343) 
11 (7-17) 
(n=343) 
  
Non-survivors 
7 (3-33) 
(n=16) 
16 (9-36) 
(n=13) 
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Figure 3.2 Mortality curve at 180 days 
 
 
 
 
urgency of surgery, the intervention was associated with a slight reduction in the primary 
outcome for the elective surgery sub-group.  No interaction was found for surgical procedure 
category, the intervention was associated with a slight reduction in the primary outcome for 
patients undergoing small bowel +/- pancreas surgery. A significant interaction (p=0.019) was 
found for timing of recruitment, the intervention was associated with a reduction in the 
primary outcome for patients recruited later (RR 0.59 [0.41-0.84] compared with earlier at 
each site (RR 1.51 [0.75-3.01]. 
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3.7 Discussion 
 
In high-risk patients undergoing major abdominal surgery involving the gastrointestinal tract, 
when compared with usual care, use of this peri-operative, cardiac output-guided, 
haemodynamic therapy algorithm was not associated with a significant reduction in the 
composite primary outcome of pre-defined moderate or major post-operative complications 
and mortality at 30 days following surgery. However, after incorporating the results of this 
large clinical trial into an updated Cochrane review of published trials, there was strong 
evidence that cardiac output-guided, haemodynamic therapy is associated with a clinically 
important reduction in the number of patients who develop complications after surgery.338 
In the OPTIMISE trial, there  was no difference in the secondary outcomes of POMS defined 
morbidity at day 7; infectious complications, critical care-free days or all cause mortality at 
30 days; all cause mortality at 180 days; or acute hospital length of stay. However, the 
findings of the updated systematic review suggest this treatment approach is associated with 
a significant reduction in the number of patients who develop post-operative infection as 
well as in duration of hospital stay. The findings of the mortality analyses were of borderline 
significance but remain consistent with benefit.   
 
This is the largest trial of a peri-operative, cardiac output-guided, haemodynamic therapy 
algorithm, to date. OPTIMISE was designed to address several limitations in the previous 
evidence base.99 The large sample size allowed for comparison of the cardiac output-guided 
haemodynamic therapy algorithm with usual peri-operative care, avoiding problems 
associated with alternative ‘control’ treatment algorithms which do not reflect typical 
practice.341 A large number of algorithms for cardiac output guided haemodynamic therapy 
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have been published describing a variety of options in terms of haemodynamic end-points, 
use of inotropic agents and cardiac output monitoring. We used an algorithm suited to the 
care of patients during and after major gastrointestinal surgery, that was supported by solid 
clinical and mechanistic evidence and a good cardiovascular safety profile.41, 42, 46, 131, 164, 208, 
221, 343, 344 The β2-agonist dopexamine has mild inotropic and vasodilator effects and is the 
most widely studied agent in this context. The findings of a meta-regression analysis 
suggested that dopexamine infusion at low dose is associated with improved outcomes 
following major surgery.164 Further modifications were made by an expert group to allow 
delivery in the operating room and post-anaesthetic care unit by both medical and nursing 
staff and in particular to ensure admission to critical care was not necessary for compliance 
with the intervention. Importantly, the high rate of compliance with the haemodynamic 
therapy algorithm used in this trial suggests this treatment approach is feasible for use in 
routine clinical practice. A widely used cardiac output monitoring technology was employed 
(although our findings are not specific to this device). In keeping with the pragmatic nature 
of the trial, no attempt was made to standardise the choice of colloid in either group. Recent 
evidence has suggested an increased incidence of acute kidney injury in critically ill patients 
receiving starch-based, colloid solutions.195, 196 While we do not have individual patient data 
describing the use of starch, a post-hoc survey of investigators suggested few patients 
received this. A recent systematic review identified no evidence of acute kidney injury 
associated with the use of starch solutions in surgical patients.198  
 
A potential weakness of OPTIMISE may be the use of a primary outcome that was a 
composite of moderate or major post-operative complications and mortality. The 
components of this outcome measure may reflect benefit, no effect or harm associated with 
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the intervention.  We controlled for bias by assessing and grading this outcome according to 
pre-defined criteria and, although it is not possible to blind all clinical staff administering 
complex interventions, our data suggest excellent compliance with blinding for patient 
outcome assessment. Finally, the event rate in the usual care arm was slightly lower than 
expected and cross-over in terms of cardiac output monitoring in the usual care group was 
more frequent than predicted, factors that reduced the power of the trial. Although 
emergency surgery was one of our inclusion criteria, we were only able to recruit a small 
number of these patients. The approach to recruiting elective and emergency patients is 
quite different and the design of future trials should take this into account. Myocardial injury 
is the most important adverse effect of haemodynamic therapy algorithms; there was a low 
rate of cardiovascular serious adverse events within 24 hours of the intervention and the 
incidence of cardiovascular events was similar between the groups at 30 days following 
surgery. The trial findings also suggests that cardiac output-guided fluid therapy need not 
result in excessive fluid administration but may lead to a more individualised approach to 
achieving the correct dose of fluid, as and when required. Finally, a pre-specified analysis of 
timing of recruitment suggested that a learning curve may have existed, consistent both with 
an expectation for trials of complex interventions and from previous experience from 
implementation in this field, and this warrants consideration in future research in this area.347  
 
3.8 Conclusion 
 
In this large multi-centre trial, the use of a peri-operative, cardiac output-guided, 
haemodynamic therapy algorithm for the administration of intra-venous fluid and a low-dose 
inotrope (dopexamine) was not associated with a significant reduction in a composite 
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primary outcome of pre-defined moderate or major post-operative complications and 
mortality at 30 days following surgery.  
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CHAPTER FOUR  Per protocol analysis of compliance 
 
The Compliance to a Goal Directed Therapy Protocol in a pragmatic 
randomised control trial – A per protocol analysis of the OPTIMISE trial 
 
4.1 Introduction 
GDT has been shown in a number of studies to improve outcomes for patients undergoing 
major abdominal surgery.43, 46, 68, 69 However one of the barriers to introducing GDT is the 
complexity of the intervention and the potential difficulty of following a GDT protocol. The 
evidence base that is used to promote the widespread adoption of GDT is based on a large 
number of small studies and subsequent meta-analyses demonstrating their efficacy71, 207, 220, 
348 Most GDT studies or studies on any complex intervention do not report on the ability of 
clinical teams to adhere to the protocol or explore the reasons behind any potential variable 
compliance.349 Compliance to these algorithms under trial conditions is likely to be much 
greater amongst small single centre trials with the ability to deploy large resources to a 
relatively small trial population. Studies examining compliance in other areas of medicine have 
shown a variable adherence to protocols after they are recommended for use in clinical 
practice.212, 350 The ability of a pragmatic randomised controlled trial to answer a question 
regarding the effectiveness of a complex intervention requires to study the fidelity to the 
intervention and any reason why adherence to the protocol might be low.229, 231 In addition to 
identifying the degree of compliance, it is important to assess if deviation from the protocol 
has the potential to affect the observed result of the trial. If the results of a per protocol 
analysis of patients compliant to their group allocation was very different from the observed 
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outcome this could suggest that there is difficulty in following the algorithm rather than the 
intervention being ineffective. 
The OPTIMISE trial was the largest pragmatic randomised controlled trial of GDT and had 
resource implications associated with delivering the intervention. There was no significant 
difference in the primary outcome measure between the GDT group and the usual care group. 
Resource use in the introduction of a GDT algorithm is an important consideration and the 
OPTIMISE trial gave an opportunity to study the barriers that resource limitation may present. 
Two secondary analyses were performed in this large data set to assess the applicability of the 
GDT algorithm in a practical setting and see what extra resources were required to effectively 
deliver this intervention. In particular the extra requirement for staff to deliver the 
intervention and the potential for a learning curve with the introduction of what would be a 
new GDT algorithm to the participating hospitals. 
I hypothesised that a significant improvement in the primary outcome would be observed in 
the patients in the OPTIMISE trial group who were fully adherent to the protocol of the 
treatment group to which they were allocated.  
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4.2 Methods  
The OPTIMISE trial is described in the previous chapter. The trial recruited a total of 734 
patients from 17 different sites within the United Kingdom. All patients were undergoing 
major abdominal surgery involving the luminal bowel that lasted longer than ninety minutes 
and were either over 50 years old with a predefined co-morbidity or over 65 years old. The 
GDT intervention was as described in the previous chapter and is listed in the appendix 
(appendix 2). The algorithm was commenced at the start of anaesthesia and continued until 
six hours post-surgery with the end of surgery being defined as at the insertion of the final 
wound suture. Trial data was collected on paper CRF and then placed into a secure website 
that had an identical electronic CRF. Randomisation was performed through a secure Internet-
based data entry system and this allowed for a 3% one-way cross-over rate due to the use of 
cardiac output monitoring in the usual care group.  
The data collected included all primary and secondary outcome measures and data regarding 
adherence to the protocol. The adherence to the protocol was assessed in the following 
categories. There were three main expected protocol deviations. Two in the GDT group, which 
were not receiving a cardiac output monitor and not receiving the correct dose of 
dopexamine. The third was the use of a cardiac output monitor in the usual care group. 
Further protocol deviations studied included if surgery was performed, the type or length of 
surgery and the length of time that the intervention was performed for post-operatively. The 
patient group who did not have any of the above protocol deviations were considered 
compliant to the algorithm. This was a post-hoc analysis of the OPTIMISE utilising the data 
that was collected throughout the study. Determination of the adherence to protocol was 
initially made by myself and confirmed after discussion with the chief investigator.  
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The initial data set collected information on the presence and any help that research staff 
were giving during the trial. This was extracted from the electronic CRF as part of the initial 
data set. The first ten patients from each participating site were removed from the dataset 
and the analysis was rerun to determine if there was a significant difference in outcomes 
between these patient cohorts. Both of these analysis were secondary pre-specified analysis 
of the OPTIMISE trial.   
 
4.3 Statistical Analysis 
The data was presented in the form of a Microsoft word excel spreadsheet. Statistical tests 
were performed using STATA software. The data was sorted to exclude those patients who 
were deemed not to have been compliant to the treatment arm they were randomised to. 
Categorical data were compared using Fisher’s exact test. Adjustment for baseline data was 
made using a logistic regression model including age, gender, urgency of surgery, surgical 
procedure category, ASA grade, planned location following surgery, renal impairment, 
diabetes mellitus, risk factors for cardiac or respiratory disease and random effect of site. 
Baseline variables were selected for inclusion in the adjusted analysis according to 
anticipated relationship with outcome, including all variables used in the minimisation 
algorithm. Results for primary and secondary outcomes are reported as relative risks (RR) 
with 95% confidence intervals (CI). Results for the primary outcome are additionally reported 
as absolute risk reduction (ARR) with 95% CI. Results of the logistic regression model are 
reported as adjusted odds ratios (OR) with 95% CI, with unadjusted OR for comparison. 
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4.4 Results 
The number of patients in the treatment group of the OPTIMISE trial who were compliant with 
the algorithm was 334 of 367. This represents 91% of the total patients allocated to this group 
in the trial. 330 of 362 patients in the usual care group had no predefined protocol deviations 
(figure 4.1).  
The reasons for the non-compliance of all the patients excluded are shown (table 4.1). The 
demographics of both groups are shown (table 4.2) with no significant differences seen. The 
number of patients in the per protocol GDT group with the primary outcome was 118/334 and 
the number of patients in the per protocol usual care group with the primary outcome was 
140/330 (p 0.06) (table 4.3). Laboratory confirmed blood stream infections was the only noted 
difference between the two groups when individual complications were analysed (table 4.4). 
Ensuring compliance to the protocol in the GDT group used more resources than the usual 
care group. The use of medical staff during the operation was similar in both groups but more 
medical input was required for the six hours following surgery. There was more nursing input 
both during and after the operation for the GDT group than in the usual care  group. Input in 
the GDT group was largely focused in advising on or delivering the intervention and in the 
usual care group was for data collection and observation (table 4.5). There was a significant 
reduction in the primary outcome between the GDT and usual care groups once the first ten 
patients randomised at the individual sites had been excluded from the analysis (p 0.019) 
(table 4.6). 
Figure 4.1 Graphical representation of the compliance of the respective treatment groups 
in the OPTIMISE trial 
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GDT = Goal Directed Therapy compliance (334/367) 
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Table 4.1 Reasons for protocol deviations 
 
 
GDT      Usual care 
 
(n±362) (n=367) 
Failure to administer dopexamine to 
a haemodynamic therapy algorithm 
patient 7(1.9) NIA 
Administration of incorrect dose of 
dopexamine to haemodynamic 
therapy algorithm patient: 26 (7.1) NIA 
Lowest rate or dopexamine less than 
0.5 ug/kg/min 8 (2.2) NIA 
Highest rate of dopexamine greater 
than 0.5 ug/kg/min 1 (0.3) NIA 
Dopexamine administered for less 
than six hours 20 (5.4) NIA 
Failure to monitor cardiac output in 
haemodynamic therapy algorithm 
patient 3 (0.8) NIA 
Administration of dopexamine to 
usual care patient NIA 1 (0.3) 
Use of cardiac output monitoring in 
usual care patient NIA 31 (8.6) 
Overall compliance (none of above 
met) 334 (91.0) 330 (91.2) 
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Table 4.2 Baseline patient characteristics of per protocol patients 
 
 
 GDT  UC 
[334] [330] 
Age Mean (SD) 71.3 (8.3) 72.3 (8.5) 
 Median (IQR) 72 (66, 77) 73 (67, 78) 
Gender Male, n(%) 210 (62.9%) 210 (63.6%) 
 Female, n(%) 124 (37.1%) 120 (36.4%) 
Urgency of surgery Elective, n(%) 322 (96.4%) 318 (96.4%) 
 Non-elective, n(%) 12 (3.6%) 12 (3.6%) 
Planned surgical 
procedure Upper gastrointestinal, n(%) 100 (29.9%) 108 (32.7%) 
 Lower gastrointestinal, n(%) 149 (44.6%) 142 (43.0%) 
 Small bowel +/- pancreas, n(%) 80 (24.0%) 76 (23.0%) 
 Urological/gynaecological surgery n(%) 5 (1.5%) 4 (1.2%) 
ASA I, n(%) 20 (6.0%) 23 (7.0%) 
 II, n(%) 184 (55.1%) 163 (49.4%) 
 III, n(%) 127 (38.0%) 136 (41.2%) 
 IV, n(%) 3 (0.9%) 8 (2.4%) 
Planned location 
following surgery Ward, n(%) 48 (14.4%) 48 (14.5%) 
 Post-surgical recovery unit, n(%) 3 (0.9%) 7 (2.1%) 
 Critical care unit level 2, n(%) 251 (75.1%) 249 (75.5%) 
 Critical care unit level 3, n(%) 32 (9.6%) 26 (7.9%) 
Baseline renal 
impairment Yes, n(%) 22 (6.6%) 12 (3.6%) 
 No, n(%) 312 (93.4%) 318 (96.4%) 
Baseline diabetes 
mellitus Yes, n(%) 53 (15.9%) 57 (17.3%) 
 No, n(%) 281 (84.1%) 273 (82.7%) 
Baseline risk factors 
for cardiac or 
respiratory disease Yes, n(%) 104 (31.1%) 103 (31.2%) 
 No, n(%) 230 (68.9%) 227 (68.8%) 
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Table 4.3 Results of primary outcome within the whole cohort  
 
 
 
 
 
Table 4.4 Individual primary complications reported in the intention to treat and per 
protocol groups  
Complication (outcome) 
Whole Cohort,  
OR (95% CI) 
Intention to treat Per Protocol 
Paralytic ileus 0.72 (0.40, 1.31) 0.64 (0.33, 1.23) 
Acute kidney injury 0.99 (0.50, 1.98) 0.99 (0.46, 2.10) 
Superficial Infection 0.73 (0.39, 1.37) 0.66 (0.34, 1.29) 
Deep incisional Infection 0.30 (0.11, 0.83) 0.24 (0.08, 0.72) 
Organ/space Infection 0.53 (0.30, 0.93) 0.53 (0.29, 0.97) 
Laboratory confirmed bloodstream infection 0.39 (0.15, 1.01) 0.22 (0.06, 0.78) 
Nosocomial pneumonia 0.91 (0.56, 1.47) 0.90 (0.54, 1.47) 
  
Method Whole Cohort, OR (95% CI) P-Value 
Intention to treat 0.75 (0.56, 1.01) 0.06 
Per Protocol 0.74 (0.54, 1.01) 0.06 
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Table 4.5 Staff present from investigation team during intervention period 
All data presented as n (%). Does not include one usual care patient randomised in error and four 
patients (three usual care and one GDT) who did not undergo surgery. One patient (GDT) missing 
data on additional staff present. 
 Goal Directed Therapy 
(n =366) 
Usual Care 
(n= 362) 
During Surgery Six hours 
following 
surgery 
During Surgery Six hours 
following 
surgery 
Additional staff present 
 Nurse 212 (57.9) 228 (62.3) 79 (21.8) 33 (9.1) 
Doctor 77 (21.0) 83 (22.7) 83 (22.9) 7 (1.9) 
Nurse and 
Doctor 
60 (16.4) 33 (9.0) 7 (1.9) 0 (0) 
Role of additional staff 
 Observation 6 (1.6) 7 (1.9) 98 (27.1) 5 (1.4) 
Data 
collection 
10 (2.7) 9 (2.5) 20 (5.5) 22 (6.1) 
Advising on 
intervention 
94 (25.7) 54 (14.8) 36 (9.9) 8 (2.2) 
Delivering 
intervention 
239 (65.3) 274 (74.9) 15 (4.1) 5 (1.4) 
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Table 4.6 Pre-specified sub-group analyses of timing of recruitment for primary outcome 
Data presented as n (%). *Excludes eight patients (two hemodynamic therapy algorithm, six usual 
care) from two sites which recruited fewer than 10 patients. Does not include one usual care patient 
randomized in error and three patients (one usual care patient and two hemodynamic therapy) who 
withdrew consent. 
 
  GDT Usual care Adjusted 
odds ratio 
(95% CI) 
Test for 
interaction 
p-value 
Timing of 
recruitment 
    0.019 
 Earlier (first ten 
patients per site) 
33 (42.3) 
(n=78) 
28 (34.1) 
(n=82) 
1.51  
(0.75-3.01) 
 
 Later (all 
subsequent 
patients) 
100 (35.0) 
(n=286) 
129 (46.7) 
(n=276) 
0.59  
(0.41-0.84) 
 
 
4.5 Discussion 
The main finding of this analysis was that compliance to this GDT algorithm was excellent with 
over 90% of patients being adherent to their protocol group. The exclusion of the patients 
who were not compliant with their allocated treatment group did not show a significant 
difference between the two groups with a primary outcome that was a composite of all 
complications. The GDT group had more patients excluded than the usual care group and this 
finding is not unexpected. The protocol for the trial was designed to ensure that the control 
group had comparable perioperative care except for the use of a cardiac output monitor to 
guide fluid therapy. While this allowed the standard of care to be flexible, it was  designed to 
prevent poor practice being the cause of any observed difference and to avoid dictating a 
treatment algorithm in the usual care group. The trial design allowed for up to a three per 
cent crossover in the usual care group who went on to receive cardiac output monitoring.  
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Compliance to algorithms has not been studied in great detail in general, and not specifically 
in regard to the introduction of complex interventions to the surgical population.215 Studies in 
other fields of healthcare have shown a poorer compliance to complex intervention 
algorithms than our study349, 350 although these results have to be taken in context of resource 
management which is discussed later. These studies suggest that compliance to these complex 
medical algorithms is usually around 50-60%. Protocol deviations in healthcare studies are 
predefined and included with the results but often not commented on. The reasons for lack 
of compliance to algorithms in trials is not often reported outside of intention to treat large 
pragmatic trials and we would encourage such reporting as it would allow further comparisons 
if the intervention is to be adopted into clinical practice. This would allow a benchmark for 
future studies of complex interventions that include compliance. Although the compliance of 
over 90% to our protocol appears excellent it is under trial conditions and how that translates 
to its compliance in clinical practice is difficult to assess. However it is difficult to see what 
further study could be done to assess compliance prior to the introduction of a complex 
algorithm such as GDT. The secondary analysis of the primary outcome in those patients who 
were adherent to their treatment group did not show a significant difference between the 
groups. The lack of difference seen between the intention to treat group and the per protocol 
group suggest that the deviations from the protocol did not impact the overall outcome of the 
study.  
There were large resource implications particularly for healthcare personnel in delivering the 
GDT algorithm and this likely to represent a significant obstacle to the introduction of GDT. 
This suggests there would have to be initial investment in staff to ensure the compliance rate 
that was seen in the OPTIMISE trial. However it is unlikely that the investment needs to be in 
 161   
extra staff as the majority of high risk surgical patients will have minimum of 2:1 nursing for 
at least six hours afterwards either in the critical care unit or post anaesthetic care unit. This 
investment in staff is most likely to be in educating staff around the delivery of the 
intervention. The improvement in outcomes seen after the first ten patients from each site 
were removed for the analysis, suggests that the algorithm was easy to learn and that once 
the algorithm is learned this GDT algorithm is effective. This observed learning curve is a 
further barrier to the introduction of GDT as the treatment may be considered to be 
ineffective before the algorithm is properly learned and implemented. 
There are some strengths in this analysis. It uses data from the largest study of a specific GDT 
algorithm that I am aware of. This compromises a large data set in a pragmatic setting which 
strengths the applicability of the algorithm to clinical care. However in performing this analysis 
we move the purpose of the trial from being pragmatic to exploratory. Although this 
potentially reduces the applicability of the algorithm to clinical practice it informs the clinician 
of the potential barriers in introducing this particular algorithm. This has the advantage of 
providing a source of validation for compliance to this GDT algorithm used and allows 
confidence in using the specific algorithm for further studies.  This review of compliance was 
a post-hoc analysis of the data and therefore can only indicate a future direction of research. 
The results are interesting but need further validation in future studies. The observed resource 
use in the GDT group and the analysis removing the first ten patients recruited at each site 
were pre-specified though the results should also be interpreted with caution. Resource use 
was self-reported and did not report on the seniority of the staff required to be compliant to 
the algorithm. Similarly the results of the pre-specified analysis removing the first ten patients 
recruited from each site should be interpreted with caution. This group was not subject to a 
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randomisation process meaning that these results should only be used to help frame 
hypothesis for future studies. 
Further study should focus on the reporting of compliance in large pragmatic trials especially 
as these studies are designed, in part, to assess the ability of the intervention to affect 
outcomes in clinical practice. Equipoise is required to assess compliance in large studies. This 
can be difficult in pragmatic trials because, preceding them, there is usually a large evidence 
base of small trials and many clinicians may have lost equipoise over the research question 
despite the lack of a large pragmatic trial. This may be further compounded in a study that 
enrolled high risk surgical patients as a clinicians equipoise may equally be challenged by the 
co-morbidities of the individual patient in addition to the specific research question.249 
Equipoise in the trial of complex interventions such as GDT has not been evaluated. Clinician 
refusal as reason for the patient not being randomised into the OPTIMISE trial was not studied 
but is likely to be higher than was originally predicted. This effect may be the reason that a 
younger population than might have been expected was recruited into the OPTIMISE trial. The 
apparent clinical effect of this GDT algorithm warrants further investigation with any study 
examining clinician equipoise, compliance and resource use, alongside the primary outcome 
measure, to identify any further barriers to the introduction of GDT. 
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4.6 Conclusion 
In a subsequent analysis of the largest study of GDT using a pre-specified algorithm we found 
that compliance to the algorithm was excellent. This suggests that the algorithm was easy to 
follow and can be implemented in clinical practice if it is shown to have a positive impact on 
patient outcomes after major surgery. Further analyses demonstrated the presence of a 
learning curve associated with this complex intervention alongside increase resource use 
which potentially present further barriers to the introduction of GDT. These potential 
barriers alongside clinical equipoise should be assessed in any further large pragmatic trials 
of GDT.  
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CHAPTER FIVE  Predictive value of dynamic preload markers 
 
Dynamic preload markers to predict fluid responsiveness during and after 
major gastrointestinal surgery: an observational substudy of the OPTIMISE 
trial. 
 
5.1 Introduction 
 
Estimates suggest that over 230 million patients undergo surgery worldwide each year with 
mortality reported to be between 1 and 4%.2, 4 Complications and deaths are most frequent 
among high-risk patients, those who are older or have co-morbid disease and undergo major 
gastrointestinal or vascular surgery. Importantly, patients who develop complications, but 
survive to leave hospital, suffer reduced long-term survival.19, 208, 335 It is accepted that the 
dose of intravenous fluid has an important effect on patient outcomes, in particular following 
major gastrointestinal surgery. However, fluid is widely prescribed according to subjective 
criteria leading to wide variation in clinical practice.4, 351 One possible solution is the use of 
dynamic markers of preload responsiveness, such as Stroke Volume Variation (SVV) and Pulse 
Pressure Variation (PPV), which describe the degree of haemodynamic change which occurs 
during the respiratory cycle.174 Larger values suggest hypovolaemia, but may also occur if the 
heart rhythm is irregular or the patient is breathing spontaneously. Dynamic markers may 
simplify the approach to fluid therapy during the perioperative period, whilst reducing the 
number of fluid challenges administered simply to test the patients’ volume status. SVV and 
PPV have both been used as end-points for fluid therapy in two small randomised trials with 
promising results,47 whilst more recent studies of the predictive value of SVV and PPV for fluid 
responsiveness have yielded inconsistent findings.173, 179, 352-357  This may relate to differences 
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in patient populations, the specific methods used to test fluid responsiveness (in particular 
the volume of the intravenous fluid bolus), and to factors that introduce additional variation 
in cardiac output across the respiratory cycle. Commentaries have highlighted the need for 
further research to determine the appropriate use of haemodynamic end-points provided by 
minimally invasive cardiac output monitoring.358 OPTIMISE is a recently completed multi-
centre randomised trial of cardiac output guided haemodynamic therapy in high-risk patients 
undergoing major gastrointestinal surgery that used the LiDCO rapid as the cardiac output 
monitor.200  The objective of the primary trial was to determine the clinical effectiveness of 
this approach in routine practice where the circumstances of patient care are less well 
controlled than in small efficacy trials. Given the potential value of SVV and PPV to simplify 
intravenous fluid therapy, we incorporated a sub-study to determine the accuracy of these 
variables in predicting fluid responsiveness within the same context, in order to establish their 
utility in implementing the trial intervention into routine clinical practice. We hypothesised 
that SVV and PPV as measured by the LiDCO rapid would accurately predict an increase in 
stroke volume of ≥10% in response to an intravenous fluid bolus.  
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5.2 Methods 
5.2.1 Study design 
The OPTIMISE trial, is a multi-centre, observer-blinded, randomised controlled trial conducted 
in seventeen hospitals in the United Kingdom. The trial findings including the study protocol 
are presented in detail previously in this thesis. This sub-study was conducted in two 
participating hospitals. Adult patients aged 50 years or over undergoing major abdominal 
surgery involving the gastrointestinal tract of expected duration greater than 90 minutes were 
eligible for recruitment provided they satisfied one of the following criteria: age ≥65 years, 
presence of a risk factor for cardiac or respiratory disease, acute or chronic renal impairment 
(serum creatinine ≥130 μmol l-1), diabetes mellitus or non-elective surgery. Exclusion criteria 
were refusal of consent, pregnancy, acute arrhythmias or myocardial ischaemia prior to 
enrolment and patients receiving palliative treatment only. Patients with chronic atrial 
fibrillation were eligible for inclusion. OPTIMISE was approved by the East London & City 
Research Ethics Committee (09/H0703/23) and the Medical and Healthcare products 
Regulatory Agency and registered with Controlled Trials (ISRCTN04386758). Written informed 
consent was obtained from all patients prior to surgery. 
 
5.2.2 Clinical management 
The intervention period commenced with induction of anaesthesia and continued until six 
hours after surgery was complete. All patients received standard measures to maintain 
oxygenation (SpO2 ≥94%), haemoglobin (>80 g L-1), core temperature (37 °C) and heart rate 
(<100 bpm). 5% dextrose was administered at 1 ml-1 kg-1 hr-1 to satisfy maintenance fluid 
requirements. Mean arterial pressure was maintained between 60 and 100 mmHg using an 
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alpha adrenoceptor agonist or vasodilator as required. In the control group additional fluid 
was administered at the discretion of the clinician guided by pulse rate, arterial pressure, urine 
output, core-peripheral temperature gradient, serum lactate and base excess. 
Patients randomised to the intervention received intravenous fluid and inotropic therapy 
guided by a haemodynamic therapy algorithm informed by cardiac output monitoring (LiDCO 
rapid, LiDCO Ltd, Cambridge, UK) as determined by the OPTIMISE trial protocol. This 
algorithm included the use of 250ml intravenous fluid challenges with colloid solution as 
required in order to achieve and maintain a maximal value of stroke volume. Fluid 
responsiveness was defined as an increase in stroke volume equal to or greater than 10%. 
Patients also received an intravenous infusion of dopexamine at a fixed rate of 0.5 μg kg-1 
min-1 (Cephalon, Welwyn Garden City, UK). The dose of dopexamine was reduced if the heart 
rate increased above 120% of baseline value or 100bpm (whichever was greater) for more 
than 30 minutes despite adequate anaesthesia and analgesia. If the heart rate did not 
decrease despite dose reduction, the dopexamine infusion was discontinued. 
Some additional measures were taken for sub-study patients. During mechanical ventilation, 
the tidal volume was standardised to 8 ml kg-1 with a positive end-expiratory pressure of 5 
cm H2O prior to fluid administration, as recommended by previous investigators.127, 359 All 
fluid boluses were marked as an event on the monitor. Data describing the first three fluid 
challenges during surgery and the first three fluid challenges after surgery were recorded. The 
following baseline physiological data were recorded one minute before administration of the 
fluid bolus: tidal volume (Vt), respiratory rate (RR), spontaneous ventilation, heart rhythm, 
epidural infusion of local anaesthetic, intravenous infusion of vasoactive drugs and recent 
bolus doses of vasoactive agents. Baseline data also included whether the patient was 
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undergoing laparoscopy at the time of the fluid challenge and if so, the associated intra-
abdominal pressure (IAP). A 250ml intravenous colloid bolus was then administered within 60 
seconds using a 50 ml syringe. Physiological and other data were then recorded again five 
minutes after the bolus was commenced. 
 
5.3 Statistical analysis 
There is no standard approach to sample size calculations for comparing AUROC; instead we 
planned to recruit 100 patients as the largest feasible sample size. Standard receiver operating 
characteristic (ROC) curves were constructed and area under these curves (AUROC) calculated 
to quantify overall prognostic discrimination for fluid responsiveness. AUROC was then 
compared to the null value of 0.5 using a paired non-parametric technique. ROC curves were 
obtained by averaging 1,000 populations bootstrapped from the original study population, as 
previously described.360 This method limits the impact of outlier values and allows for more 
robust calculations. To account for multiple fluid challenges given to each patient, a clustering 
method was used to adjust for the intra-patient correlation. The response to a fluid challenge 
can also be influenced by other factors such as baseline cardiovascular status. The ROC curves 
were adjusted using regression modelling for the following covariates: irregular cardiac 
rhythm (yes or no), heart rate, mean arterial pressure, central venous pressure, respiratory 
rate, epidural infusion of local anaesthetic (yes or no), vasoactive drug infusion (yes or no), 
vasoactive drug bolus within 20 minutes preceding fluid challenge (yes or no), closed abdomen 
OR open abdomen OR laparoscopy, and spontaneous ventilation (yes or no).361 Two models 
were constructed to compare model fit before and after adjustment. The best threshold of a 
ROC curve was chosen as that which maximised the Youden index (sensitivity + specificity-
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1).362 Predictive accuracy is described using the standard terms poor (AUROC 0.6-0.7), fair 
(AUROC 0.7-0.8), good (AUROC 0.8-0.9) and excellent (AUROC 0.9-1.0). AUROC data are 
presented with 95% confidence intervals. Other data are presented as mean (SD) where 
normally distributed or median (IQR) where not normally distributed. Statistical analysis was 
performed using STATA MP 13.1 (STATA Corp, USA). 
 
5.4 Results 
One hundred patients were recruited between August 2010 and October 2012, all of whom 
completed the study assessments and are included in the analysis. Baseline patient 
characteristics are presented in Table 5.1. Details of clinical management including 
intravenous fluid and vasoactive drug therapy are presented in Table 5.2. Two patients 
received fluid challenges with hydroxyl-ethyl starch solution, the remaining 98 with gelatin 
solution. In 44 instances, a fluid challenge was not indicated according to the trial intervention 
algorithm, two during surgery and 42 after surgery, giving a total of 556 fluid challenges all of 
which were included in the analysis. 
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Table 5.1 Baseline patient characteristics 
Data presented as mean (sd) or n (%).*Baseline data missing on two patients 
 n=98  
Age (year) 71 (51-93) 
Sex Male 61 (62%) 
Female 37 (38%) 
Elective Surgery 91 (93%) 
Non-elective surgery 7 (7%) 
Renal impairment (Creatinine >130 µmol litre−1 10 (10%) 
Diabetes mellitus 21 (79%) 
Risk factor for cardiac or respiratory disease 38 (39%) 
Chronic atrial fibrillation 2 (2%) 
Upper gastrointestinal surgery 26 (26%) 
Lower gastrointestinal surgery 36 (37%) 
Small bowel and pancreatic surgery 36 (37%) 
ASA grade  
I 
II 
III 
IV 
 
5 (5%) 
48 (49%) 
44 (45%) 
1 (1%) 
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Table 5.2 Clinical management of patients during intervention period.  
Data presented as mean (SD), median (IQR) or n (%) 
 n =98 
Duration of surgery 277 (93) 
Anaesthetic technique 
General anaesthetic only 
General anaesthetic plus epidural 
 
18 (19%) 
79 (81%) 
I.V. Crystalloid (ml) 
During surgery 
During 6h after surgery 
 
2500 (1500 -3000) 
630 (435 - 800) 
IV colloid (ml) 
During surgery  
During surgery 6h after surgery 
 
1250 (1000) 
750 (5000 – 1000) 
Blood products (ml) 
During surgery 
During 6h after surgery 
 
556 (315 -747) 
313 (276 -851) 
Bolus vasopressor or inotrope agent used during intervention 
period 
86 (88%) 
Vasopressor or inotrope infusion (other than dopexamine) used 
during intervention period 
22 (22%) 
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Overall, 28.6% (129 of 556) of fluid challenges were associated with an increase in stroke 
volume of ≥10%. During surgery, 29.8% (88 of 295) fluid challenges were positive and after 
surgery 27.2% (71 of 261) were positive. The distribution of SVV and PPV data is shown in 
Figure 5.1. Data describing sensitivity, specificity, AUROC and optimal threshold values are 
shown in Table 5.3. During surgery, the performance of SVV and PPV was on the borderline 
between poor and fair predictive value (Figure 5.2). After surgery, both variables were poor 
predictors of fluid responsiveness due to reduced specificity although optimal threshold 
values changed only slightly (Figure 5.3). For mechanically ventilated patients, the predictive 
value improved slightly and both were almost fair predictors of fluid responsiveness with 
minor changes in the optimal threshold value (Figure 5.4). During spontaneous ventilation SVV 
and PPV were both poor predictors of fluid responsiveness (Figure 5.5). There was little change 
in AUROC after adjustment for pre-specified covariates suggesting these results are robust 
(Table 5.4 and Table 5.5). In order to understand the impact of high outlier values of SVV and 
PPV, we performed a sensitivity analysis excluding observations above the 95th centile (Table 
5.6). The predictive value of SVV and PPV improved slightly for measurements during surgery 
and mechanical ventilation but remained poor for measurements after surgery and during 
spontaneous ventilation. The optimal threshold values remained unchanged. We also 
performed a sensitivity analysis excluding 319 fluid challenges (53%) performed during 
laparoscopy, spontaneous ventilation or any form of abnormal cardiac rhythm (Table 5.7). The 
predictive values improved slightly for SVV and PPV in this sensitivity analysis. The optimal 
threshold values remained unchanged. 
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Figure 5.1 Distribution of Stroke Volume Variation (SVV) and Pulse Pressure Variation 
(PPV) data during and after surgery  
(showing outlier values) 
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Table 5.3 Comparison of AUROC before and after adjustments, sensitivity, specificity, and 
optimal threshold value 
Stroke Volume Variation (SVV) and Pulse Pressure Variation (PPV). CI, 95% confidence 
intervals 
 
 AUROC (CI) AUROC after 
adjustment (CI) 
Sensitivity  Specificity Optimal 
Threshold 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
During surgery 
SVV 0.69 (0.62 – 0.77) 0.69 (0.62 – 0.77) 76% 66% 10% 73% 69% 
PPV 0.70 (0.62 - 0.77) 0.70 (0.62 - 0.77) 75% 61% 12% 82% 54% 
After surgery 
SVV 0.69 (0.63 0.78) 0.69 (0.63 -0.78) 69% 56% 11% 73% 52% 
PPV 0.64 (0.56 – 0.73) 0.64 (0.56 – 0.73) 84% 41% 10% 83% 54% 
Spontaneously breathing 
SVV 0.69 (0.61 -0.77) 0.69 (0.61 -0.77) 69% 56% 11% 74% 52% 
PPV 0.63 (0.56 -0.72) 0.63 (0.56 0.72) 85% 41% 10% 83% 43% 
Mechanically ventilated 
SVV 0.68 (0.63 -0.76) 0.68 (0.63 -0.76)  76% 66% 10% 73% 69% 
PPV 0.69 (0.61 -0.77) 0.69 (0.61 -0.77) 74% 61% 12% 82% 54% 
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Figure 5.2 AUROC curves for SVV and PPV during surgery. 
AUROC SVV: 0.69 (0.62–0.77); AUROC PPV: 0.70 (0.62–0.77) 
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Figure 5.3 ROC curves for SVV and PPV after surgery. 
AUROC SVV: 0.69 (0.63–0.78); AUROC PPV: 0.64 (0.56–0.73) 
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Figure 5.4 AUROC curves for SVV and PPV during spontaneous breathing.  
AUROC SVV: 0.69 (0.61–0.77); AUROC PPV: 0.63 (0.56–0.72) 
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Figure  5.5 AUROC curves for SVV and PPV during mechanical ventilation (with no 
spontaneous breathing). 
 AUROC SVV: 0.68 (0.63–0.76); AUROC PPV: 0.69 (0.61–0.77) 
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Table 5.4 Comparison of baseline variables that were adjusted for during surgery and after 
surgery 
Data presented as mean (SD) or n (%) as appropriate. *During surgery, mean arterial pressure (p=0.02) 
and recent bolus use of vasoactive drugs (p=0.02) were significant predictors in discriminating 
between positive and negative fluid challenges when measuring SVV. Whether a patient had an open 
or closed abdomen or was undergoing laparoscopic surgery was a significant predictor in fluid 
responsiveness when measuring PPV (p<0.05). After surgery, irregular cardiac rhythm status was 
significantly associated with fluid responsiveness in both SVV (p<0.05) and PPV (p<0.01). The other 
covariates were not significantly associated with fluid responsiveness. 
 During surgery (n=294) After surgery (n=261) 
  
SVV 
p-value 
PPV 
p-value 
 
SVV 
p-value 
PPV 
p-value 
Irregular cardiac rhythm 5 (2%) 0.63 0.81 4 (2%) *<0.05 *<0.01 
Epidural infusion 222 (37%) 0.89 0.89 200 (77%) 0.19 0.18 
Vasoactive drug infusion 
Metaraminol 
Norepinephrine 
 
11 (2%) 
10 (2%) 
0.81 0.46 
 
1 (0.2%) 
24 (4%) 
0.29 0.73 
Vasoactive drug bolus 
Ephedrine 
Metaraminol 
 
3 (1%) 
33 (6%) 
*0.02 0.72 
 
0 (0%) 
2 (0.3%) 
0.17 0.10 
Spontaneous breathing 1 (0.2%) - - 253 (42%) 0.31 0.31 
Open abdomen 
Closed abdomen 
Laparoscopy 
150 (51%) 
88 (30%) 
56 (19%) 
0.27 *0.05 
8 (3%) 
256 (97%) 
0 (0%) 
0.39 0.67 
Heart rate 74 (17) 0.26 0.37 86 (15) 0.63 0.63 
Mean arterial pressure 73 (17) *0.02 0.09 84 (17) 0.84 0.84 
Respiratory rate 13 (1) 0.92 0.97 16 (2) 0.27 0.27 
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Table 5.5 Comparison of baseline variables for spontaneously ventilated and mechanically 
ventilated patients 
Data presented as mean (SD) or n (%) as appropriate. *During spontaneous breathing, irregular cardiac 
rhythm (p<0.01) was significant predictors in discriminating between positive and negative fluid 
challenges when measuring PPV. For mechanically ventilated patients, open abdomen or closed 
abdomen or laparoscopy was a significant predictor in fluid responsiveness when measuring 
PPV (p=0.02). The other covariates were not significantly associated with fluid responsiveness. 
 
 Spontaneously breathing (n=254) 
Mechanically ventilated 
(n= 301) 
  
SVV 
p-value 
PPV 
p-value 
 
SVV 
p-value 
PPV 
p-value 
Irregular cardiac rhythm 4 (2%) 0.07 *<0.01 5 (2%) 0.95 0.46 
Epidural infusion 195 (77%) 0.06 0.09 227 (75%) 0.44 0.61 
Vasoactive drug infusion 
Metaraminol 
Norepinephrine 
 
1 (0.5%) 
22 (9%) 
0.34 0.84 
 
11 (4%) 
12 (4%) 
0.46 0.29 
Vasoactive drug bolus 
Ephedrine 
Metaraminol 
 
0 (0%) 
2 (1%) 
0.18 0.11 
 
3 (1%) 
33 (11%) 
0.03 0.71 
Open abdomen 
Closed abdomen 
Laparoscopy 
7 (3%) 
246 (3%) 
0 (0%) 
0.68 0.13 
151 (50%) 
94 (31%) 
56 (19%) 
0.15 *0.02 
Heart rate 86 (16) 0.79 0.44 74 (18) 0.22 0.27 
Mean arterial pressure 81 (17) 0.67 0.45 72 (17) 0.17 0.39 
Respiratory rate 16 (2) 0.50 0.52 13 (1) 0.88 0.71 
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Table 5.6 Sensitivity analysis: Comparison of area under receiver operating characteristic 
curves (AUROC) before and after adjustment for covariates, sensitivity, specificity and 
optimal threshold value   
Stroke Volume Variation (SVV) and Pulse Pressure Variation (PPV). CI, 95% confidence 
intervals. 
 
 AUROC (CI) AUROC after 
adjustment (CI) 
Sensitivity  Specificity Optimal 
Threshold 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
Intra-operative 
SVV 0.71 (0.64 – 0.77) 0.67 (0.60 – 0.75) 74% 69% 10% 70% 72% 
PPV 0.72 (0.66 – 0.79) 0.71 (0.64 – 0.79) 72% 65% 12% 80% 54% 
Post-operative 
SVV 0.70 (0.63 - 0.77) 0.66 (0.56 -0.74) 66% 61% 11% 70% 58% 
PPV 0.65 (0.58 – 0.72) 0.61 (0.51 – 0.69) 83% 44% 10% 81% 47% 
Spontaneously breathing 
SVV 0.70 (0.63 -0.77) 0.65 (0.55 -0.73) 66% 60% 11% 70% 56% 
PPV 0.63 (0.56 -0.72) 0.63 (0.56 0.72) 83% 44% 10% 81% 46% 
Mechanically ventilated 
SVV 0.71 (0.64 -0.77) 0.67 (0.59 -0.75)  73% 69% 10% 70% 72% 
PPV 0.69 (0.61 -0.77) 0.69 (0.61 -0.77) 72% 65% 12% 80% 57% 
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Table 5.7 Sensitivity analysis: Comparison of area under receiver operating characteristic 
curves (AUROC), sensitivity, specificity and optimal threshold value 
Stroke Volume Variation (SVV) and Pulse Pressure Variation (PPV) after exclusion of 319 
fluid challenges (53%) performed during laparoscopy, spontaneous ventilation or any form 
of abnormal cardiac rhythm. CI, 95% confidence intervals. 
 
 AUROC (CI) Sensitivity  Specificity Optimal 
Threshold 
Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
SVV 0.70 (0.62 – 0.78) 71% 71% 10% 67% 74% 
PPV 0.72 (0.64 – 0.80) 70% 66% 12% 77% 60% 
 
5.5 Discussion 
The principal finding of this study is that the performance of both SVV and PPV was on the 
borderline between poor and fair prediction of fluid responsiveness during surgery. After 
surgery, neither variable was a useful predictor of fluid responsiveness, primarily because of 
poor performance during spontaneous ventilation, which resulted in reduced specificity. 
These findings were essentially unchanged after adjustment for covariates and accounting for 
repeated measures taken during a series of six fluid challenges during and after surgery. 
Predictive value improved slightly in a sensitivity analysis excluding unusually high values of 
SVV and PPV. Our findings contrast with those of the widely quoted systematic review 
undertaken by Marik and colleagues in 2009.174 The findings of this previous review, which 
included trials primarily of mechanically ventilated patients in intensive care, suggested good 
or excellent predictive value for both SVV and PPV. Importantly, the incidence of fluid 
responsiveness was greater than 50% amongst the component studies in this systematic 
review but less than 30% in the study presented here. This difference may in turn relate to 
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the size of fluid challenge, which was 500 ml or greater in many previous studies but only 
250ml in the current work. The findings of studies published since Marik’s review have been 
inconsistent, with widely differing results in terms of predictive accuracy.173, 179, 352-357 The 
largest study to date reported a good predictive value of PPV to predict fluid responsiveness 
in 413 patients undergoing surgery.173 There are several key differences between this 
previous study and the current work. We analysed three fluid challenges during, and three 
fluid challenges after major gastrointestinal surgery giving 556 study episodes. We used a 
rapid 250 ml fluid bolus administered within one minute and a positive fluid challenge was 
defined as an increase in stroke volume of 10% or more within 5 minutes. In the previous 
work, 413 patients were included but only 12% underwent gastrointestinal surgery. Each 
patient was studied only once giving 413 fluid challenge episodes consisting of a 500 ml bolus 
administered over 10-20 minutes with a positive fluid challenge defined as an increase in 
cardiac output of 15% or more. In the previous study, PPV was calculated manually whilst in 
the current work, this measurement was made using the LiDCO rapid system. The method 
of calculating SVV and PPV may differ between proprietary monitors. These differences may 
help to explain the contrasting findings of the two studies. In accordance with previous work, 
we standardised mechanical ventilation with a tidal volume of 8 ml kg-1 during the fluid 
challenge.127, 359  There is ongoing debate about the most appropriate tidal volume for 
mechanical ventilation during surgery, with contrasting findings from recent studies. Whilst 
the tidal volume used in this study is on the borderline of the contrasting ranges 
recommended in these recent studies,122, 363 concerns regarding the safety of ventilation at 
higher tidal volumes may further limit the utility of SVV and PPV as measured by the LiDCO 
rapid. 
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In terms of individual fluid challenges, this is the largest study of the predictive accuracy of 
dynamic markers of preload responsiveness we are aware of, and the second largest in terms 
of numbers of patients recruited. We utilised a cardiac output monitoring technology which 
can be used both during and after surgery (in awake, extubated patients), which has been 
extensively evaluated in terms of accuracy, and has been in widespread clinical use for more 
than ten years.342  
It is the only study of which we are aware, to make adjustments for important covariates 
encountered in routine clinical practice, relating to baseline physiological status, surgical 
procedure and respiratory management. We also take account of the multiple fluid challenges 
performed in each patient as part of our statistical analysis. However, there are also some 
potential limitations to this work. The volume of intravenous colloid used in each fluid 
challenge may be considered by some to be insufficient to result in a measurable change in 
stroke volume, although the approach to fluid challenge used does reflect normal practice in 
the UK. We also included patient data regardless of possible confounding factors such as 
irregular heart rhythm, or pneumo-peritoneum. The findings of recent studies have suggested 
that midline thoracotomy and changes in intra-abdominal pressure may affect the predictive 
value of SVV and PPV.364, 365 In a few cases, SVV and PPV values were unusually high and some 
commentators argue that clinicians would not use high outlier values to guide fluid therapy. 
However, we note that exclusion of high outliers in our sensitivity analysis did not 
substantially alter our findings. We also conducted a sensitivity analysis which excluded all 
measurements taken during laparoscopy, spontaneous ventilation or any form of abnormal 
cardiac rhythm. Whilst this did result in some improvement in predictive accuracy, the 
exclusion of more than half the fluid challenges clearly limits the utility of SVV and PPV in 
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guiding intravenous fluid therapy by the LiDCO rapid system. Whilst we took several steps 
to account for sources of measurement error in our analysis, it is possible that our findings do 
not represent the optimal performance which could be achieved when using these variables 
as predictors of fluid responsiveness. However, our objective was to study these variables as 
they will be used in routine clinical practice, rather than in a carefully controlled and 
standardised environment which does not reflect usual clinical care. The measures we took 
to standardise the fluid challenge process may more closely reflect those that a busy clinician 
is able to take in a normal working environment. Nonetheless, it is possible that predictive 
accuracy could be improved with clinical training to better recognise the circumstances under 
which SVV and PPV measurement is likely to be inaccurate. A number of haemodynamic end-
points have been proposed for intravenous fluid therapy and it is possible that alternative 
end-points may have greater predictive accuracy than those studied in this work. 
 
5.6 Conclusions 
In this study, the predictive accuracy of SVV and PPV as measured by the LiDCO rapid for 
fluid responsiveness was not adequate for routine use during or after major gastrointestinal 
surgery. Our findings also confirm the established view that these variables should not be 
used for predicting fluid responsiveness in spontaneously breathing patients. Whilst it may 
be possible to make valid use of these variables in more specific patient groups, under more 
controlled physiological circumstances, this may limit the convenience and simplicity of these 
variables. A much larger study would be needed to define the circumstances under which SVV 
and PPV could be recommended to guide intravenous fluid therapy in routine clinical practice. 
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CHAPTER SIX  Acute kidney injury and Goal Directed Therapy 
 
The role of Goal Directed Therapy in the prevention of Acute Kidney Injury 
after Major Gastrointestinal Surgery: a sub-study of the OPTIMISE trial 
 
6.1 Introduction 
While the mortality and morbidity associated with surgery appears to be decreasing 9 the 
increasing volume of surgical procedures in an aging population means that complications 
following major surgery continue to be major health burden, 366 particularly in high risk 
surgical populations.12 Investigation of post-operative complications shows the development 
of perioperative AKI 367, 368 has been associated with a greater 30-day mortality, increased 
length of stay and development of chronic kidney disease.367, 369, 370 The incidence of kidney 
injury varies by surgical setting and patient population, but overall around 13% of patients 
following major abdominal surgery develop AKI.367, 368  
The introduction of the consensus definitions of AKI using urine output and changes in serum 
creatinine 23 have revolutionised the field of AKI research by standardising definitions 
between studies and emphasising the important clinical consequences of all AKI, not just the 
small proportion requiring renal replacement therapy. However using this criteria to diagnose 
AKI after major surgery is complicated by the physiological response which affects urine 
output and creatinine generation making the diagnosis and therefore management of early 
AKI after surgery difficult.371, 372 Use of a more sensitive biomarkers of renal injury may 
improve our identification of AKI. The early identification of patients with AKI would allow the 
early initiation of management of AKI to avoid further kidney injury and its consequences.314 
The management of AKI includes the avoidance of nephrotoxic agents, appropriate fluid 
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resuscitation and maintenance of adequate kidney perfusion pressures.373-375 Urinary 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a biomarker that has been used in a 
number of settings identify patients at risk of developing AKI.308, 376-383   
GDT algorithms utilise intravenous fluids and low dose inotropic drugs to optimise cardiac 
output in the high-risk surgical patients. Several studies have shown this intervention to 
reduce the number of complications in the high-risk patient population.77, 384, 385 GDT has been 
shown to be effective in reducing AKI after surgery.218, 386 The OPTIMISE study was a large 
multicentre randomised controlled trial to assess the effect of a pragmatic GDT algorithm in 
reducing complications after major gastrointestinal surgery.200  The OPTIMISE study did not 
show a reduction in AKI in the patient group receiving GDT (GDT 17/368 vs UC 17/365). 
However the use of a more sensitive biomarker may demonstrate a reduction in AKI following 
this intervention. Accordingly we measured urinary NGAL and NGAL:creatinine387 ratio at 24 
and 72 hours following major gastrointestinal surgery to assess in there was a reduction in 
AKI rates in the GDT group. 
 
6.2 Methods 
The OPTIMISE trial was approved by the East London and City Research Ethics Committee 
(09/H0703/23) and the Medical and Healthcare Products Regulatory Agency 
(ISRCTN04386758).  Approval was also given for the collection and storage of blood and urine 
for further analysis. The trial was sponsored by Queen Mary University of London and the 
urinary biomarker analysis was carried out at the University of Dublin. 
 
 188   
6.2.1 Data Collection 
The OPTIMISE trial recruited patients over 65 or those patients over 50 with a specified co-
morbidity undergoing major gastrointestinal surgery lasting more than ninety minutes. 
Patients were randomised into receiving a GDT algorithm or usual care using a computer-
generated dynamic procedure (minimisation) with a random component. To ensure 
consistent care across both groups certain perioperative parameters were predefined. These 
were keeping the heart rate between 60-100 beats per minute, a mean arterial pressure of 
between 60-100mmHg, oxygen saturations greater than 94% and haemoglobin greater than 
80g dl-1. The algorithm used cardiac output monitoring (LiDCO) to optimise left ventricular 
stroke volume and a low dose dopexamine infusion (0.5mcg/kg/min) for the duration of 
surgery and six hours post-operatively. All patients in the OPTIMISE trial were followed up 
during their hospital stay and until 30 days post-operatively. The development of any 
complication was decided by the follow up narrative given to the principal investigator or 
nominated deputy if aware of the allocation. Four of the seventeen sites involved in recruiting 
patients for OPTIMISE recruited into the biomarker sub-study. 
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Figure 6.1 Flow Diagram 
 
  
Assessed for eligibility  
(n= 310) 
Excluded (n= 23) 
Unable to obtain sample at 24 or 72 
hours after surgery (n=23) 
 
 
No sample obtained (n=18) 
 
Pre-operative 
(n=269) 
72 Hours 
(n=272) 
24 Hours 
(n=236) 
Included 
 (n= 287) 
No sample obtained (n=51) 
 
No sample obtained (n=15) 
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6.2.2 Outcome measures 
Biomarker AKI was defined as a concentration of urinary NGAL equal to or greater than 
150ng/ml measured at 24 or 72 hours after surgery. As a secondary outcome measure urinary 
NGAL:creatinine ratio was measured and a ratio or greater than 0.4 was considered diagnostic 
of AKI. AKI was defined in the protocol as AKI stage 2 or greater using the creatinine criteria 
of the Kidney Disease Improving Global Outcomes (KDIGO) definition, which is a doubling of 
serum creatinine relative to pre-operative baseline or reduction in urine output (when a 
catheter was available) up to thirty days after surgery.  
 
6.2.3 Sample collection 
Urine samples were collected preoperatively and at 24 and 72 hours post-operatively. The 
urine samples were from a sample provided by the patient or withdrawn from an indwelling 
urinary catheter. These were placed into three separate microcentrifuge tubes for each time 
point and frozen at -80oC. Urine samples were stored prior to being sent to a central 
laboratory for batched analysis. 
 
6.2.4 Laboratory Measurement of Urinary Biomarkers 
Urinary NGAL and urinary creatinine were measured in all samples. The Creatinine (CRENZu) 
assay was performed on Abbott Architect ci4100 Clinical Analyser and the NGAL assay was 
performed on Abbott Architect I4100SR Clinical Analyser. The two analysers are located in the 
UCD CRC Biomarker Core Lab, SVUH Dublin. Prior to testing instrument calibration was 
performed, followed by imprecision testing (4x duplicates of each control per day for 3 days); 
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in addition duplicates of each control were run each day. A total CV of <10% was considered 
acceptable for N-GAL, while CV of <3.6% was considered acceptable for CRENZu. 
CRENZu assay involved enzymatic hydrolysis of creatinine into a number of intermediates 
which eventually react with assay reagents to produce quinoeimine dye. The amount of dye 
produced is proportional to the amount of creatinine present in the original sample and can 
be quantified optically. 3.6ul of sample is analysed in each assay.  
NGAL is analysed using a two-step immunoassay for the quantitative determination of NGAL 
in human urine using CMIA technology with flexible assay protocols, referred to as Chemiflex. 
70 microl of sample is analysed in each standard assay. Samples reading above range 
(>1500ng/ml) were diluted ¼ and re-assayed.  Results are presented as NGAL concentration 
and NGAL:Creatinine ratio to standardise for differences in urinary concentration. As the 
validity for standardisation for urinary concentration has been questioned our primary 
analysis was based on absolute urinary NGAL concentration. 
 
6.3 Statistical Analysis 
Statistical analysis was performed in R v3.3.3 (R Foundation for Statistical Computing, Vienna, 
Austria) using RStudio v1.0.136 (RStudio Inc, Boston, MA, USA). Continuous data are 
presented median with interquartile range (IQR) and compared with the Wilcoxon rank sum 
test, categorical data were compared using Fisher’s exact test. Predictive accuracy of the 
biomarker level for AKI outcome was assessed by calculation of the receiver operating 
characteristic area under the curve (ROC-AUC) with 95% confidence intervals computed with 
2000 stratified bootstrap replicates.388 
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6.4 Results 
287 of the 734 patients enrolled in the OPTMISE trial were included in this biomarker sub-
study analysis. Of the 287 patients 144 were in the GDT  group and 143 were in the usual care 
group. As in the main OPTMISE trial the patients in the usual care group were older but there 
was no other significant difference in co-morbidities or in surgical procedure or type (Table 
6.1). 
 
6.4.1 Incidence of AKI in GDT group versus Usual Care 
There was no difference in the incidence of AKI between the GDT and usual care (UC) groups 
as measured by urinary NGAL (31/144 vs 28/143; p 0.88) and no difference in the urinary 
NGAL between the groups at 24 hours (GDT 53.50 ng/ml UC group 44.10 ng/ml p 0.38) or at 
72 (GDT 45.10 ng/ml UC 41.15 ng/ml p 0.50) hours after surgery (Figure 6.1). Similarly to the 
overall study there was no difference in the rate of AKI as diagnosed by the KDIGO criteria in 
either GDT or usual care group (UC) in the biomarker sub study group (GDT 9/144, UC 11/143 
p 0.80) (Table 6.2). There was similarly no difference at 24 (GDT 0.45 vs UC 0.43 p 0.63) or 72 
(GDT 0.66 vs UC 0.63 p 0.62) hours after surgery (Figure 6.2). 
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Table 6.1 Baseline Characteristics of Study Population 
 
   GDT Usual Care 
  144 143 
 Age (median[IQR]) 70.0 [65.5,75.0] 72  [67.0,77.0] 
 Gender = F (%) 57 (39.9) 49 (34) 
 urgency = N(%) 7 (4.9) 6 (4.2) 
 weight (median[IQR]) 72.00 (61.50,83.00) 75.00 (64.75,87.25) 
Risk Factors    
 Renal disease (%) 7 (4.9) 4 (2.8) 
 Diabetes Mellitus (%) 20 (14.0) 26 (18.1) 
 Cardiorespiratory Disease 45 (31.5) 51 (35.4 
ASA    
 ASA 1 (%) 8 (5.6) 7 (4.9) 
 ASA 2 (%) 85 (59.4) 68 (47.2) 
 ASA 3 (%) 49 (34.3) 67 (46.5) 
 ASA 4 (%) 1 (0.7) 2 (1.4) 
Surgical 
Procedure 
   
 Laparoscopic (%) 19 (13.3) 23 (16.0) 
 Open (%) 107 (74.8) 109 (75.7) 
 Laparoscopic converted to 
open (%) 
17 (11.9) 12 (8.3) 
Procedure 
type 
   
 Upper Gastrointestinal (%) 51 (35.7) 55 (38.2) 
 Lower Gastrointestinal (%) 37 (25.9) 40 (27.8) 
 Small Bowel, Pancreas or 
both (%) 
52 (37.1) 48 (33.3) 
 Urological or Gynaecological 
surgery involving the gut (%) 
2 (1.4) 1 (0.7) 
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Table 6.2 Outcomes Goal Directed Therapy versus Usual Care 
 
 
 ALL Goal Directed 
Therapy Group 
Usual Care 
Group 
p 
value 
Death at 180 days 
(%) 
34 (11.8) 15 (10.4) 19 (13.3) 0.569 
Critical Care Free 
Days (median 
[IQR]) 
27.00 
[24.00, 
28.00] 
27.00 [25.00, 
28.00] 
26.00 [23.00, 
28.00] 
0.274 
24 hour NGAL 
>150 ng/ml (%) 
42 (15.4%) 20 (14.3%) 22 (16.4%) 0.74 
72 hour NGAL > 
150 ng/ml 
32 (15.7%) 18 (17%) 14 (14.2%) 0.71 
Acute Kidney 
Injury (%) stage 2-3 
20 (7.0) 9 (6.2) 11 (7.7) 0.804 
Any primary 
complication (%) 
143 (49.8) 59 (41.0) 84 (58.7) 0.004 
Infective 
complication (%) 
92 (32.1) 35 (24.3) 57 (39.9) 0.007 
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Figure 6.1 Urinary NGAL.  Goal Directed Therapy versus Usual Care 
 
 
 
GDT: goal directed therapy 
Relationship between the presence of a biomarker of acute kidney injury (urinary neutrophil 
gelatinase-associated lipase) and allocation to a goal directed therapy algorithm or usual care for 
perioperative fluid therapy in a high risk surgical population at three time points (before surgery, 24 
hours after surgery and 72 hours after surgery). 
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Figure 6.2  Urinary NGAL: creatinine ratio. Goal Directed Therapy versus Usual Care 
 
 
 
GDT: goal directed therapy 
Relationship between the presence of a biomarker of acute kidney injury (urinary neutrophil 
gelatinase-associated lipase) and its ratio to urinary creatinine (urinary neutrophil gelatinase-
associated lipase: creatinine ratio) and allocation to a goal directed therapy algorithm or usual care 
for perioperative fluid therapy in a high risk surgical population at three time points (before surgery, 
24 hours after surgery and 72 hours after surgery).  
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6.4.2 Relationship between post-operative NGAL and AKI diagnosis 
In those patients who developed AKI there was no significant difference in pre-operative 
urinary NGAL compared to those patients who did develop AKI (No AKI 13.30 AKI 8.10 p 0.83). 
However, a significant difference in urinary NGAL was observed at both 24 hours (No AKI 
45.65 AKI 78.00 p 0.01) and at 72 hours after surgery (No AKI 40.10 AKI 129.60 p <0.001) 
(Figure 6.3). Similar results were observed using the NGAL:creatinine ratio at 24 hours (No 
AKI 0.43 AKI 0.82 p 0.015) and 72 hours (No AKI 0.60 AKI 4.01 p 0.001) (Figure 6.4).  
 
  
 198   
Table 6.3   Outcomes No Acute Kidney Injury versus Acute Kidney Injury 
 
 
 
 
Total No Acute 
Kidney Injury 
Acute Kidney 
Injury 
P value 
N 287 267 20  
GENDER = M (%)    180 (62.7)     165 (61.8)      15 (75.0)  0.348 
Age (median [IQR])  70.00 [66.00, 
76.00] 
 70.00 [66.00, 
76.00] 
 69.00 [65.75, 
76.50] 
0.68 
NGAL (median IQR)     
Status at The End of Acute 
Hospital Stay (%) 
    13 (4.6)       4 (1.5)       9 (47.4)  <0.001 
Days on the Intensive Care Unit 
(median [IQR]) 
  3.00 [2.00, 5.20]   3.00 [1.95, 
5.00] 
 10.65 [3.63, 
18.10] 
<0.001 
Critical Care Free days (median 
[IQR]) 
 27.00 [24.00, 
28.00] 
 27.00 [25.00, 
28.00] 
 11.50 [0.00, 
20.50] 
<0.001 
Multi Organ Dysfunction 
Syndrome (%) 
    24 (8.4)      10 (3.8)      14 (70.0)  <0.001 
Surgical Site Infection (%)     31 (10.8)      25 (9.4)       6 (30.0)  0.013 
Any Primary Complication (%)    143 (49.8)     123 (46.1)      20 (100.0)             <0.001 
Infective Complications (%)     92 (32.1)      79 (29.6)      13 (65.0)  0.002 
Postoperative Hospital Length of 
Stay (median [IQR]) 
 12.00 [9.00, 
17.00] 
 12.00 [9.00, 
16.00] 
 20.00 [11.50, 
43.50] 
0.016 
Death (%)     34 (11.8)      25 (9.4)       9 (45.0)  <0.001 
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Table 6.4 NGAL and NGAL:creatinine ratio at pre-specified timepoints 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  All GDT UC p value 
PRE      
 n 269 137 132  
 NGAL 
(median 
[IQR]) 
12.70 [5.40, 
42.50] 
12.60 [5.70, 41.90] 14.55 [5.05, 
42.55] 
0.877 
 NGCRR 
(median 
[IQR]) 
 0.19 [0.09, 0.61]  0.18 [0.09, 0.57]  0.20 [0.09, 
0.67] 
0.865 
24h      
 n 236 139 134  
 NGAL 
(median 
[IQR]) 
42.40 [21.48, 
88.30] 
 53.50 [22.40, 
118.60] 
 44.10 [20.50, 
80.20] 
0.379 
 NGCRR 
(median 
[IQR]) 
 0.63 [0.32, 1.33]   0.45 [0.23, 0.95]   0.43 [0.21, 
0.89] 
0.629 
72h      
 n 273 124 112  
 NGAL 
(median 
[IQR]) 
 48.50 [21.60, 
104.60] 
45.10 [21.67, 
94.35] 
41.15 [19.67, 
87.00] 
0.503 
 NGCRR 
(median 
[IQR]) 
  0.44 [0.23, 0.92]  0.66 [0.32, 1.50]  0.63 [0.32, 
1.10] 
0.62 
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Figure 6.3  Urinary NGAL. No Acute Kidney Injury versus Acute Kidney Injury 
 
 
 
No AKI: no acute kidney injury; AKI: acute kidney injury 
 
Relationship between the presence of a biomarker of acute kidney injury (urinary neutrophil 
gelatinase-associated lipase) and the diagnosis of acute kidney injury by Kidney Disease: Improving 
Global Outcomes (KDIGO) stage two and three in a high risk surgical population at three time points 
(before surgery, 24 hours after surgery and 72 hours after surgery). 
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Figure 6.4 Urinary NGAL: creatinine ratio. No Acute Kidney Injury versus Acute Kidney 
Injury 
 
 
No AKI: no acute kidney injury; AKI: acute kidney injury 
Relationship between the presence of a biomarker of acute kidney injury (urinary neutrophil 
gelatinase-associated lipase) and its ratio to urinary creatinine (urinary neutrophil gelatinase 
associated lipase: creatinine ratio) and the diagnosis of acute kidney injury by Kidney Disease: 
Improving Global Outcomes (KDIGO) stage two and three in a high risk surgical population at three 
time points (before surgery, 24 hours after surgery and 72 hours after surgery).  
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6.5 Discussion 
This sub study of the OPTIMISE trial did not show any difference in the urinary NGAL 
concentration or urinary NGAL:creatinine ratio after major abdominal surgery in a high risk 
patient population randomised to receive either a GDT algorithm or usual care. There was 
similarly no difference noted in urinary NGAL concentrations or urinary NGAL: creatinine ratio 
at discrete time points of 24 or 72 hours after surgery. We found that there was a significant 
difference in urinary NGAL concentration and urinary NGAL:creatinine ratio between those 
patients who developed KDIGO defined AKI and those patients who did not. This study 
confirmed the overall findings of the OPTIMISE trial that this GDT algorithm did not lessen the 
likelihood of the development of moderate to severe AKI. Our findings in this sub-study are 
in contrast to previous studies of GDT in high risk surgical patient groups which have 
demonstrated a reduction in post-operative AKI. However, similarly to our findings in this 
study, recent studies have also suggested no AKI reduction from a GDT algorithm in major 
abdominal surgery.224 This study suggested that a high standard of care in the usual care 
group meant similar amounts of fluid were given to both haemodynamic therapy and usual 
care groups and may explain why a reduction in AKI was found in earlier studies of GDT which 
hace shown significant differences between the groups in the amount of fluid given. A recent 
study in patients undergoing major urological surgery who received restrictive fluid therapy 
against usual care demonstrated an increase in AKI in the fluid restricted group.389 Another 
explanation may be the lack of haemodynamic targets in the older trials of GDT for the 
standard care group. The OPTIMISE trial specified broad haemodynamic targets for the usual 
care group to ensure a good standard of care with perioperative studies showing that even 
short periods of hypotension can have adverse effects on kidney function. The contrasting 
findings are difficult to explain fully but recent studies of GDT such as OPTIMISE, suggest that 
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reduction of AKI after surgery is no longer seen in high risk surgical patients receiving GDT 
though a recent meta-analysis suggested there was still a benefit of reducing AKI in more 
recent trials of GDT.348 There are several limitations to our study. We recruited as many 
patients as possible into this study but it may be underpowered to detect any difference in 
the groups. However, no difference was shown in the main OPTIMISE study group reflecting 
our findings.  
Only KDIGO stage 2 and stage 3 were recorded as a complication in the OPTIMISE study and 
therefore stage 1 AKI was not assessed. Other studies have shown that stage 1 AKI has a poor 
prognosis and it is possible that GDT has a potential effect on these patients that we have not 
demonstrated here. However, it is unlikely that the intervention had an effect on KIDGO stage 
one as there was no difference in urinary NGAL or urinary NGAL:creatinine ratio between the 
intervention and usual care groups. The OPTIMISE study did not record when the AKI 
developed so it is not possible to assess NGAL as a predictive biomarker of early kidney injury 
although there was no difference in the pre-operative urinary NGAL concentration between 
the patient group who developed AKI and the group who did not. There is no universally 
agreed biomarker of kidney injury and NGAL has been shown to increase in inflammatory 
states even when kidney function is not affected. This heterogeneity of NGAL as a biomarker 
has led to expressions of doubt of the usefulness of NGAL as specific kidney injury biomarker. 
However, this heterogenicity is more commonly reported in studies using plasma NGAL 
biomarker and this study purposefully used the urinary NGAL biomarker to specifically 
address this. In this study, urinary NGAL was found to correlate with AKI at both 24 and 72 
hours after surgery. Urinary NGAL has no universally agreed optimal threshold to diagnose 
AKI. There have been many different cut off values used to determine the optimal cut off 
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urinary NGAL in predicting AKI. Ranges have been between 20-460 ng/ml307, 312 have been 
used in previous studies, though a more recent review suggests a cut off 80ng/ml.313 This 
study used a cut off value of 150ng/ml though there is little literature regarding NGAL urinary 
cut off values on non-cardiac surgery. 
The time that the samples were obtained is also a limitation. Previous studies have measured 
either urinary or plasma NGAL up to 24 hours after surgery but we measured urinary NGAL at 
24 and 72 hours after surgery. However, the strong correlation of urinary NGAL concentration 
and urinary NGAL:creatinine ratio demonstrates the ability of urinary NGAL to diagnose AKI 
after surgery and demonstrate no difference in the primary outcome. Urinary and plasma 
NGAL alongside KIM-1, TIMP-2 and IGFBP7 have been shown to predict AKI after major 
cardiac surgery but there are few studies examining the ability of biomarkers to predict renal 
outcomes after major abdominal surgery. The timing of our sampling does not allow the 
assessment of urinary NGAL or urinary NGAL:creatinine ratio as a predictive kidney injury 
biomarker except to comment it was not predictive of AKI when measured pre-operatively. 
Further research assessing the ability of urinary NGAL to predict AKI immediately after high 
risk surgery is required to determine the predictive ability of the biomarker in this setting. 
The perioperative incidence of AKI is difficult to quantify but two big studies have suggested 
an overall incidence of between 12-13%. The incidence of AKI in OPTIMISE was much lower 
at 5% though the OPTIMISE study only measured stage 2 and stage 3 AKI. The discrepancy 
may arise from the difficulty in recognising and diagnosing AKI based on creatinine rises and 
urine output. The patient specific response of both creatinine production and urine output in 
a perioperative population undergoing major surgery has the potential to miss a diagnosis of 
AKI that is based on creatinine rise and urine output.  
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We are not aware of any larger studies that have used renal biomarkers to assess post-
operative AKI after GDT in the high risk non-cardiac surgical patient. The importance of post-
operative AKI and the difficulty in identifying it using a combination of creatinine rise and 
urine output has increased the interest in the ability of a renal specific biomarker to identify 
post-operative AKI. There have been several different biomarkers and combination of 
biomarkers that have been used to attempt to identify early AKI in the post-operative setting 
including KIM-1, TIMP-2 and IGFBP7. There is currently no consensus as to the best renal 
biomarker to use after cardiac or non-cardiac surgery but this study shows that urinary NGAL 
and urinary NGAL:creatinine is an appropriate test to use to identify post-operative AKI in a 
high risk surgical patient population. Using a more sensitive biomarker of AKI suggested a 
group of patients who had AKI but no significant changes in either serum creatinine or urine 
output to be diagnosed by KDIGO criteria stage two and three. However there remained no 
difference in the incidence of AKI between the GDT and UC groups when these patients were 
added to the analysis. 
Interestingly urinary NGAL and urinary NGAL:creatinine ratio was better at identifying AKI at 
72 hours than at 24 hours post-operatively. A study that measured NGAL at 2 and 6 hours 
demonstrated that only sustained renal injury, defined as kidney injury persisting beyond 24 
hours, was identified by NGAL rise. The biomarker increase that was seen in our study at 24 
and in particular 72 hours suggests that these rises may represent KDIGO stage 2 or 3 that 
occurred in the post-operative period. This may suggest that sustained renal injury after major 
surgery is a post-operative complication rather than an intra-operative one.  
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A very promising approach for the use of renal biomarkers is to identify those at risk of post-
operative AKI after major surgery and use a preventive strategy to reduce the incidence of 
AKI. It would also allow the identification of those patient who were at further risk of 
deterioration of renal function so appropriate surveillance and follow up could be arranged. 
However this requires validation of the predictive ability of kidney injury biomarkers alongside 
the standardisation of which biomarker(s) to use and agreement on appropriate treatment 
to prevent post-operative AKI. The current use of kidney injury biomarkers is in the trial 
setting as a sensitive marker of AKI to help decide what treatments are successful in reducing 
the incidence of AKI after major surgery. 
 
6.6 Conclusion 
In this biomarker sub-study we did not observe any difference in urinary NGAL concentration, 
or any other biochemical marker of AKI, between the patient group having a GDT intervention 
and those patients who did not. This is in keeping with the finding from the OPTIMISE trial 
that found no effect on incidence of AKI between the two groups. The incidence of AKI as 
defined by KDIGO was lower than observed in other perioperative studies though only 
moderate to severe AKI episodes were captured. Urinary NGAL and urinary NGAL:creatinine 
ratio were able to identify AKI at both 24 and 72 hours after surgery and the biomarker 
incidence of AKI was comparable to other perioperative studies. The development of AKI after 
major surgery is a significant cause of morbidity and mortality postoperatively but there 
remains a lack of interventions available to the perioperative physician to prevent or treat it. 
Future studies assessing the impact of GDT on the incidence of AKI should measure all stages 
of AKI to ensure any effect of GDT on mild AKI is captured. In addition, GDT trials should 
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measure renal injury biomarkers to assess the impact of GDT on the incidence of AKI. Future 
research of kidney injury should focus on the predictive ability of kidney injury biomarkers to 
identify early kidney injury in the postoperative period. If the predictive value of kidney injury 
biomarkers is shown they can be used to select patient groups that would benefit from any 
interventions available to prevent the development of AKI. 
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CHAPTER SEVEN  CONCLUSIONS AND FUTURE WORK 
 
7.1 Introduction 
This thesis sought to investigate the pragmatic aspects of GDT administration and to identify 
and study issues regarding the uncertainty of the effectiveness of GDT outside an explanatory 
trial setting. This involved measuring the effectiveness of dynamic measures of fluid 
responsiveness PPV and SVV and if they were suitable to be included in pragmatic GDT 
algorithms and to assess impact of GDT in reducing AKI after major surgery. We used data 
from the largest trial of a specific GDT algorithm, the OPTIMISE trial, to explore a number of 
the different barriers identified around the introduction of GDT.200 The results showed that 
there is still a lack of statistically proven benefit for GDT in the high risk surgical population 
but there was a suggested benefit for a treatment effect of GDT. The results showed that with 
compliance to this specific GDT algorithm there was no change in the reduction of overall 
complications though identified resource allocation and a learning curve as potential barriers 
to the introduction of GDT Sub studies of the OPTIMISE trial suggested that GDT algorithms 
should still use rise in stroke volume as the targeted endpoint and that GDT does not reduce 
AKI and therefore this is not the mechanism (if any) by which GDT exerts its effect. Further 
work should centre round large pragmatic trials using a similar algorithm but investigating 
infective complications rather than a composite of complications and mortality. 
 
7.2 Summary 
The large number of people undergoing surgery and in particular the large amount of high 
risk surgery undertaken suggest that surgery is a significant global health issue.390 With the 
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increase in surgical procedures particularly in high income countries the impact of therapies 
that reduce morbidity and mortality in the surgical population is increased. High income 
countries have older surgical populations coupled with increasing demand for more complex 
surgery leads to an increase in the high risk surgical population. The use of a specific therapy 
such as GDT to reduce morbidity in this group would potentially have a large impact. However 
there has not been widespread adoption of GDT despite a number of trials and several meta-
analysis suggesting improvement in a variety of different patient outcomes.46, 68, 72, 74 An older 
population undergoing high risk gastrointestinal surgery had been identified from the 
literature as the group that benefits most from GDT in small, explanatory trials.12 We used a 
large pragmatic study design to test the hypotheses that a GDT algorithm would reduce the 
number of complications and death at 30 days after major abdominal surgery. The pragmatic 
design was to bridge the gap in the evidence base moving GDT on from an intervention shown 
to work in very specific circumstances to a therapy that could be delivered to patients in large 
health care systems. There has been criticism of the ability of large pragmatic trials to answer 
specific research questions around complex interventions.391 This editorial argued that there 
are too many confounding factors within the design of a pragmatic trial and the research 
question is best answered with literature review of smaller more precise trials alongside 
observational and cohort studies. This would be less time consuming and cheaper but most 
importantly, they argue, would acknowledge changing medical practice and allow a fairer 
‘real world, comparison. There are significant methodological flaws with this approach as a 
systematic review of a large number of small trials may just echo bias within smaller positive 
studies as it is often hard to find smaller negative outcomes studies in the published 
literature.392 Observational studies do not account for bias within the study group allocation 
and should be used primarily to generate hypotheses regarding medical care not to confirm 
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them. Similarly cohort studies would not give a definitive answer. Both cohort studies and 
observational studies on the scale required would be expensive and have to be so vast as to 
introduce an unacceptable amount of variability. In our study we addressed some of the 
issues raised with the use of pragmatic randomised controlled trials to evaluate perioperative 
interventions. The study was conducted over the shortest possible time period taking just 
over two years to complete. There was a broad standard of care introduced for both arms of 
the study that did not dictate care but ensured best practice was followed. The only significant 
change in medical practice that occurred during the trial period was the withdrawal of 
hetastarches from the U.K.195, 196 This was investigated and a sensitivity analysis done which 
demonstrated there was no difference between the groups. Notwithstanding some of the 
flaws discussed in the methods, a well-designed pragmatic randomised controlled trial 
remains the gold standard to assess a complex intervention. The primary outcome showed 
no statistical difference between the groups but there was a suggested clinical benefit for 
those patients in the GDT group. This inconclusive result may be explained by the study being 
underpowered and this is most likely due to the lack or equipoise regarding GDT in ‘sick’ 
patients. The OPTIMISE study recruited a far larger proportion of American Society of 
Anaesthesiology (ASA) grade one and two patients than was expected into the trial. This study 
also failed to recruit a significant number of patients undergoing emergency laparotomies for 
bowel injury. The consequence of this was that the complication rate in the control group was 
44.5% lower than the expected rate of 50% requiring the intervention group to also have a 
much reduced complication rate in order to be statistically significant. This may have been 
compounded by recent trial evidence showing potential harm of GDT in a fitter younger group 
of patients undergoing major abdominal surgery95 though other studies do suggest benefit 
for this patient group from GDT.97 Further investigation of the GDT algorithm is still warranted 
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looking at a more targeted patient group for a difference in a specific group of complications. 
The patient group that is most likely to benefit from GDT is one that is older and frailer with 
more medical co-morbidities. This group is becoming a larger proportion of the high risk 
surgical population and targeted therapy in this group ids more likely to improve overall 
outcomes from surgery. 
To determine if GDT still has a statistically significant effect on a high risk population a number 
of secondary analyses were done with the OPTIMISE data to assess compliance to the 
algorithm. The difficulty of applying complex interventions to clinical practice from studies 
has not been greatly studied but complex interventions appear to have a lower than expected 
compliance when transferred to clinical practice.212, 213 In trialling this GDT algorithm in a 
pragmatic trial we hypothesised that compliance to the algorithm would be high and that a 
pragmatic trial would be a better marker of the reproducibility of the algorithm in ‘real life’ 
clinical practice. I also hypothesised that taking out those patients who were non-compliant 
would result in a statistically significant difference between the two groups. The non-
compliance protocol was designed into the trial and applied to those patients who had one 
of the three following protocol deviations. Those in the intervention arm who either had not 
received cardiac output monitoring, those in the intervention arm who did not receive the 
correct dose of dopexamine and those in the control arm who received cardiac output 
monitoring. Our subsequent analysis of the OPTIMISE trial suggested that the compliance to 
this specific GDT algorithm was good and the deviations from the protocol made no difference 
to the overall outcome of the trial. This suggests that the results of the OPTIMISE trial will not 
differ significantly from those that would be seen in clinical practice if this algorithm were to 
be widely adopted. The pre-specified analyses which observed the resource required to 
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deliver the intervention and that observed the difference in outcomes after a suitable learning 
period have also helped to identify potential barriers to the introduction of GDT. The analysis 
of resource allocation demonstrated an increased presence of medical and nursing staff for 
the GDT group. This was expected due to the nature of the trial protocol but a large 
proportion of the time was to deliver or advise on delivering the intervention. This combined 
with the finding of a significant learning curve before the algorithm appeared to be effective 
suggest there would have to be a large investment in staff and their education prior to the 
widespread introduction of a GDT algorithm.  
The intervention study group in selected study sites was used to assess the effectiveness of 
dynamic parameters to predict fluid responsiveness. This required the group that was being 
studied to have certain conditions within their perioperative care to ensure the accuracy of 
the findings.174 The sub study group agreed that it was reasonable to add into the 
perioperative care of this patient group parameters that are required for the dynamic 
measures assessed, pulse pressure variation and stroke volume variation, to be accurate. This 
included ventilation at a tidal volume of 8 mls kg-1 with a minimal amount of positive end 
expiatory pressure (PEEP), ensuring that the patient was paralysed and fully mechanically 
ventilated where appropriate. However the largest study of fluid responsiveness that 
assessed the ability of PPV and SVV to predict fluid responsiveness used 500ml fluid 
boluses.173 This has been supplemented by a more recent observational study again 
demonstrating that PPV and SPV were good predictors of fluid responsiveness.353 However, 
we did not feel this was an accurate reflection of the usual size of fluid bolus given in clinical 
care in a high risk patient undergoing major surgery. In addition, this change to the bolused 
fluid amount would have required alterations to the overall OPTIMISE protocol of a 250ml 
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bolus and so 250ml fluid boluses were studied. Our sub-study of the OPTIMISE trial found that 
the dynamic measures PPV and SVV were poor to fair predictors of fluid responsiveness in a 
pragmatic intraoperative and post-operative setting. Several studies have shown benefit of 
the use of PPV and SVV in guiding fluid therapy in major abdominal surgery.96, 152, 180 The two 
exploratory studies found PPV and SVV to be good predictors of fluid responsiveness but 
suggested that overall PPV was the more accurate. Studies that have shown positive 
outcomes using dynamic measures as part of a GDT algorithm in major surgery have either 
used these predictors as one part of the algorithm or as the sole indicator for fluid therapy. 
Both approaches have been successful but neither has been examined in trial of over 200 
patients. Salzwedel et al trialled a GDT algorithm of PPV, CI trending and mean arterial 
pressure against usual care in a study group of 160 patients and found an improvement in 
infective outcomes.47 Lopes et al have used a similar approach using PPV only.158 Rather than 
incorporating non-dynamic parameters into their algorithm they used PPV at greater than 
10% to trigger a fluid bolus and maintain PPV within an acceptable limit. They showed a 
reduction in post-operative complications and length of stay in a study group of 33 patients. 
A meta-analysis in 2014 showed a decrease in postoperative morbidity and in length of stay 
but commented on the heterogenicity of the studies and suggested that larger studies were 
done to evaluate the applicability of these measure in clinical practice.74 The likelihood of a 
binary state of fluid responsiveness in patients is unlikely and to address this issue a ‘grey 
zone’ has been proposed.173 This suggests a tolerance of limits above which the patient is very 
likely to be fluid responsive and below which the patient is very unlikely to be fluid responsive. 
The narrower the gap the more accurate the parameter is in predicting fluid responsiveness. 
The grey zone is best described in PPV and ranges between 9-13% although other studies 
have found it to range as widely between 4-17%. Using this approach allows the parameter 
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to be more accurate as it moves away from having to describe a single cut off or optimal point 
above which the majority of patients will be fluid responsive. However, in describing a grey 
zone we describe a situation in which the clinician is uncertain of the patients response to 
fluid. The authors who first described the grey zone advocate either waiting and observing 
changes in PPV or treating the parameter as a non-dynamic parameter and stressing the 
system with a fluid challenge. The first appears sub-optimal as adherence to GDT protocols 
relies on optimising the patients fluid therapy as soon as possible and the second approach 
means losing the main benefit of using dynamic markers of fluid responsiveness which is to 
avoid superfluous fluid challenges. The current evidence suggests that clinicians should be 
aiming for an ‘goldilocks’ or just right approach to fluid with neither too much or too little 
which means that most patients will be in the grey zone for some part of their perioperative 
care. The OPTIMISE study had a similar amount of fluid given to patients in both arms of the 
trial suggesting that there is less risk of fluid overload than seen in previous studies which 
would appear to lessen the importance of dynamic measures of fluid responsiveness. The 
conclusion of our study is that GDT studies should continue to use SV increase as a measure 
of fluid responsiveness rather than dynamic measures of fluid responsiveness. These 
measures have not been shown to be reliable enough in the clinical setting on which to base 
fluid therapy. Future work is needed to assess these dynamic measures of fluid 
responsiveness in a larger, randomised controlled trial. This would allow a direct comparison 
of their utility against the static measure of fluid responsiveness that has been shown to 
improve outcomes as part of a GDT algorithm such as stroke volume. Further analysis of the 
waveform variation may allow a mathematical solution which precludes the need for pre-
specified physiological requirements prior to assessing the patient. Without this evidence 
base to support it the utility of these measures decreases significantly. 
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Two biomarker studies were pre-planned sub-studies of the OPTIMISE trial. A study examining 
the biomarker (troponin) defined myocardial injury demonstrated no increase in biomarker 
proven cardiac injury at 30 days post-operatively.222 A criticism of GDT has been the potential 
for cardiac injury secondary to the deleterious effects of fluid overload and the potential 
tachycardia seen when using low dose positive inotropes that are also positive chronotropes. 
This study added to others which demonstrated no increase in myocardial injury as a result 
of GDT but as there was no difference it also suggested that a cardiac protective effect was 
not the mechanism by which GDT improved outcomes. A previous study measuring the 
impact of GDT on post-operative inflammatory states after major surgery demonstrated no 
difference in inflammatory biomarkers between GDT groups and a control group.131 A 
subsequent post hoc analysis suggested there was a reduction in AKI in the GDT groups. There 
are biologically plausible mechanisms by which GDT may protect from kidney injury, 
specifically by the avoidance of hypotension and hypovolaemia. Both hypotension and 
hypovolaemia are known to be causes of AKI in patients undergoing major surgery. However, 
there was no renal protection benefit as measured by the incidence of KIDGO 2 or 3 AKI seen 
in the OPTIMISE study. In the subsequent analysis of the compliant OPTIMISE cohort there 
was no renal protective benefit seen in the patient group who had GDT. A further issue of 
using just KIDGO classifications 2 and 3 is the potential to miss more subtle kidney injury. 
 The troponin biomarker used to identify and quantify myocardial injury is preformed and has 
high specificity and sensitivity for cardiac injury. At the time of writing no similar biomarker 
has been identified for renal injury. There have been a number of different biomarkers which 
indicate renal injury most of which are formed and released in response to renal injury and 
can be measured either in the urine or the blood after major surgery. The urinary NGAL 
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marker was chosen for our biomarker sub-study to identify renal injury after major surgery 
and to assess if GDT had any renal protective benefit. In our biomarker sub study of the 
OPTIMISE trial there was no reduction in kidney injury between the two groups. The lack of 
changes in the biomarker measuring AKI suggests that there is no protective or deleterious 
effect on the kidney with GDT and that further studies should examine other organ systems 
to elicit what benefit GDT may have. A possible explanation for this result is the high standard 
of care in both groups that ensured that there was no prolonged hypotension and any 
hypovolaemia was unlikely as the clinician was empowered to mandate their own fluid 
therapy. In addition both study arms received similar amounts of fluid ensuring the control 
group was unlikely to hypovolaemic relative to the GDT group. As the understanding of 
perioperative fluid administration improves and clinicians understand more fully the 
consequences of too much or too little fluid during this period the incidence of AKI may 
decrease. This is coupled with an increased awareness of  the importance of AKI as a 
complication and the clinical management required to avoid AKI. This includes the avoidance 
of Non-Steroidal Anti-Inflammatory drugs (NSAIDs) and hypotension. If the decrease in AKI is 
related to improvement in the fluid management of the high risk patient then GDT was 
unlikely to have had a mechanistic protective effect on the kidneys that had been noted in 
previous trials. The OPTIMISE trial and this biomarker sub-study both suggest that GDT has 
no renal protective effect. However, it remains important to measure AKI within GDT studies 
even if it is not directly influenced by GDT. In any study where hypotension and hypovolaemia 
can be affected by trial protocols AKI appears to be an important marker of equitable care 
between the two groups. By measuring AKI between the two groups clinicians could reassure 
themselves that any significant differences in other outcomes are not related to trial conduct. 
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7.3 Fluids 
One of the more significant influences over GDT therapy that this thesis has not addressed is 
the choice of fluid used in the algorithm. There are been several reasons for this. There are a 
wide choice of commercial intravenous fluids available and the availability to the clinician is 
often dictated by the hospital or healthcare system. In individual patients there are specific 
reasons for avoiding certain types of fluid and to dictate fluid choices to clinicians in these 
circumstances would not be feasible. The pragmatic design of the OPTIMISE study allowed 
the free choice of colloid to clinicians regardless of the study group the patient was 
randomised too. The uncertainty surrounding fluid choices in the perioperative period for the 
high risk patient is based on a number of different factors that require further exploration out 
with the context of studies on the impact of GDT. Nevertheless the choice of fluid may directly 
impact the uptake of GDT by clinicians wishing more autonomy in their choice or indirectly by 
appearing to or actually influencing the outcomes of trials of GDT. This second is unlikely to 
have had a large impact given the wide range of fluids used in trials of GDT that have shown 
positive outcomes but the withdrawal of hetastarches during the trial period of OPTIMISE 
demonstrated the importance of fluid choice. This highlights the lack of an ideal or even 
consensus fluid for surgical patients that would be used in GDT. 
 
7.4 Strengths and Weaknesses 
There are a number of strengths of the research in this thesis. The data used is from the 
largest pragmatic randomised controlled trial of a GDT algorithm in a well-defined high risk 
surgical group. The design of the trial was also a strength as it followed existing 
recommendations for the investigation of complex interventions. It was an intention to treat 
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(ITT) trial which allowed for the protocol deviations and non-compliance that are likely to be 
a happen in a clinical application of the algorithm. This approach minimises type one error 
and follows the CONSORT recommendations for randomised controlled trials. ITT has been 
criticised because the inclusion of patients who have not received the intervention and those 
who crossover between groups may lead to an underestimation of the treatment effect 
leading to a potential type two error. The ITT approach requires as complete as possible data 
collection which was another strength of this thesis as there was very little missing data. The 
algorithm was also a strength. The algorithm used was very similar to previous algorithms 
that had shown benefit in smaller trials and was reviewed by experts of GDT to reach a Delphi 
consensus of what constituted the current best practice for a GDT algorithm. The study was 
carried out in multiple centres across the United Kingdom which allowed the algorithm to be 
evaluated in different settings with different institutional requirements and care pathways in 
place. This is the recommended strategy for investigating a complex intervention such as GDT. 
There were clearly defined primary and secondary outcome measures that allowed the 
secondary analysis of this data to take place. The definitions of these outcomes measure were 
carefully written to cover all possibilities and ensure consistent capture of data. A large 
number of outcomes were defined to ensure that all possible adverse outcomes would be 
recorded. The self-assessment of blinding was an assessment of bias which is difficult to 
quantify in an open label trial such as OPTIMISE. These all helped the veracity of the result of 
the main OPTIMISE trial and allowed the result to be applicable to clinical practice. The 
requirement for non-use of the cardiac output monitor in the control arm was felt to be an 
unnecessary stipulation by some clinicians as they felt they would like cardiac output 
monitoring and would simply not use the trial GDT algorithm. However the purpose of the 
trial was to establish if a consensus GDT algorithm was better than clinician guided fluid 
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therapy alone. Therefore, it could not be ruled out that some clinicians would incorporate 
some, most or even all of the trial algorithm while using cardiac output monitoring and that 
by allowing the use of cardiac output monitoring we would be evaluating several different 
GDT algorithms, each individual to the treating clinician, in the control arm against the trial 
GDT algorithm. This would leave the trial underpowered and potentially turn into an analysis 
of the effect of low dose dopexamine which was not the purpose of the trial. 
The sub-study is the largest evaluation of the dynamic measures of fluid responsiveness PPV 
and SVV in a pragmatic trial setting. The stated perioperative conditions under which they 
were measured were considered to be practicable and achievable and we were able to 
achieve them in all patients studied. There was a dedicated researcher assessing the 
conditions under which the bolus was given which may be considered a strength and a 
weakness. It ensured that these conditions were always met in the trial but means another 
step that has to be undertaken within a complex intervention if these parameters were to be 
used. Multiple fluid boluses were studied which allowed the assessment of PPV and SVV fluid 
responsiveness throughout the perioperative period. Further the change in fluid 
responsiveness allowed these measures to be assessed not only between patients but also 
with intra-patient variability that is seen through major surgery and the immediate recovery. 
There were 100 patients included in the study, but it may not have sufficient power to 
demonstrate the efficacy of these dynamic measures. There remains a possibility that the 
findings of this study were confounded by the algorithm of the specific cardiac output monitor 
used, though pulse power analysis has been validated, under ideal conditions, with these 
parameters. 
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The biomarker study used urinary NGAL, a more accurate biomarker than creatinine, to 
establish if using a GDT algorithm reduced the incidence of AKI after major surgery in the high-
risk surgical patient. Urinary NGAL  has been shown to identify AKI after cardiac surgery. It is 
a more sensitive marker than creatinine and using urinary NGAL identified an AKI rate of 13% 
which has been seen in other studies of perioperative AKI. The samples were collected at 
different time points that allowed us to examine the development of AKI throughout the 
perioperative period but in doing so transient AKI may be missed. Only one biomarker of AKI 
was used in this study when there are several available which have been shown to be good 
markers of AKI in postoperative patients though it is unlikely there would have been a 
different result had another biomarker been used. These findings reflected the findings of the 
main OPTIMISE trial with no difference between the two groups but there remians a 
possibility that this study was underpowered to detect any changes. 
This thesis has used a major randomised controlled trial to investigate the barriers to the use 
of GDT in high-risk major gastrointestinal surgery. There is a lot of evidence suggesting that 
GDT is of benefit to these patients. The evidence base is predominately small,  single centre 
randomised controlled trials with a significant amount of heterogeneity and this combined 
with the lack of large trials may hinder the introduction of GDT in specific patient groups. The 
large pragmatic trial of GDT in a specific patient group helps to address this though the 
equivocal findings of the OPTIMISE trial did not give a definitive answer. Identifying the 
haemodynamic variable which GDT algorithms should use would reduce the heterogenicity 
of any proposed GDT algorithm. Dynamic measures of fluid responsiveness are a promising 
variable having been shown to be extremely accurate under ideal conditions. A strength of 
this thesis is that we have examined these variables under pragmatic conditions. However, it 
 221   
was not a randomised controlled trial specifically designed to answer the question of the 
value of these variables in a GDT algorithm. It is important to establish the mechanism by 
which GDT confers benefit and our biomarker study confirmed the findings of the main study 
that perioperative AKI is not reduced by a GDT algorithm.  
 
7.5 Future work 
This work has identified a number of different barriers to the introduction of GDT in high-risk 
surgery. The high-risk patient undergoing gastrointestinal surgery is known to benefit from 
GDT but there are large differences in the targeted haemodynamic variables in the algorithms 
that have been used. There is a lack of large pragmatic trials regarding GDT algorithms within 
this patient group and within the small, efficacy trials in the evidence base there is large 
heterogeneity in the GDT algorithms used. In order to overcome barriers to the introduction 
of GDT it is important to establish a robust evidence base with an agreed algorithm. A large, 
pragmatic trial with a consensus GDT algorithm would allow clinicians to have more 
confidence in the evidence base for GDT and introduce it into their practice if it demonstrated 
a positive outcome or not if it did not. The results of the OPTIMISE trial have not resolved the 
dilemma within the evidence base and further large, pragmatic studies are required. Further 
analysis of the OPTIMISE trial suggests that future studies using this algorithm should focus 
on an older elective surgical population undergoing high risk surgery. The OPTIMISE 2 study 
has already started recruiting in this older population undergoing high risk gastrointestinal 
surgery and the results should confirm or refute the findings of the analysis of the OPTIMISE 
study in chapter four.  
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The uncertainty about the usefulness of dynamic variables of fluid responsiveness within GDT 
algorithms is also a barrier to the introduction of GDT. The use of dynamic variables of fluid 
responsiveness increases heterogeneity among the algorithms used creating uncertainty over 
which algorithm to use. An independent pragmatic study examining the usefulness of these 
variables in fluid therapy and surgery would help to reduce this uncertainty. However any trial 
undertaken should not examine their use in ideal conditions but instead look at the practical 
utility of these variables in clinical practice. It is important to establish how useful these 
variables are to the clinician treating the patient in real time. Our work suggests it is unlikely 
they will reach the accuracy that is seen under the ideal conditions they have previously been 
studied under but a large, pragmatic study focusing on their accuracy within normal clinical 
parameters would allow them to be properly used (or not) in GDT algorithms.  
The most difficult barrier to overcome will be to establish the method by which GDT exerts 
its effect. The work in this thesis suggests that is not through AKI reduction and did not 
highlight a reduction in cardiac or gastrointestinal complications as a probable mechanism. 
That the lack of effect on these complications are specific to this algorithm cannot be 
discounted and it may be that different algorithms reduce the event rate of different 
complications though that seems unlikely despite the heterogeneity. A large, pragmatic trial 
like OPTIMISE 2 will be able to assess all common postoperative complications to confirm or 
refute the findings of the OPTIMISE trial regarding specific reductions in complications. 
However while this trial would establish the role by which GDT exerts its effect it would not 
establish the mechanism by which it was achieved. This would require further biomarker 
studies examining the role of GDT and the production of known inflammatory pathway 
mediators and suppressors. There have few studies looking at the impact of GDT during major 
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surgery and the inflammatory response and this is probably the most promising avenue to 
explore to establish any mechanism by which GDT may work. 
 
 224   
References 
1. Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, et al. 
Estimate of the global volume of surgery in 2012: an assessment supporting improved 
health outcomes. Lancet. 2015;385 Suppl 2:S11. 
2. Weiser TG, Regenbogen SE, Thompson KD, Haynes AB, Lipsitz SR, Berry WR, et al. An 
estimation of the global volume of surgery: a modelling strategy based on available data. 
Lancet. 2008;372(9633):139-44. 
3. Alkire BC, Raykar NP, Shrime MG, Weiser TG, Bickler SW, Rose JA, et al. Global access 
to surgical care: a modelling study. Lancet Glob Health. 2015;3(6):e316-23. 
4. Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C, et al. Mortality after 
surgery in Europe: a 7 day cohort study. Lancet. 2012;380(9847):1059-65. 
5. International Surgical Outcomes Study g. Global patient outcomes after elective 
surgery: prospective cohort study in 27 low-, middle- and high-income countries. Br J 
Anaesth. 2016;117(5):601-9. 
6. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative 
mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128-37. 
7. Shah N, Hamilton M. Clinical review: Can we predict which patients are at risk of 
complications following surgery? Crit Care. 2013;17(3):226. 
8. Sankar A, Beattie WS, Wijeysundera DN. How can we identify the high-risk patient? 
Curr Opin Crit Care. 2015;21(4):328-35. 
9. Abbott TEF, Fowler AJ, Dobbs TD, Harrison EM, Gillies MA, Pearse RM. Frequency of 
surgical treatment and related hospital procedures in the UK: a national ecological study 
using hospital episode statistics. Br J Anaesth. 2017;119(2):249-57. 
10. Bridgewater B, Hickey GL, Cooper G, Deanfield J, Roxburgh J, Society for 
Cardiothoracic Surgery in Great B, et al. Publishing cardiac surgery mortality rates: lessons 
for other specialties. BMJ. 2013;346:f1139. 
11. Vallance AE, Fearnhead NS, Kuryba A, Hill J, Maxwell-Armstrong C, Braun M, et al. 
Effect of public reporting of surgeons' outcomes on patient selection, "gaming," and 
mortality in colorectal cancer surgery in England: population based cohort study. BMJ. 
2018;361:k1581. 
12. Pearse RM, Harrison DA, James P, Watson D, Hinds C, Rhodes A, et al. Identification 
and characterisation of the high-risk surgical population in the United Kingdom. Crit Care. 
2006;10(3):R81. 
13. Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study I, Devereaux 
PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, et al. Association between 
postoperative troponin levels and 30-day mortality among patients undergoing noncardiac 
surgery. JAMA. 2012;307(21):2295-304. 
14. Pearse RM, Rhodes A, Moreno R, Pelosi P, Spies C, Vallet B, et al. EuSOS: European 
surgical outcomes study. Eur J Anaesthesiol. 2011;28(6):454-6. 
15. Moonesinghe SR, Mythen MG, Grocott MP. Patient-related risk factors for 
postoperative adverse events. Curr Opin Crit Care. 2009;15(4):320-7. 
16. Myles PS, Williams DL, Hendrata M, Anderson H, Weeks AM. Patient satisfaction 
after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J 
Anaesth. 2000;84(1):6-10. 
 225   
17. Toner A, Hamilton M. The long-term effects of postoperative complications. Curr 
Opin Crit Care. 2013;19(4):364-8. 
18. Tjeertes EK, Ultee KH, Stolker RJ, Verhagen HJ, Bastos Goncalves FM, Hoofwijk AG, et 
al. Perioperative Complications are Associated With Adverse Long-Term Prognosis and 
Affect the Cause of Death After General Surgery. World J Surg. 2016;40(11):2581-90. 
19. Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ, et al. 
Determinants of long-term survival after major surgery and the adverse effect of 
postoperative complications. Ann Surg. 2005;242(3):326-41; discussion 41-3. 
20. Roche JJ, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and postoperative 
complications on mortality after hip fracture in elderly people: prospective observational 
cohort study. BMJ. 2005;331(7529):1374. 
21. Brown SR, Mathew R, Keding A, Marshall HC, Brown JM, Jayne DG. The impact of 
postoperative complications on long-term quality of life after curative colorectal cancer 
surgery. Ann Surg. 2014;259(5):916-23. 
22. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth 
universal definition of myocardial infarction (2018). Eur Heart J. 2018. 
23. (KDIGO). KDIGO. Section 2: AKI Definition. Kidney Int Suppl. (2011) 2012(2):19-36. 
24. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new 
proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 
2004;240(2):205-13. 
25. Myles PS, Grocott MP, Boney O, Moonesinghe SR, Group CO-S. Standardizing end 
points in perioperative trials: towards a core and extended outcome set. Br J Anaesth. 
2016;116(5):586-9. 
26. Abbott TEF, Fowler AJ, Pelosi P, Gama de Abreu M, Moller AM, Canet J, et al. A 
systematic review and consensus definitions for standardised end-points in perioperative 
medicine: pulmonary complications. Br J Anaesth. 2018;120(5):1066-79. 
27. Buggy DJ, Freeman J, Johnson MZ, Leslie K, Riedel B, Sessler DI, et al. Systematic 
review and consensus definitions for standardised endpoints in perioperative medicine: 
postoperative cancer outcomes. Br J Anaesth. 2018;121(1):38-44. 
28. Myles PS, Boney O, Botti M, Cyna AM, Gan TJ, Jensen MP, et al. Systematic review 
and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) 
initiative: patient comfort. Br J Anaesth. 2018;120(4):705-11. 
29. Varadhan KK, Neal KR, Dejong CH, Fearon KC, Ljungqvist O, Lobo DN. The enhanced 
recovery after surgery (ERAS) pathway for patients undergoing major elective open 
colorectal surgery: a meta-analysis of randomized controlled trials. Clin Nutr. 
2010;29(4):434-40. 
30. Nelson G, Ramirez PT, Ljungqvist O, Dowdy SC. Enhanced Recovery Program and 
Length of Stay After Laparotomy on a Gynecologic Oncology Service: A Randomized 
Controlled Trial. Obstet Gynecol. 2017;129(6):1139. 
31. Simpson JC, Moonesinghe SR, Grocott MP, Kuper M, McMeeking A, Oliver CM, et al. 
Enhanced recovery from surgery in the UK: an audit of the enhanced recovery partnership 
programme 2009-2012. Br J Anaesth. 2015;115(4):560-8. 
32. Lassen K, Soop M, Nygren J, Cox PB, Hendry PO, Spies C, et al. Consensus review of 
optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) 
Group recommendations. Arch Surg. 2009;144(10):961-9. 
33. Yuill KA, Richardson RA, Davidson HI, Garden OJ, Parks RW. The administration of an 
oral carbohydrate-containing fluid prior to major elective upper-gastrointestinal surgery 
 226   
preserves skeletal muscle mass postoperatively--a randomised clinical trial. Clin Nutr. 
2005;24(1):32-7. 
34. Henriksen MG, Hessov I, Dela F, Hansen HV, Haraldsted V, Rodt SA. Effects of 
preoperative oral carbohydrates and peptides on postoperative endocrine response, 
mobilization, nutrition and muscle function in abdominal surgery. Acta Anaesthesiol Scand. 
2003;47(2):191-9. 
35. Noblett SE, Watson DS, Huong H, Davison B, Hainsworth PJ, Horgan AF. Pre-
operative oral carbohydrate loading in colorectal surgery: a randomized controlled trial. 
Colorectal Dis. 2006;8(7):563-9. 
36. Awad S, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of randomised 
controlled trials on preoperative oral carbohydrate treatment in elective surgery. Clin Nutr. 
2013;32(1):34-44. 
37. Smith MD, McCall J, Plank L, Herbison GP, Soop M, Nygren J. Preoperative 
carbohydrate treatment for enhancing recovery after elective surgery. Cochrane Database 
Syst Rev. 2014(8):CD009161. 
38. Hausel J, Nygren J, Lagerkranser M, Hellstrom PM, Hammarqvist F, Almstrom C, et al. 
A carbohydrate-rich drink reduces preoperative discomfort in elective surgery patients. 
Anesth Analg. 2001;93(5):1344-50. 
39. Helminen H, Viitanen H, Sajanti J. Effect of preoperative intravenous carbohydrate 
loading on preoperative discomfort in elective surgery patients. Eur J Anaesthesiol. 
2009;26(2):123-7. 
40. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of 
supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest. 
1988;94(6):1176-86. 
41. Boyd O, Grounds RM, Bennett ED. A randomized clinical trial of the effect of 
deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical 
patients. JAMA. 1993;270(22):2699-707. 
42. Wilson J, Woods I, Fawcett J, Whall R, Dibb W, Morris C, et al. Reducing the risk of 
major elective surgery: randomised controlled trial of preoperative optimisation of oxygen 
delivery. BMJ. 1999;318(7191):1099-103. 
43. Gan TJ, Soppitt A, Maroof M, el-Moalem H, Robertson KM, Moretti E, et al. Goal-
directed intraoperative fluid administration reduces length of hospital stay after major 
surgery. Anesthesiology. 2002;97(4):820-6. 
44. Sinclair S, James S, Singer M. Intraoperative intravascular volume optimisation and 
length of hospital stay after repair of proximal femoral fracture: randomised controlled trial. 
BMJ. 1997;315(7113):909-12. 
45. Lobo SM, Salgado PF, Castillo VG, Borim AA, Polachini CA, Palchetti JC, et al. Effects 
of maximizing oxygen delivery on morbidity and mortality in high-risk surgical patients. Crit 
Care Med. 2000;28(10):3396-404. 
46. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-
directed therapy after major surgery reduces complications and duration of hospital stay. A 
randomised, controlled trial [ISRCTN38797445]. Crit Care. 2005;9(6):R687-93. 
47. Salzwedel C, Puig J, Carstens A, Bein B, Molnar Z, Kiss K, et al. Perioperative goal-
directed hemodynamic therapy based on radial arterial pulse pressure variation and 
continuous cardiac index trending reduces postoperative complications after major 
abdominal surgery: a multi-center, prospective, randomized study. Crit Care. 
2013;17(5):R191. 
 227   
48. Goepfert MS, Richter HP, Zu Eulenburg C, Gruetzmacher J, Rafflenbeul E, Roeher K, 
et al. Individually optimized hemodynamic therapy reduces complications and length of stay 
in the intensive care unit: a prospective, randomized controlled trial. Anesthesiology. 
2013;119(4):824-36. 
49. Sinatra R. Causes and consequences of inadequate management of acute pain. Pain 
Med. 2010;11(12):1859-71. 
50. Morran CG, Finlay IG, Mathieson M, McKay AJ, Wilson N, McArdle CS. Randomized 
controlled trial of physiotherapy for postoperative pulmonary complications. Br J Anaesth. 
1983;55(11):1113-7. 
51. Bozzetti F, Braga M, Gianotti L, Gavazzi C, Mariani L. Postoperative enteral versus 
parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised 
multicentre trial. Lancet. 2001;358(9292):1487-92. 
52. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z, Ad Hoc EWG. Nutritional risk 
screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin 
Nutr. 2003;22(3):321-36. 
53. Partridge JS, Harari D, Martin FC, Dhesi JK. The impact of pre-operative 
comprehensive geriatric assessment on postoperative outcomes in older patients 
undergoing scheduled surgery: a systematic review. Anaesthesia. 2014;69 Suppl 1:8-16. 
54. Hagsten B, Svensson O, Gardulf A. Early individualized postoperative occupational 
therapy training in 100 patients improves ADL after hip fracture: a randomized trial. Acta 
Orthop Scand. 2004;75(2):177-83. 
55. Pinto A, Faiz O, Davis R, Almoudaris A, Vincent C. Surgical complications and their 
impact on patients' psychosocial well-being: a systematic review and meta-analysis. BMJ 
Open. 2016;6(2):e007224. 
56. Stone AB, Grant MC, Pio Roda C, Hobson D, Pawlik T, Wu CL, et al. Implementation 
Costs of an Enhanced Recovery After Surgery Program in the United States: A Financial 
Model and Sensitivity Analysis Based on Experiences at a Quaternary Academic Medical 
Center. J Am Coll Surg. 2016;222(3):219-25. 
57. Elias KM, Stone AB, McGinigle K, Tankou JI, Scott MJ, Fawcett WJ, et al. The 
Reporting on ERAS Compliance, Outcomes, and Elements Research (RECOvER) Checklist: A 
Joint Statement by the ERAS((R)) and ERAS((R)) USA Societies. World J Surg. 2018. 
58. Westfall JM, Mold J, Fagnan L. Practice-based research--"Blue Highways" on the NIH 
roadmap. JAMA. 2007;297(4):403-6. 
59. Green LW, Ottoson JM, Garcia C, Hiatt RA. Diffusion theory and knowledge 
dissemination, utilization, and integration in public health. Annu Rev Public Health. 
2009;30:151-74. 
60. Paton F, Chambers D, Wilson P, Eastwood A, Craig D, Fox D, et al. Effectiveness and 
implementation of enhanced recovery after surgery programmes: a rapid evidence 
synthesis. BMJ Open. 2014;4(7):e005015. 
61. Peden C. J ST, Martin G, Kahan B, Thomson A, Rivett K, et al. Effectiveness of a 
national quality improvement programme to improve survival after emergency abdominal 
surgery: A stepped-wedge cluster randomised trial. The Lancet. 2019;in press. 
62. Swan HJ, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D. Catheterization of 
the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med. 
1970;283(9):447-51. 
63. Ganz W, Donoso R, Marcus HS, Forrester JS, Swan HJ. A new technique for 
measurement of cardiac output by thermodilution in man. Am J Cardiol. 1971;27(4):392-6. 
 228   
64. Clowes GH, Jr., Vucinic M, Weidner MG. Circulatory and metabolic alterations 
associated with survival or death in peritonitis: clinical analysis of 25 cases. Ann Surg. 
1966;163(6):866-85. 
65. Bland RD, Shoemaker WC. Common physiologic patterns in general surgical patients: 
hemodynamic and oxygen transport changes during and after operation in patients with and 
without associated medical problems. Surg Clin North Am. 1985;65(4):793-809. 
66. Bland RD, Shoemaker WC, Abraham E, Cobo JC. Hemodynamic and oxygen transport 
patterns in surviving and nonsurviving postoperative patients. Crit Care Med. 1985;13(2):85-
90. 
67. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of 
systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 
1994;330(24):1717-22. 
68. Wakeling HG, McFall MR, Jenkins CS, Woods WG, Miles WF, Barclay GR, et al. 
Intraoperative oesophageal Doppler guided fluid management shortens postoperative 
hospital stay after major bowel surgery. Br J Anaesth. 2005;95(5):634-42. 
69. Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized clinical trial assessing 
the effect of Doppler-optimized fluid management on outcome after elective colorectal 
resection. Br J Surg. 2006;93(9):1069-76. 
70. Kaufmann T, Clement RP, Scheeren TWL, Saugel B, Keus F, van der Horst ICC. 
Perioperative goal-directed therapy: A systematic review without meta-analysis. Acta 
Anaesthesiol Scand. 2018. 
71. Cecconi M, Corredor C, Arulkumaran N, Abuella G, Ball J, Grounds RM, et al. Clinical 
review: Goal-directed therapy-what is the evidence in surgical patients? The effect on 
different risk groups. Crit Care. 2013;17(2):209. 
72. Grocott MP, Dushianthan A, Hamilton MA, Mythen MG, Harrison D, Rowan K, et al. 
Perioperative increase in global blood flow to explicit defined goals and outcomes after 
surgery: a Cochrane Systematic Review. Br J Anaesth. 2013;111(4):535-48. 
73. Rollins KE, Lobo DN. Intraoperative Goal-directed Fluid Therapy in Elective Major 
Abdominal Surgery: A Meta-analysis of Randomized Controlled Trials. Ann Surg. 
2016;263(3):465-76. 
74. Benes J, Giglio M, Brienza N, Michard F. The effects of goal-directed fluid therapy 
based on dynamic parameters on post-surgical outcome: a meta-analysis of randomized 
controlled trials. Crit Care. 2014;18(5):584. 
75. Corcoran T, Rhodes JE, Clarke S, Myles PS, Ho KM. Perioperative fluid management 
strategies in major surgery: a stratified meta-analysis. Anesth Analg. 2012;114(3):640-51. 
76. Osawa EA, Rhodes A, Landoni G, Galas FR, Fukushima JT, Park CH, et al. Effect of 
Perioperative Goal-Directed Hemodynamic Resuscitation Therapy on Outcomes Following 
Cardiac Surgery: A Randomized Clinical Trial and Systematic Review. Crit Care Med. 
2016;44(4):724-33. 
77. Som A, Maitra S, Bhattacharjee S, Baidya DK. Goal directed fluid therapy decreases 
postoperative morbidity but not mortality in major non-cardiac surgery: a meta-analysis and 
trial sequential analysis of randomized controlled trials. J Anesth. 2017;31(1):66-81. 
78. Vistisen ST, Keus E, Scheeren TWL. Methodology in systematic reviews of goal-
directed therapy: improving but not perfect. Br J Anaesth. 2017;119(1):18-21. 
79. Venn R, Steele A, Richardson P, Poloniecki J, Grounds M, Newman P. Randomized 
controlled trial to investigate influence of the fluid challenge on duration of hospital stay 
and perioperative morbidity in patients with hip fractures. Br J Anaesth. 2002;88(1):65-71. 
 229   
80. Habicher M, Balzer F, Mezger V, Niclas J, Muller M, Perka C, et al. Implementation of 
goal-directed fluid therapy during hip revision arthroplasty: a matched cohort study. 
Perioper Med (Lond). 2016;5:31. 
81. Ziegler DW, Wright JG, Choban PS, Flancbaum L. A prospective randomized trial of 
preoperative "optimization" of cardiac function in patients undergoing elective peripheral 
vascular surgery. Surgery. 1997;122(3):584-92. 
82. Valentine RJ, Duke ML, Inman MH, Grayburn PA, Hagino RT, Kakish HB, et al. 
Effectiveness of pulmonary artery catheters in aortic surgery: a randomized trial. J Vasc 
Surg. 1998;27(2):203-11; discussion 11-2. 
83. Van der Linden PJ, Dierick A, Wilmin S, Bellens B, De Hert SG. A randomized 
controlled trial comparing an intraoperative goal-directed strategy with routine clinical 
practice in patients undergoing peripheral arterial surgery. Eur J Anaesthesiol. 
2010;27(9):788-93. 
84. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-
directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 
2001;345(19):1368-77. 
85. Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the 
use of preemptive hemodynamic intervention to improve postoperative outcomes in 
moderate and high-risk surgical patients. Anesth Analg. 2011;112(6):1392-402. 
86. Dalfino L, Giglio MT, Puntillo F, Marucci M, Brienza N. Haemodynamic goal-directed 
therapy and postoperative infections: earlier is better. A systematic review and meta-
analysis. Crit Care. 2011;15(3):R154. 
87. Ackland GL, Iqbal S, Paredes LG, Toner A, Lyness C, Jenkins N, et al. Individualised 
oxygen delivery targeted haemodynamic therapy in high-risk surgical patients: a 
multicentre, randomised, double-blind, controlled, mechanistic trial. Lancet Respir Med. 
2015;3(1):33-41. 
88. Detsky AS, Abrams HB, McLaughlin JR, Drucker DJ, Sasson Z, Johnston N, et al. 
Predicting cardiac complications in patients undergoing non-cardiac surgery. J Gen Intern 
Med. 1986;1(4):211-9. 
89. Boyd O, Jackson N. How is risk defined in high-risk surgical patient management? Crit 
Care. 2005;9(4):390-6. 
90. Mythen MG, Webb AR. Perioperative plasma volume expansion reduces the 
incidence of gut mucosal hypoperfusion during cardiac surgery. Arch Surg. 1995;130(4):423-
9. 
91. Polonen P, Ruokonen E, Hippelainen M, Poyhonen M, Takala J. A prospective, 
randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. 
Anesth Analg. 2000;90(5):1052-9. 
92. Aya HD, Cecconi M, Hamilton M, Rhodes A. Goal-directed therapy in cardiac surgery: 
a systematic review and meta-analysis. Br J Anaesth. 2013;110(4):510-7. 
93. Cecconi M, Fasano N, Langiano N, Divella M, Costa MG, Rhodes A, et al. Goal-
directed haemodynamic therapy during elective total hip arthroplasty under regional 
anaesthesia. Crit Care. 2011;15(3):R132. 
94. Giglio M, Dalfino L, Puntillo F, Rubino G, Marucci M, Brienza N. Haemodynamic goal-
directed therapy in cardiac and vascular surgery. A systematic review and meta-analysis. 
Interact Cardiovasc Thorac Surg. 2012;15(5):878-87. 
 230   
95. Challand C, Struthers R, Sneyd JR, Erasmus PD, Mellor N, Hosie KB, et al. Randomized 
controlled trial of intraoperative goal-directed fluid therapy in aerobically fit and unfit 
patients having major colorectal surgery. Br J Anaesth. 2012;108(1):53-62. 
96. Ramsingh DS, Sanghvi C, Gamboa J, Cannesson M, Applegate RL, 2nd. Outcome 
impact of goal directed fluid therapy during high risk abdominal surgery in low to moderate 
risk patients: a randomized controlled trial. J Clin Monit Comput. 2013;27(3):249-57. 
97. Calvo-Vecino JM, Ripolles-Melchor J, Mythen MG, Casans-Frances R, Balik A, Artacho 
JP, et al. Effect of goal-directed haemodynamic therapy on postoperative complications in 
low-moderate risk surgical patients: a multicentre randomised controlled trial (FEDORA 
trial). Br J Anaesth. 2018;120(4):734-44. 
98. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, et al. A randomized, 
controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl 
J Med. 2003;348(1):5-14. 
99. MacDonald N, Pearse RM. Peri-operative hemodynamic therapy: only large clinical 
trials can resolve our uncertainty. Crit Care. 2011;15(3):122. 
100. Clowes GH, Jr., Farrington GH, Zuschneid W, Cossette GR, Saravis C. Circulating 
factors in the etiology of pulmonary insufficiency and right heart failure accompanying 
severe sepsis (peritonitis). Ann Surg. 1970;171(5):663-78. 
101. Cobo JC, Abraham E, Bland RD, Shoemaker WC. Sequential hemodynamic and 
oxygen transport abnormalities in patients with acute pancreatitis. Surgery. 1984;95(3):324-
30. 
102. Treacher DF, Leach RM. Oxygen transport-1. Basic principles. BMJ. 
1998;317(7168):1302-6. 
103. Leach RM, Treacher DF. The pulmonary physician in critical care * 2: oxygen delivery 
and consumption in the critically ill. Thorax. 2002;57(2):170-7. 
104. Belda FJ, Aguilera L, Garcia de la Asuncion J, Alberti J, Vicente R, Ferrandiz L, et al. 
Supplemental perioperative oxygen and the risk of surgical wound infection: a randomized 
controlled trial. JAMA. 2005;294(16):2035-42. 
105. Hopf HW, Hunt TK, West JM, Blomquist P, Goodson WH, 3rd, Jensen JA, et al. Wound 
tissue oxygen tension predicts the risk of wound infection in surgical patients. Arch Surg. 
1997;132(9):997-1004; discussion 5. 
106. Greif R, Akca O, Horn EP, Kurz A, Sessler DI, Outcomes Research G. Supplemental 
perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med. 
2000;342(3):161-7. 
107. Meyhoff CS, Wetterslev J, Jorgensen LN, Henneberg SW, Hogdall C, Lundvall L, et al. 
Effect of high perioperative oxygen fraction on surgical site infection and pulmonary 
complications after abdominal surgery: the PROXI randomized clinical trial. JAMA. 
2009;302(14):1543-50. 
108. Myles PS, Leslie K, Chan MT, Forbes A, Paech MJ, Peyton P, et al. Avoidance of 
nitrous oxide for patients undergoing major surgery: a randomized controlled trial. 
Anesthesiology. 2007;107(2):221-31. 
109. Kurz A, Fleischmann E, Sessler DI, Buggy DJ, Apfel C, Akca O, et al. Effects of 
supplemental oxygen and dexamethasone on surgical site infection: a factorial randomized 
trialdouble dagger. Br J Anaesth. 2015;115(3):434-43. 
110. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New WHO 
recommendations on intraoperative and postoperative measures for surgical site infection 
 231   
prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16(12):e288-
e303. 
111. Myles PS, Kurz A. Supplemental oxygen and surgical site infection: getting to the 
truth. Br J Anaesth. 2017;119(1):13-5. 
112. Helmerhorst HJ, Roos-Blom MJ, van Westerloo DJ, de Jonge E. Association Between 
Arterial Hyperoxia and Outcome in Subsets of Critical Illness: A Systematic Review, Meta-
Analysis, and Meta-Regression of Cohort Studies. Crit Care Med. 2015;43(7):1508-19. 
113. Helmerhorst HJ, Arts DL, Schultz MJ, van der Voort PH, Abu-Hanna A, de Jonge E, et 
al. Metrics of Arterial Hyperoxia and Associated Outcomes in Critical Care. Crit Care Med. 
2017;45(2):187-95. 
114. Damiani E, Adrario E, Girardis M, Romano R, Pelaia P, Singer M, et al. Arterial 
hyperoxia and mortality in critically ill patients: a systematic review and meta-analysis. Crit 
Care. 2014;18(6):711. 
115. Tsuchiya M, Sato EF, Inoue M, Asada A. Open abdominal surgery increases 
intraoperative oxidative stress: can it be prevented? Anesth Analg. 2008;107(6):1946-52. 
116. Kucukakin B, Gogenur I, Reiter RJ, Rosenberg J. Oxidative stress in relation to 
surgery: is there a role for the antioxidant melatonin? J Surg Res. 2009;152(2):338-47. 
117. Rosenfeldt F, Wilson M, Lee G, Kure C, Ou R, Braun L, et al. Oxidative stress in 
surgery in an ageing population: pathophysiology and therapy. Exp Gerontol. 2013;48(1):45-
54. 
118. Imberger G, McIlroy D, Pace NL, Wetterslev J, Brok J, Moller AM. Positive end-
expiratory pressure (PEEP) during anaesthesia for the prevention of mortality and 
postoperative pulmonary complications. Cochrane Database Syst Rev. 2010(9):CD007922. 
119. de Jong MAC, Ladha KS, Vidal Melo MF, Staehr-Rye AK, Bittner EA, Kurth T, et al. 
Differential Effects of Intraoperative Positive End-expiratory Pressure (PEEP) on Respiratory 
Outcome in Major Abdominal Surgery Versus Craniotomy. Ann Surg. 2016;264(2):362-9. 
120. Anaesthesiology PNIftCTNotESo, Hemmes SN, Gama de Abreu M, Pelosi P, Schultz 
MJ. High versus low positive end-expiratory pressure during general anaesthesia for open 
abdominal surgery (PROVHILO trial): a multicentre randomised controlled trial. Lancet. 
2014;384(9942):495-503. 
121. Lumb AB, Slinger P. Hypoxic pulmonary vasoconstriction: physiology and anesthetic 
implications. Anesthesiology. 2015;122(4):932-46. 
122. Futier E, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A, et al. A 
trial of intraoperative low-tidal-volume ventilation in abdominal surgery. N Engl J Med. 
2013;369(5):428-37. 
123. Guay J, Ochroch EA. Intraoperative use of low volume ventilation to decrease 
postoperative mortality, mechanical ventilation, lengths of stay and lung injury in patients 
without acute lung injury. Cochrane Database Syst Rev. 2015(12):CD011151. 
124. Acute Respiratory Distress Syndrome N, Brower RG, Matthay MA, Morris A, 
Schoenfeld D, Thompson BT, et al. Ventilation with lower tidal volumes as compared with 
traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. 
N Engl J Med. 2000;342(18):1301-8. 
125. Petrucci N, De Feo C. Lung protective ventilation strategy for the acute respiratory 
distress syndrome. Cochrane Database Syst Rev. 2013(2):CD003844. 
126. Myatra SN, Prabu NR, Divatia JV, Monnet X, Kulkarni AP, Teboul JL. The Changes in 
Pulse Pressure Variation or Stroke Volume Variation After a "Tidal Volume Challenge" 
 232   
Reliably Predict Fluid Responsiveness During Low Tidal Volume Ventilation. Crit Care Med. 
2017;45(3):415-21. 
127. De Backer D, Heenen S, Piagnerelli M, Koch M, Vincent JL. Pulse pressure variations 
to predict fluid responsiveness: influence of tidal volume. Intensive Care Med. 
2005;31(4):517-23. 
128. Myatra SN, Monnet X, Teboul JL. Use of 'tidal volume challenge' to improve the 
reliability of pulse pressure variation. Crit Care. 2017;21(1):60. 
129. Gutterman DD, Chabowski DS, Kadlec AO, Durand MJ, Freed JK, Ait-Aissa K, et al. The 
Human Microcirculation: Regulation of Flow and Beyond. Circ Res. 2016;118(1):157-72. 
130. Gruartmoner G, Mesquida J, Ince C. Fluid therapy and the hypovolemic 
microcirculation. Curr Opin Crit Care. 2015;21(4):276-84. 
131. Jhanji S, Vivian-Smith A, Lucena-Amaro S, Watson D, Hinds CJ, Pearse RM. 
Haemodynamic optimisation improves tissue microvascular flow and oxygenation after 
major surgery: a randomised controlled trial. Crit Care. 2010;14(4):R151. 
132. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is 
altered in patients with sepsis. Am J Respir Crit Care Med. 2002;166(1):98-104. 
133. Chappell D, Westphal M, Jacob M. The impact of the glycocalyx on microcirculatory 
oxygen distribution in critical illness. Curr Opin Anaesthesiol. 2009;22(2):155-62. 
134. Ince C. The microcirculation is the motor of sepsis. Crit Care. 2005;9 Suppl 4:S13-9. 
135. Krebs HA, Johnson WA. The role of citric acid in intermediate metabolism in animal 
tissues. FEBS Lett. 1980;117 Suppl:K1-10. 
136. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ 
failure. Virulence. 2014;5(1):66-72. 
137. Arulkumaran N, Deutschman CS, Pinsky MR, Zuckerbraun B, Schumacker PT, Gomez 
H, et al. Mitochondrial Function in Sepsis. Shock. 2016;45(3):271-81. 
138. Dare AJ, Phillips AR, Hickey AJ, Mittal A, Loveday B, Thompson N, et al. A systematic 
review of experimental treatments for mitochondrial dysfunction in sepsis and multiple 
organ dysfunction syndrome. Free Radic Biol Med. 2009;47(11):1517-25. 
139. Gardner-Thorpe J, Love N, Wrightson J, Walsh S, Keeling N. The value of Modified 
Early Warning Score (MEWS) in surgical in-patients: a prospective observational study. Ann 
R Coll Surg Engl. 2006;88(6):571-5. 
140. Goldhill DR, McNarry AF. Physiological abnormalities in early warning scores are 
related to mortality in adult inpatients. Br J Anaesth. 2004;92(6):882-4. 
141. Priebe HJ. The aged cardiovascular risk patient. Br J Anaesth. 2000;85(5):763-78. 
142. Gutierrez G, Reines HD, Wulf-Gutierrez ME. Clinical review: hemorrhagic shock. Crit 
Care. 2004;8(5):373-81. 
143. Desborough JP. The stress response to trauma and surgery. Br J Anaesth. 
2000;85(1):109-17. 
144. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Changes in 
central venous saturation after major surgery, and association with outcome. Crit Care. 
2005;9(6):R694-9. 
145. Collaborative Study Group on Perioperative Scv OM. Multicentre study on peri- and 
postoperative central venous oxygen saturation in high-risk surgical patients. Crit Care. 
2006;10(6):R158. 
146. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA, et al. Lactate 
clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized 
clinical trial. JAMA. 2010;303(8):739-46. 
 233   
147. Broder G, Weil MH. Excess Lactate: An Index of Reversibility of Shock in Human 
Patients. Science. 1964;143(3613):1457-9. 
148. Andersen LW, Mackenhauer J, Roberts JC, Berg KM, Cocchi MN, Donnino MW. 
Etiology and therapeutic approach to elevated lactate levels. Mayo Clin Proc. 
2013;88(10):1127-40. 
149. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. 
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 
2016;315(8):801-10. 
150. Jansen TC, van Bommel J, Schoonderbeek FJ, Sleeswijk Visser SJ, van der Klooster JM, 
Lima AP, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, 
open-label, randomized controlled trial. Am J Respir Crit Care Med. 2010;182(6):752-61. 
151. Arnold RC, Shapiro NI, Jones AE, Schorr C, Pope J, Casner E, et al. Multicenter study 
of early lactate clearance as a determinant of survival in patients with presumed sepsis. 
Shock. 2009;32(1):35-9. 
152. Benes J, Chytra I, Altmann P, Hluchy M, Kasal E, Svitak R, et al. Intraoperative fluid 
optimization using stroke volume variation in high risk surgical patients: results of 
prospective randomized study. Crit Care. 2010;14(3):R118. 
153. Handy JM, Soni N. Physiological effects of hyperchloraemia and acidosis. Br J 
Anaesth. 2008;101(2):141-50. 
154. Kumar L, Kanneganti YS, Rajan S. Outcomes of implementation of enhanced goal 
directed therapy in high-risk patients undergoing abdominal surgery. Indian J Anaesth. 
2015;59(4):228-33. 
155. Englehart MS, Schreiber MA. Measurement of acid-base resuscitation endpoints: 
lactate, base deficit, bicarbonate or what? Curr Opin Crit Care. 2006;12(6):569-74. 
156. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, et al. A trial of goal-
oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J 
Med. 1995;333(16):1025-32. 
157. Abbas SM, Hill AG. Systematic review of the literature for the use of oesophageal 
Doppler monitor for fluid replacement in major abdominal surgery. Anaesthesia. 
2008;63(1):44-51. 
158. Lopes MR, Oliveira MA, Pereira VO, Lemos IP, Auler JO, Jr., Michard F. Goal-directed 
fluid management based on pulse pressure variation monitoring during high-risk surgery: a 
pilot randomized controlled trial. Crit Care. 2007;11(5):R100. 
159. Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid 
responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 
2008;134(1):172-8. 
160. Starling EH, Visscher MB. The regulation of the energy output of the heart. J Physiol. 
1927;62(3):243-61. 
161. Figueiredo A, Germano N, Guedes P, Marcelino P. The evolving concepts of 
haemodynamic support: from pulmonary artery catheter to echocardiography and 
theragnostics. Curr Cardiol Rev. 2011;7(3):136-45. 
162. Kumar A, Anel R, Bunnell E, Habet K, Zanotti S, Marshall S, et al. Pulmonary artery 
occlusion pressure and central venous pressure fail to predict ventricular filling volume, 
cardiac performance, or the response to volume infusion in normal subjects. Crit Care Med. 
2004;32(3):691-9. 
 234   
163. Mayer J, Boldt J, Mengistu AM, Rohm KD, Suttner S. Goal-directed intraoperative 
therapy based on autocalibrated arterial pressure waveform analysis reduces hospital stay 
in high-risk surgical patients: a randomized, controlled trial. Crit Care. 2010;14(1):R18. 
164. Pearse RM, Belsey JD, Cole JN, Bennett ED. Effect of dopexamine infusion on 
mortality following major surgery: individual patient data meta-regression analysis of 
published clinical trials. Crit Care Med. 2008;36(4):1323-9. 
165. Singer M. The FTc is not an accurate marker of left ventricular preload. Intensive 
Care Med. 2006;32(7):1089; author reply 91. 
166. Kou S, Caballero L, Dulgheru R, Voilliot D, De Sousa C, Kacharava G, et al. 
Echocardiographic reference ranges for normal cardiac chamber size: results from the 
NORRE study. Eur Heart J Cardiovasc Imaging. 2014;15(6):680-90. 
167. Scheuren K, Wente MN, Hainer C, Scheffler M, Lichtenstern C, Martin E, et al. Left 
ventricular end-diastolic area is a measure of cardiac preload in patients with early septic 
shock. Eur J Anaesthesiol. 2009;26(9):759-65. 
168. Chew MS. Haemodynamic monitoring using echocardiography in the critically ill: a 
review. Cardiol Res Pract. 2012;2012:139537. 
169. Malbrain ML, Marik PE, Witters I, Cordemans C, Kirkpatrick AW, Roberts DJ, et al. 
Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a 
systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther. 
2014;46(5):361-80. 
170. Monnet X, Teboul JL. Volume responsiveness. Curr Opin Crit Care. 2007;13(5):549-
53. 
171. Joshi GP. Intraoperative fluid restriction improves outcome after major elective 
gastrointestinal surgery. Anesth Analg. 2005;101(2):601-5. 
172. Braunwald E, Ross J, Jr. Applicability of Starling's Law of the Heart to Man. Circ Res. 
1964;15:SUPPL 2:169-81. 
173. Cannesson M, Le Manach Y, Hofer CK, Goarin JP, Lehot JJ, Vallet B, et al. Assessing 
the diagnostic accuracy of pulse pressure variations for the prediction of fluid 
responsiveness: a "gray zone" approach. Anesthesiology. 2011;115(2):231-41. 
174. Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform 
derived variables and fluid responsiveness in mechanically ventilated patients: a systematic 
review of the literature. Crit Care Med. 2009;37(9):2642-7. 
175. Tavernier B, Makhotine O, Lebuffe G, Dupont J, Scherpereel P. Systolic pressure 
variation as a guide to fluid therapy in patients with sepsis-induced hypotension. 
Anesthesiology. 1998;89(6):1313-21. 
176. Buettner M, Schummer W, Huettemann E, Schenke S, van Hout N, Sakka SG. 
Influence of systolic-pressure-variation-guided intraoperative fluid management on organ 
function and oxygen transport. Br J Anaesth. 2008;101(2):194-9. 
177. Kubitz JC, Forkl S, Annecke T, Kronas N, Goetz AE, Reuter DA. Systolic pressure 
variation and pulse pressure variation during modifications of arterial pressure. Intensive 
Care Med. 2008;34(8):1520-4. 
178. Cannesson M, Desebbe O, Rosamel P, Delannoy B, Robin J, Bastien O, et al. Pleth 
variability index to monitor the respiratory variations in the pulse oximeter 
plethysmographic waveform amplitude and predict fluid responsiveness in the operating 
theatre. Br J Anaesth. 2008;101(2):200-6. 
179. Zimmermann M, Feibicke T, Keyl C, Prasser C, Moritz S, Graf BM, et al. Accuracy of 
stroke volume variation compared with pleth variability index to predict fluid 
 235   
responsiveness in mechanically ventilated patients undergoing major surgery. Eur J 
Anaesthesiol. 2010;27(6):555-61. 
180. Forget P, Lois F, de Kock M. Goal-directed fluid management based on the pulse 
oximeter-derived pleth variability index reduces lactate levels and improves fluid 
management. Anesth Analg. 2010;111(4):910-4. 
181. Maguire S, Rinehart J, Vakharia S, Cannesson M. Technical communication: 
respiratory variation in pulse pressure and plethysmographic waveforms: intraoperative 
applicability in a North American academic center. Anesth Analg. 2011;112(1):94-6. 
182. Bundgaard-Nielsen M, Secher NH, Kehlet H. 'Liberal' vs. 'restrictive' perioperative 
fluid therapy--a critical assessment of the evidence. Acta Anaesthesiol Scand. 
2009;53(7):843-51. 
183. Srinivasa S, Kahokehr A, Soop M, Taylor M, Hill AG. Goal-directed fluid therapy- a 
survey of anaesthetists in the UK, USA, Australia and New Zealand. BMC Anesthesiol. 
2013;13:5. 
184. Lobo SM, Lobo FR, Polachini CA, Patini DS, Yamamoto AE, de Oliveira NE, et al. 
Prospective, randomized trial comparing fluids and dobutamine optimization of oxygen 
delivery in high-risk surgical patients [ISRCTN42445141]. Crit Care. 2006;10(3):R72. 
185. Myburgh JA, Mythen MG. Resuscitation fluids. N Engl J Med. 2013;369(13):1243-51. 
186. Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative 
anemia in noncardiac surgery: a single-center cohort study. Anesthesiology. 
2009;110(3):574-81. 
187. Ferraris VA, Davenport DL, Saha SP, Austin PC, Zwischenberger JB. Surgical outcomes 
and transfusion of minimal amounts of blood in the operating room. Arch Surg. 
2012;147(1):49-55. 
188. O’Shaughnessy WB. Proposal of a new method of treating the new blue cholera 
epidemic by injecting of highly oxidised salts into the venous system. Lancet. 1831;17:366-
71. 
189. Latta T. Malignant Cholera Documents communicated by the Central Board of 
Health, London, relative to the treatment of cholera by the copious injection of aqueous and 
saline fluids into the veins. . Lancet. 1832;18:274-80. 
190. Fisher M. Fluids. Classic Papers in Critical Care. 2003:303-25. 
191. Milliam D. The History of Intravenous Therapy. Journal of Intravenous Nursing. 
1996;19(5-14). 
192. Artz CP, Howard JM, Frawley JP. Clinical observations on the use of dextran and 
modified fluid gelatin in combat casualties. Surgery. 1955;37(4):612-21. 
193. Prough DS, Bidani A. Hyperchloremic metabolic acidosis is a predictable 
consequence of intraoperative infusion of 0.9% saline. Anesthesiology. 1999;90(5):1247-9. 
194. Wilkes NJ, Woolf R, Mutch M, Mallett SV, Peachey T, Stephens R, et al. The effects of 
balanced versus saline-based hetastarch and crystalloid solutions on acid-base and 
electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg. 
2001;93(4):811-6. 
195. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl starch 
or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367(20):1901-11. 
196. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, et al. 
Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 
2012;367(2):124-34. 
 236   
197. Prowle JR, Pearse RM. Is it the end of the road for synthetic starches in critical 
illness? No place for hydroxyethyl starch solutions in treatment of patients with sepsis. BMJ. 
2013;346:f1805. 
198. Gillies MA, Habicher M, Jhanji S, Sander M, Mythen M, Hamilton M, et al. Incidence 
of postoperative death and acute kidney injury associated with i.v. 6% hydroxyethyl starch 
use: systematic review and meta-analysis. Br J Anaesth. 2014;112(1):25-34. 
199. Vervloet D, Senft M, Dugue P, Arnaud A, Charpin J. Anaphylactic reactions to 
modified fluid gelatins. J Allergy Clin Immunol. 1983;71(6):535-40. 
200. Pearse RM, Harrison DA, MacDonald N, Gillies MA, Blunt M, Ackland G, et al. Effect 
of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes 
following major gastrointestinal surgery: a randomized clinical trial and systematic review. 
JAMA. 2014;311(21):2181-90. 
201. Thomas-Rueddel DO, Vlasakov V, Reinhart K, Jaeschke R, Rueddel H, Hutagalung R, 
et al. Safety of gelatin for volume resuscitation--a systematic review and meta-analysis. 
Intensive Care Med. 2012;38(7):1134-42. 
202. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin 
replacement in patients with severe sepsis or septic shock. N Engl J Med. 
2014;370(15):1412-21. 
203. Roberts I, Blackhall K, Alderson P, Bunn F, Schierhout G. Human albumin solution for 
resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev. 
2011(11):CD001208. 
204. Excellence NIfHa. Clinical Guideline 32 CG32 Nutritional Support for Adults: oral 
nutritional support, enteral tube feeding and parental nutrition Update. . 2014. 
205. Rinehart J, Alexander B, Le Manach Y, Hofer C, Tavernier B, Kain ZN, et al. Evaluation 
of a novel closed-loop fluid-administration system based on dynamic predictors of fluid 
responsiveness: an in silico simulation study. Crit Care. 2011;15(6):R278. 
206. Rinehart J, Lilot M, Lee C, Joosten A, Huynh T, Canales C, et al. Closed-loop assisted 
versus manual goal-directed fluid therapy during high-risk abdominal surgery: a case-control 
study with propensity matching. Crit Care. 2015;19:94. 
207. Lees N, Hamilton M, Rhodes A. Clinical review: Goal-directed therapy in high risk 
surgical patients. Crit Care. 2009;13(5):231. 
208. Bangash MN, Patel NS, Benetti E, Collino M, Hinds CJ, Thiemermann C, et al. 
Dopexamine can attenuate the inflammatory response and protect against organ injury in 
the absence of significant effects on hemodynamics or regional microvascular flow. Crit 
Care. 2013;17(2):R57. 
209. Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised 
controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ. 
2010;340:c1066. 
210. Thabane L, Kaczorowski J, Dolovich L, Chambers LW, Mbuagbaw L, Investigators C. 
Reducing the confusion and controversies around pragmatic trials: using the Cardiovascular 
Health Awareness Program (CHAP) trial as an illustrative example. Trials. 2015;16:387. 
211. O'Neal JB, Shaw AD. Goal-directed therapy: what we know and what we need to 
know. Perioper Med (Lond). 2015;4(1):1. 
212. Panella M, Marchisio S, Di Stanislao F. Reducing clinical variations with clinical 
pathways: do pathways work? Int J Qual Health Care. 2003;15(6):509-21. 
213. Candy B, Vickerstaff V, Jones L, King M. Description of complex interventions: 
analysis of changes in reporting in randomised trials since 2002. Trials. 2018;19(1):110. 
 237   
214. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, Group C. Methods and 
processes of the CONSORT Group: example of an extension for trials assessing 
nonpharmacologic treatments. Ann Intern Med. 2008;148(4):W60-6. 
215. Datta J, Petticrew M. Challenges to evaluating complex interventions: a content 
analysis of published papers. BMC Public Health. 2013;13:568. 
216. Investigators A, Group ACT, Peake SL, Delaney A, Bailey M, Bellomo R, et al. Goal-
directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371(16):1496-
506. 
217. Pro CI, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, et al. A randomized 
trial of protocol-based care for early septic shock. N Engl J Med. 2014;370(18):1683-93. 
218. Brienza N, Giglio MT, Marucci M, Fiore T. Does perioperative hemodynamic 
optimization protect renal function in surgical patients? A meta-analytic study. Crit Care 
Med. 2009;37(6):2079-90. 
219. Arulkumaran N, Corredor C, Hamilton MA, Ball J, Grounds RM, Rhodes A, et al. 
Cardiac complications associated with goal-directed therapy in high-risk surgical patients: a 
meta-analysis. Br J Anaesth. 2014;112(4):648-59. 
220. Giglio MT, Marucci M, Testini M, Brienza N. Goal-directed haemodynamic therapy 
and gastrointestinal complications in major surgery: a meta-analysis of randomized 
controlled trials. Br J Anaesth. 2009;103(5):637-46. 
221. Pearse RM, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett D. The incidence 
of myocardial injury following post-operative Goal Directed Therapy. BMC Cardiovasc 
Disord. 2007;7:10. 
222. Gillies MA, Shah AS, Mullenheim J, Tricklebank S, Owen T, Antonelli J, et al. 
Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic 
therapy: a substudy of the OPTIMISE Trial. Br J Anaesth. 2015;115(2):227-33. 
223. Kapoor PM, Magoon R, Rawat R, Mehta Y. Perioperative utility of goal-directed 
therapy in high-risk cardiac patients undergoing coronary artery bypass grafting: "A clinical 
outcome and biomarker-based study". Ann Card Anaesth. 2016;19(4):638-82. 
224. Schmid S, Kapfer B, Heim M, Bogdanski R, Anetsberger A, Blobner M, et al. 
Algorithm-guided goal-directed haemodynamic therapy does not improve renal function 
after major abdominal surgery compared to good standard clinical care: a prospective 
randomised trial. Crit Care. 2016;20:50. 
225. Rau BM, Frigerio I, Buchler MW, Wegscheider K, Bassi C, Puolakkainen PA, et al. 
Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in 
secondary peritonitis: a prospective, international multicenter study. Arch Surg. 
2007;142(2):134-42. 
226. Jebali MA, Hausfater P, Abbes Z, Aouni Z, Riou B, Ferjani M. Assessment of the 
accuracy of procalcitonin to diagnose postoperative infection after cardiac surgery. 
Anesthesiology. 2007;107(2):232-8. 
227. Mokart D, Merlin M, Sannini A, Brun JP, Delpero JR, Houvenaeghel G, et al. 
Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early 
markers of postoperative sepsis after major surgery. Br J Anaesth. 2005;94(6):767-73. 
228. Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, et 
al. Framework for design and evaluation of complex interventions to improve health. BMJ. 
2000;321(7262):694-6. 
 238   
229. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, et al. Developing 
and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 
2008;337:a1655. 
230. Black N. Why we need observational studies to evaluate the effectiveness of health 
care. BMJ. 1996;312(7040):1215-8. 
231. Eldridge S, Spencer A, Cryer C, Parsons S, Underwood M, Feder G. Why modelling a 
complex intervention is an important precursor to trial design: lessons from studying an 
intervention to reduce falls-related injuries in older people. J Health Serv Res Policy. 
2005;10(3):133-42. 
232. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process 
evaluation of complex interventions: Medical Research Council guidance. BMJ. 
2015;350:h1258. 
233. Sada F, Krasniqi A, Hamza A, Gecaj-Gashi A, Bicaj B, Kavaja F. A randomized trial of 
preoperative oral carbohydrates in abdominal surgery. BMC Anesthesiol. 2014;14:93. 
234. Nygren J, Thorell A, Ljungqvist O. Preoperative oral carbohydrate therapy. Curr Opin 
Anaesthesiol. 2015;28(3):364-9. 
235. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality 
and major morbidity, II: observational studies. Lancet. 2001;357(9254):455-62. 
236. Murdoch TB, Detsky AS. The inevitable application of big data to health care. JAMA. 
2013;309(13):1351-2. 
237. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 
2016;21(4):125-7. 
238. Johnson KE, Tachibana C, Coronado GD, Dember LM, Glasgow RE, Huang SS, et al. A 
guide to research partnerships for pragmatic clinical trials. BMJ. 2014;349:g6826. 
239. Chalkidou K, Tunis S, Whicher D, Fowler R, Zwarenstein M. The role for pragmatic 
randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials. 
2012;9(4):436-46. 
240. Topazian R, Bollinger J, Weinfurt KP, Dvoskin R, Mathews D, Brelsford K, et al. 
Physicians' perspectives regarding pragmatic clinical trials. J Comp Eff Res. 2016;5(5):499-
506. 
241. Rothwell PM. External validity of randomised controlled trials: "to whom do the 
results of this trial apply?". Lancet. 2005;365(9453):82-93. 
242. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical 
research for decision making in clinical and health policy. JAMA. 2003;290(12):1624-32. 
243. Patsopoulos NA. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 
2011;13(2):217-24. 
244. Zwarenstein M, Oxman A, Pragmatic Trials in Health Care S. Why are so few 
randomized trials useful, and what can we do about it? J Clin Epidemiol. 2006;59(11):1125-
6. 
245. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A 
pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. 
CMAJ. 2009;180(10):E47-57. 
246. Angus DC. Fusing Randomized Trials With Big Data: The Key to Self-learning Health 
Care Systems? JAMA. 2015;314(8):767-8. 
247. Edwards SJ, Braunholtz DA, Lilford RJ, Stevens AJ. Ethical issues in the design and 
conduct of cluster randomised controlled trials. BMJ. 1999;318(7195):1407-9. 
 239   
248. Campbell MK, Elbourne DR, Altman DG, group C. CONSORT statement: extension to 
cluster randomised trials. BMJ. 2004;328(7441):702-8. 
249. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. 
What influences recruitment to randomised controlled trials? A review of trials funded by 
two UK funding agencies. Trials. 2006;7:9. 
250. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster 
randomised trial: rationale, design, analysis, and reporting. BMJ. 2015;350:h391. 
251. Hemming K, Lilford R, Girling AJ. Stepped-wedge cluster randomised controlled trials: 
a generic framework including parallel and multiple-level designs. Stat Med. 2015;34(2):181-
96. 
252. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med 
Res Methodol. 2006;6:54. 
253. Walter SD, Turner RM, Macaskill P, McCaffery KJ, Irwig L. Estimation of treatment 
preference effects in clinical trials when some participants are indifferent to treatment 
choice. BMC Med Res Methodol. 2017;17(1):29. 
254. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the 
ultimate strategy for individualizing medicine? Per Med. 2011;8(2):161-73. 
255. Scuffham PA, Nikles J, Mitchell GK, Yelland MJ, Vine N, Poulos CJ, et al. Using N-of-1 
trials to improve patient management and save costs. J Gen Intern Med. 2010;25(9):906-13. 
256. Cournand A, Ranges HA, Riley RL. Comparison of Results of the Normal 
Ballistocardiogram and a Direct Fick Method in Measuring the Cardiac Output in Man. J Clin 
Invest. 1942;21(3):287-94. 
257. Hadian M, Pinsky MR. Evidence-based review of the use of the pulmonary artery 
catheter: impact data and complications. Crit Care. 2006;10 Suppl 3:S8. 
258. Connors AF, Jr., Speroff T, Dawson NV, Thomas C, Harrell FE, Jr., Wagner D, et al. The 
effectiveness of right heart catheterization in the initial care of critically ill patients. 
SUPPORT Investigators. JAMA. 1996;276(11):889-97. 
259. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, et al. Assessment 
of the clinical effectiveness of pulmonary artery catheters in management of patients in 
intensive care (PAC-Man): a randomised controlled trial. Lancet. 2005;366(9484):472-7. 
260. Funk DJ, Moretti EW, Gan TJ. Minimally invasive cardiac output monitoring in the 
perioperative setting. Anesth Analg. 2009;108(3):887-97. 
261. Saugel B, Cecconi M, Wagner JY, Reuter DA. Noninvasive continuous cardiac output 
monitoring in perioperative and intensive care medicine. Br J Anaesth. 2015;114(4):562-75. 
262. Truijen J, Westerhof BE, Kim YS, Stok WJ, de Mol BA, Preckel B, et al. The effect of 
haemodynamic and peripheral vascular variability on cardiac output monitoring: 
thermodilution and non-invasive pulse contour cardiac output during cardiothoracic 
surgery. Anaesthesia. 2018. 
263. Fraser AG. Inge Edler and the origins of clinical echocardiography. Eur J Echocardiogr. 
2001;2(1):3-5. 
264. Frazin L, Talano JV, Stephanides L, Loeb HS, Kopel L, Gunnar RM. Esophageal 
echocardiography. Circulation. 1976;54(1):102-8. 
265. Gowda RM, Khan IA, Vasavada BC, Sacchi TJ, Patel R. History of the evolution of 
echocardiography. Int J Cardiol. 2004;97(1):1-6. 
266. Concha PM, Mertz KV, Cortinez FL, Zuniga DA, Pinedo MG. [Transesophageal 
echocardiography to monitor fluid administration during the perioperative period]. Rev Med 
Chil. 2011;139(9):1157-62. 
 240   
267. Mathur SK, Singh P. Transoesophageal echocardiography related complications. 
Indian J Anaesth. 2009;53(5):567-74. 
268. Cholley BP, Singer M. Esophageal Doppler: noninvasive cardiac output monitor. 
Echocardiography. 2003;20(8):763-9. 
269. Sakka SG, Reuter DA, Perel A. The transpulmonary thermodilution technique. J Clin 
Monit Comput. 2012;26(5):347-53. 
270. Stewart GN. Researches on the Circulation Time and on the Influences which affect 
it. J Physiol. 1897;22(3):159-83. 
271. Monnet X, Persichini R, Ktari M, Jozwiak M, Richard C, Teboul JL. Precision of the 
transpulmonary thermodilution measurements. Crit Care. 2011;15(4):R204. 
272. Monnet X, Anguel N, Naudin B, Jabot J, Richard C, Teboul JL. Arterial pressure-based 
cardiac output in septic patients: different accuracy of pulse contour and uncalibrated 
pressure waveform devices. Crit Care. 2010;14(3):R109. 
273. Monnet X, Anguel N, Jozwiak M, Richard C, Teboul JL. Third-generation 
FloTrac/Vigileo does not reliably track changes in cardiac output induced by norepinephrine 
in critically ill patients. Br J Anaesth. 2012;108(4):615-22. 
274. Bendjelid K, Marx G, Kiefer N, Simon TP, Geisen M, Hoeft A, et al. Performance of a 
new pulse contour method for continuous cardiac output monitoring: validation in critically 
ill patients. Br J Anaesth. 2013;111(4):573-9. 
275. Cecconi M, Fawcett J, Grounds RM, Rhodes A. A Prospective Study to Evaluate the 
Accuracy of Pulse Power Analysis to Monitor Cardiac Output in Critically Ill Patients. BMC 
Anesthesiol. 2008;8:3. 
276. Cecconi M, Monti G, Hamilton MA, Puntis M, Dawson D, Tuccillo ML, et al. Efficacy of 
functional hemodynamic parameters in predicting fluid responsiveness with pulse power 
analysis in surgical patients. Minerva Anestesiol. 2012;78(5):527-33. 
277. Pearse RM, Ikram K, Barry J. Equipment review: an appraisal of the LiDCO plus 
method of measuring cardiac output. Crit Care. 2004;8(3):190-5. 
278. Linton R, Band D, O'Brien T, Jonas M, Leach R. Lithium dilution cardiac output 
measurement: a comparison with thermodilution. Crit Care Med. 1997;25(11):1796-800. 
279. Nordstrom J, Hallsjo-Sander C, Shore R, Bjorne H. Stroke volume optimization in 
elective bowel surgery: a comparison between pulse power wave analysis (LiDCOrapid) and 
oesophageal Doppler (CardioQ). Br J Anaesth. 2013;110(3):374-80. 
280. Aroom KR, Harting MT, Cox CS, Jr., Radharkrishnan RS, Smith C, Gill BS. 
Bioimpedance analysis: a guide to simple design and implementation. J Surg Res. 
2009;153(1):23-30. 
281. Bernstein DP. A new stroke volume equation for thoracic electrical bioimpedance: 
theory and rationale. Crit Care Med. 1986;14(10):904-9. 
282. Fellahi JL, Caille V, Charron C, Deschamps-Berger PH, Vieillard-Baron A. Noninvasive 
assessment of cardiac index in healthy volunteers: a comparison between thoracic 
impedance cardiography and Doppler echocardiography. Anesth Analg. 2009;108(5):1553-9. 
283. Peyton PJ, Chong SW. Minimally invasive measurement of cardiac output during 
surgery and critical care: a meta-analysis of accuracy and precision. Anesthesiology. 
2010;113(5):1220-35. 
284. Lorne E, Mahjoub Y, Diouf M, Sleghem J, Buchalet C, Guinot PG, et al. Accuracy of 
impedance cardiography for evaluating trends in cardiac output: a comparison with 
oesophageal Doppler. Br J Anaesth. 2014;113(4):596-602. 
 241   
285. Pestana D, Espinosa E, Eden A, Najera D, Collar L, Aldecoa C, et al. Perioperative goal-
directed hemodynamic optimization using noninvasive cardiac output monitoring in major 
abdominal surgery: a prospective, randomized, multicenter, pragmatic trial: POEMAS Study 
(PeriOperative goal-directed thErapy in Major Abdominal Surgery). Anesth Analg. 
2014;119(3):579-87. 
286. O'Neal JB, Shaw AD. Goal-directed therapy in the operating room: is there any 
benefit? Curr Opin Anaesthesiol. 2016;29(1):80-4. 
287. Crossingham IR, Nethercott DR, Columb MO. Comparing cardiac output monitors 
and defining agreement: A systematic review and meta-analysis. J Intensive Care Soc. 
2016;17(4):302-13. 
288. Critchley LA, Critchley JA. A meta-analysis of studies using bias and precision 
statistics to compare cardiac output measurement techniques. J Clin Monit Comput. 
1999;15(2):85-91. 
289. Squara P, Cecconi M, Rhodes A, Singer M, Chiche JD. Tracking changes in cardiac 
output: methodological considerations for the validation of monitoring devices. Intensive 
Care Med. 2009;35(10):1801-8. 
290. Bland JM, Altman DG. Statistical methods for assessing agreement between two 
methods of clinical measurement. Lancet. 1986;1(8476):307-10. 
291. Joosten A, Desebbe O, Suehiro K, Murphy LS, Essiet M, Alexander B, et al. Accuracy 
and precision of non-invasive cardiac output monitoring devices in perioperative medicine: 
a systematic review and meta-analysisdagger. Br J Anaesth. 2017;118(3):298-310. 
292. Cecconi M, Rhodes A, Poloniecki J, Della Rocca G, Grounds RM. Bench-to-bedside 
review: the importance of the precision of the reference technique in method comparison 
studies--with specific reference to the measurement of cardiac output. Crit Care. 
2009;13(1):201. 
293. Felbinger TW, Reuter DA, Eltzschig HK, Moerstedt K, Goedje O, Goetz AE. 
Comparison of pulmonary arterial thermodilution and arterial pulse contour analysis: 
evaluation of a new algorithm. J Clin Anesth. 2002;14(4):296-301. 
294. Sato Y, Motoyama S, Maruyama K, Okuyama M, Hayashi K, Nakae H, et al. 
Extravascular lung water measured using single transpulmonary thermodilution reflects 
perioperative pulmonary edema induced by esophagectomy. Eur Surg Res. 2007;39(1):7-13. 
295. Oshima K, Kunimoto F, Hinohara H, Hayashi Y, Kanemaru Y, Takeyoshi I, et al. 
Evaluation of respiratory status in patients after thoracic esophagectomy using PiCCO 
system. Ann Thorac Cardiovasc Surg. 2008;14(5):283-8. 
296. Berton C, Cholley B. Equipment review: new techniques for cardiac output 
measurement--oesophageal Doppler, Fick principle using carbon dioxide, and pulse contour 
analysis. Crit Care. 2002;6(3):216-21. 
297. Alhashemi JA, Cecconi M, Hofer CK. Cardiac output monitoring: an integrative 
perspective. Crit Care. 2011;15(2):214. 
298. Camporota L, Beale R. Pitfalls in haemodynamic monitoring based on the arterial 
pressure waveform. Crit Care. 2010;14(2):124. 
299. Kallmeyer IJ, Collard CD, Fox JA, Body SC, Shernan SK. The safety of intraoperative 
transesophageal echocardiography: a case series of 7200 cardiac surgical patients. Anesth 
Analg. 2001;92(5):1126-30. 
300. Kratz T, Campo Dell'Orto M, Exner M, Timmesfeld N, Zoremba M, Wulf H, et al. 
Focused intraoperative transthoracic echocardiography by anesthesiologists: a feasibility 
study. Minerva Anestesiol. 2015;81(5):490-6. 
 242   
301. Gueret G, Kiss G, Rossignol B, Bezon E, Wargnier JP, Miossec A, et al. Cardiac output 
measurements in off-pump coronary surgery: comparison between NICO and the Swan-
Ganz catheter. Eur J Anaesthesiol. 2006;23(10):848-54. 
302. Opotowsky AR, Hess E, Maron BA, Brittain EL, Baron AE, Maddox TM, et al. 
Thermodilution vs Estimated Fick Cardiac Output Measurement in Clinical Practice: An 
Analysis of Mortality From the Veterans Affairs Clinical Assessment, Reporting, and Tracking 
(VA CART) Program and Vanderbilt University. JAMA Cardiol. 2017;2(10):1090-9. 
303. Kim JY, Kim BR, Lee KH, Kim KW, Kim JH, Lee SI, et al. Comparison of cardiac output 
derived from FloTrac/Vigileo and impedance cardiography during major abdominal surgery. 
J Int Med Res. 2013;41(4):1342-9. 
304. Critchley LA, Lee A, Ho AM. A critical review of the ability of continuous cardiac 
output monitors to measure trends in cardiac output. Anesth Analg. 2010;111(5):1180-92. 
305. Critchley LA, Yang XX, Lee A. Assessment of trending ability of cardiac output 
monitors by polar plot methodology. J Cardiothorac Vasc Anesth. 2011;25(3):536-46. 
306. Wetterslev M, Moller-Sorensen H, Johansen RR, Perner A. Systematic review of 
cardiac output measurements by echocardiography vs. thermodilution: the techniques are 
not interchangeable. Intensive Care Med. 2016;42(8):1223-33. 
307. Han WK, Wagener G, Zhu Y, Wang S, Lee HT. Urinary biomarkers in the early 
detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol. 2009;4(5):873-
82. 
308. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, Group NM-aI. 
Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in 
acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 
2009;54(6):1012-24. 
309. Arthur JM, Hill EG, Alge JL, Lewis EC, Neely BA, Janech MG, et al. Evaluation of 32 
urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. 
Kidney Int. 2014;85(2):431-8. 
310. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin 
(NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and 
clinical evidences. Clin Chem Lab Med. 2012;50(9):1505-17. 
311. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, et al. Dual 
action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007;18(2):407-13. 
312. Heise D, Rentsch K, Braeuer A, Friedrich M, Quintel M. Comparison of urinary 
neutrophil glucosaminidase-associated lipocalin, cystatin C, and alpha1-microglobulin for 
early detection of acute renal injury after cardiac surgery. Eur J Cardiothorac Surg. 
2011;39(1):38-43. 
313. Tecson KM, Erhardtsen E, Eriksen PM, Gaber AO, Germain M, Golestaneh L, et al. 
Optimal cut points of plasma and urine neutrophil gelatinase-associated lipocalin for the 
prediction of acute kidney injury among critically ill adults: retrospective determination and 
clinical validation of a prospective multicentre study. BMJ Open. 2017;7(7):e016028. 
314. Parikh A, Rizzo JA, Canetta P, Forster C, Sise M, Maarouf O, et al. Does NGAL reduce 
costs? A cost analysis of urine NGAL (uNGAL) & serum creatinine (sCr) for acute kidney 
injury (AKI) diagnosis. PLoS One. 2017;12(5):e0178091. 
315. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury 
molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel 
immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 
1998;273(7):4135-42. 
 243   
316. Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM. Biomarkers in 
acute kidney injury - pathophysiological basis and clinical performance. Acta Physiol (Oxf). 
2017;219(3):554-72. 
317. Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C, et al. Diagnostic value of urinary kidney 
injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One. 2014;9(1):e84131. 
318. Ho J, Tangri N, Komenda P, Kaushal A, Sood M, Brar R, et al. Urinary, Plasma, and 
Serum Biomarkers' Utility for Predicting Acute Kidney Injury Associated With Cardiac 
Surgery in Adults: A Meta-analysis. Am J Kidney Dis. 2015;66(6):993-1005. 
319. Lin X, Yuan J, Zhao Y, Zha Y. Urine interleukin-18 in prediction of acute kidney injury: 
a systemic review and meta-analysis. J Nephrol. 2015;28(1):7-16. 
320. Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a 
systemic review and meta-analysis. Am J Kidney Dis. 2011;58(3):356-65. 
321. Bagshaw SM, Bellomo R. Cystatin C in acute kidney injury. Curr Opin Crit Care. 
2010;16(6):533-9. 
322. Nejat M, Pickering JW, Walker RJ, Endre ZH. Rapid detection of acute kidney injury 
by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant. 2010;25(10):3283-9. 
323. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, et al. Renal L-type fatty acid--
binding protein in acute ischemic injury. J Am Soc Nephrol. 2007;18(11):2894-902. 
324. Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, et al. Liver fatty acid-
binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 
2008;73(4):465-72. 
325. Parikh CR, Thiessen-Philbrook H, Garg AX, Kadiyala D, Shlipak MG, Koyner JL, et al. 
Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined 
biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol. 2013;8(7):1079-88. 
326. Obata Y, Kamijo-Ikemori A, Ichikawa D, Sugaya T, Kimura K, Shibagaki Y, et al. Clinical 
usefulness of urinary liver-type fatty-acid-binding protein as a perioperative marker of acute 
kidney injury in patients undergoing endovascular or open-abdominal aortic aneurysm 
repair. J Anesth. 2016;30(1):89-99. 
327. Ba Aqeel SH, Sanchez A, Batlle D. Angiotensinogen as a biomarker of acute kidney 
injury. Clin Kidney J. 2017;10(6):759-68. 
328. Alge JL, Karakala N, Neely BA, Janech MG, Tumlin JA, Chawla LS, et al. Urinary 
angiotensinogen and risk of severe AKI. Clin J Am Soc Nephrol. 2013;8(2):184-93. 
329. Alge JL, Karakala N, Neely BA, Janech MG, Velez JC, Arthur JM, et al. Urinary 
angiotensinogen predicts adverse outcomes among acute kidney injury patients in the 
intensive care unit. Crit Care. 2013;17(2):R69. 
330. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and 
validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 
2013;17(1):R25. 
331. Koyner JL, Shaw AD, Chawla LS, Hoste EA, Bihorac A, Kashani K, et al. Tissue Inhibitor 
Metalloproteinase-2 (TIMP-2)IGF-Binding Protein-7 (IGFBP7) Levels Are Associated with 
Adverse Long-Term Outcomes in Patients with AKI. J Am Soc Nephrol. 2015;26(7):1747-54. 
332. Gunnerson KJ, Shaw AD, Chawla LS, Bihorac A, Al-Khafaji A, Kashani K, et al. 
TIMP2*IGFBP7 biomarker panel accurately predicts acute kidney injury in high-risk surgical 
patients. J Trauma Acute Care Surg. 2016;80(2):243-9. 
333. Gocze I, Koch M, Renner P, Zeman F, Graf BM, Dahlke MH, et al. Urinary biomarkers 
TIMP-2 and IGFBP7 early predict acute kidney injury after major surgery. PLoS One. 
2015;10(3):e0120863. 
 244   
334. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the 
Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418-28. 
335. Head J, Ferrie JE, Alexanderson K, Westerlund H, Vahtera J, Kivimaki M, et al. 
Diagnosis-specific sickness absence as a predictor of mortality: the Whitehall II prospective 
cohort study. BMJ. 2008;337:a1469. 
336. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated with 
inpatient surgery. N Engl J Med. 2009;361(14):1368-75. 
337. Cannesson M, Pestel G, Ricks C, Hoeft A, Perel A. Hemodynamic monitoring and 
management in patients undergoing high risk surgery: a survey among North American and 
European anesthesiologists. Crit Care. 2011;15(4):R197. 
338. Grocott MP, Dushianthan A, Hamilton MA, Mythen MG, Harrison D, Rowan K, et al. 
Perioperative increase in global blood flow to explicit defined goals and outcomes following 
surgery. Cochrane Database Syst Rev. 2012;11:CD004082. 
339. Quality AfHRa. Esophageal doppler ultrasound based cardiac output monitoring for 
real time therapeutic management of hospitalized patients: a review. 2007. 
340. Excellence. NIfHaC. CardiaQ-ODM oesophageal doppler monitor. 2011. 
341. Deans KJ, Minneci PC, Suffredini AF, Danner RL, Hoffman WD, Ciu X, et al. 
Randomization in clinical trials of titrated therapies: unintended consequences of using fixed 
treatment protocols. Crit Care Med. 2007;35(6):1509-16. 
342. Marquez J, McCurry K, Severyn DA, Pinsky MR. Ability of pulse power, esophageal 
Doppler, and arterial pulse pressure to estimate rapid changes in stroke volume in humans. 
Crit Care Med. 2008;36(11):3001-7. 
343. Takala J, Meier-Hellmann A, Eddleston J, Hulstaert P, Sramek V. Effect of dopexamine 
on outcome after major abdominal surgery: a prospective, randomized, controlled 
multicenter study. European Multicenter Study Group on Dopexamine in Major Abdominal 
Surgery. Crit Care Med. 2000;28(10):3417-23. 
344. Stone MD, Wilson RJ, Cross J, Williams BT. Effect of adding dopexamine to 
intraoperative volume expansion in patients undergoing major elective abdominal surgery. 
Br J Anaesth. 2003;91(5):619-24. 
345. Grocott MP, Browne JP, Van der Meulen J, Matejowsky C, Mutch M, Hamilton MA, et 
al. The Postoperative Morbidity Survey was validated and used to describe morbidity after 
major surgery. J Clin Epidemiol. 2007;60(9):919-28. 
346. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in 
randomized clinical trials. Stat Med. 1997;16(9):1017-29. 
347. Kuper M, Gold SJ, Callow C, Quraishi T, King S, Mulreany A, et al. Intraoperative fluid 
management guided by oesophageal Doppler monitoring. BMJ. 2011;342:d3016. 
348. Chong MA, Wang Y, Berbenetz NM, McConachie I. Does goal-directed 
haemodynamic and fluid therapy improve peri-operative outcomes?: A systematic review 
and meta-analysis. Eur J Anaesthesiol. 2018;35(7):469-83. 
349. Graham L, Wright J, Walwyn R, Russell AM, Bryant L, Farrin A, et al. Measurement of 
adherence in a randomised controlled trial of a complex intervention: supported self-
management for adults with learning disability and type 2 diabetes. BMC Med Res 
Methodol. 2016;16(1):132. 
350. Eccles M, Grimshaw J, Walker A, Johnston M, Pitts N. Changing the behavior of 
healthcare professionals: the use of theory in promoting the uptake of research findings. J 
Clin Epidemiol. 2005;58(2):107-12. 
351. Pearse RM, Ackland GL. Perioperative fluid therapy. BMJ. 2012;344:e2865. 
 245   
352. Lansdorp B, Lemson J, van Putten MJ, de Keijzer A, van der Hoeven JG, Pickkers P. 
Dynamic indices do not predict volume responsiveness in routine clinical practice. Br J 
Anaesth. 2012;108(3):395-401. 
353. Biais M, Ehrmann S, Mari A, Conte B, Mahjoub Y, Desebbe O, et al. Clinical relevance 
of pulse pressure variations for predicting fluid responsiveness in mechanically ventilated 
intensive care unit patients: the grey zone approach. Crit Care. 2014;18(6):587. 
354. Ishihara H, Hashiba E, Okawa H, Saito J, Kasai T, Tsubo T. Neither dynamic, static, nor 
volumetric variables can accurately predict fluid responsiveness early after 
abdominothoracic esophagectomy. Perioper Med (Lond). 2013;2(1):3. 
355. Guinot PG, de Broca B, Abou Arab O, Diouf M, Badoux L, Bernard E, et al. Ability of 
stroke volume variation measured by oesophageal Doppler monitoring to predict fluid 
responsiveness during surgery. Br J Anaesth. 2013;110(1):28-33. 
356. Hoiseth LO, Hoff IE, Myre K, Landsverk SA, Kirkeboen KA. Dynamic variables of fluid 
responsiveness during pneumoperitoneum and laparoscopic surgery. Acta Anaesthesiol 
Scand. 2012;56(6):777-86. 
357. Willars C, Dada A, Hughes T, Green D. Functional haemodynamic monitoring: The 
value of SVV as measured by the LiDCORapid in predicting fluid responsiveness in high risk 
vascular surgical patients. Int J Surg. 2012;10(3):148-52. 
358. Chikhani M, Moppett IK. Minimally invasive cardiac output monitoring: what 
evidence do we need? Br J Anaesth. 2011;106(4):451-3. 
359. Mahjoub Y, Lejeune V, Muller L, Perbet S, Zieleskiewicz L, Bart F, et al. Evaluation of 
pulse pressure variation validity criteria in critically ill patients: a prospective observational 
multicentre point-prevalence study. Br J Anaesth. 2014;112(4):681-5. 
360. Ray P, Le Manach Y, Riou B, Houle TT. Statistical evaluation of a biomarker. 
Anesthesiology. 2010;112(4):1023-40. 
361. Janes H, Longton G, Pepe M. Accommodating Covariates in ROC Analysis. Stata J. 
2009;9(1):17-39. 
362. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff 
point. Biom J. 2005;47(4):458-72. 
363. Levin MA, McCormick PJ, Lin HM, Hosseinian L, Fischer GW. Low intraoperative tidal 
volume ventilation with minimal PEEP is associated with increased mortality. Br J Anaesth. 
2014;113(1):97-108. 
364. de Waal EE, Rex S, Kruitwagen CL, Kalkman CJ, Buhre WF. Dynamic preload indicators 
fail to predict fluid responsiveness in open-chest conditions. Crit Care Med. 2009;37(2):510-
5. 
365. Jacques D, Bendjelid K, Duperret S, Colling J, Piriou V, Viale JP. Pulse pressure 
variation and stroke volume variation during increased intra-abdominal pressure: an 
experimental study. Crit Care. 2011;15(1):R33. 
366. deaths. Nciip. Knowing the Risk: A review of peri-operative care of surgical patients. 
2011. 
367. O'Connor ME, Hewson RW, Kirwan CJ, Ackland GL, Pearse RM, Prowle JR. Acute 
kidney injury and mortality 1 year after major non-cardiac surgery. Br J Surg. 
2017;104(7):868-76. 
368. Grams ME, Sang Y, Coresh J, Ballew S, Matsushita K, Molnar MZ, et al. Acute Kidney 
Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data. 
Am J Kidney Dis. 2016;67(6):872-80. 
 246   
369. Bihorac A, Yavas S, Subbiah S, Hobson CE, Schold JD, Gabrielli A, et al. Long-term risk 
of mortality and acute kidney injury during hospitalization after major surgery. Ann Surg. 
2009;249(5):851-8. 
370. Kork F, Balzer F, Spies CD, Wernecke KD, Ginde AA, Jankowski J, et al. Minor 
Postoperative Increases of Creatinine Are Associated with Higher Mortality and Longer 
Hospital Length of Stay in Surgical Patients. Anesthesiology. 2015;123(6):1301-11. 
371. Puckett JR, Pickering JW, Palmer SC, McCall JL, Kluger MT, De Zoysa J, et al. Low 
Versus Standard Urine Output Targets in Patients Undergoing Major Abdominal Surgery: A 
Randomized Noninferiority Trial. Ann Surg. 2017;265(5):874-81. 
372. Prowle JR, Kam EP, Ahmad T, Smith NC, Protopapa K, Pearse RM. Preoperative renal 
dysfunction and mortality after non-cardiac surgery. Br J Surg. 2016;103(10):1316-25. 
373. Romagnoli S, Ricci Z, Ronco C. Therapy of acute kidney injury in the perioperative 
setting. Curr Opin Anaesthesiol. 2017;30(1):92-9. 
374. Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, et al. 
Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high 
risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive 
Care Med. 2017;43(11):1551-61. 
375. Gocze I, Jauch D, Gotz M, Kennedy P, Jung B, Zeman F, et al. Biomarker-guided 
Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective 
Randomized BigpAK Study. Ann Surg. 2018;267(6):1013-20. 
376. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, et al. Urine NGAL 
predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am 
Soc Nephrol. 2008;3(3):665-73. 
377. de Geus HR, Ronco C, Haase M, Jacob L, Lewington A, Vincent JL. The cardiac 
surgery-associated neutrophil gelatinase-associated lipocalin (CSA-NGAL) score: A potential 
tool to monitor acute tubular damage. J Thorac Cardiovasc Surg. 2016;151(6):1476-81. 
378. Liebetrau C, Dorr O, Baumgarten H, Gaede L, Szardien S, Blumenstein J, et al. 
Neutrophil gelatinase-associated lipocalin (NGAL) for the early detection of cardiac surgery 
associated acute kidney injury. Scand J Clin Lab Invest. 2013;73(5):392-9. 
379. Thanakitcharu P, Jirajan B. Determination of urinary neutrophil gelatinase-associated 
lipocalin (NGAL) cut-off level for early detection of acute kidney injury in Thai adult patients 
undergoing open cardiac surgery. J Med Assoc Thai. 2014;97 Suppl 11:S48-55. 
380. Au V, Feit J, Barasch J, Sladen RN, Wagener G. Urinary neutrophil gelatinase-
associated lipocalin (NGAL) distinguishes sustained from transient acute kidney injury after 
general surgery. Kidney Int Rep. 2016;1(1):3-9. 
381. Singer E, Schrezenmeier EV, Elger A, Seelow ER, Krannich A, Luft FC, et al. Urinary 
NGAL-Positive Acute Kidney Injury and Poor Long-term Outcomes in Hospitalized Patients. 
Kidney Int Rep. 2016;1(3):114-24. 
382. Hunsicker O, Feldheiser A, Weimann A, Liehre D, Sehouli J, Wernecke KD, et al. 
Diagnostic value of plasma NGAL and intraoperative diuresis for AKI after major 
gynecological surgery in patients treated within an intraoperative goal-directed 
hemodynamic algorithm: A substudy of a randomized controlled trial. Medicine (Baltimore). 
2017;96(28):e7357. 
383. Hjortrup PB, Haase N, Treschow F, Moller MH, Perner A. Predictive value of NGAL for 
use of renal replacement therapy in patients with severe sepsis. Acta Anaesthesiol Scand. 
2015;59(1):25-34. 
 247   
384. Giglio M, Manca F, Dalfino L, Brienza N. Perioperative hemodynamic goal-directed 
therapy and mortality: a systematic review and meta-analysis with meta-regression. 
Minerva Anestesiol. 2016;82(11):1199-213. 
385. Sun Y, Chai F, Pan C, Romeiser JL, Gan TJ. Effect of perioperative goal-directed 
hemodynamic therapy on postoperative recovery following major abdominal surgery-a 
systematic review and meta-analysis of randomized controlled trials. Crit Care. 
2017;21(1):141. 
386. Prowle JR, Chua HR, Bagshaw SM, Bellomo R. Clinical review: Volume of fluid 
resuscitation and the incidence of acute kidney injury - a systematic review. Crit Care. 
2012;16(4):230. 
387. Helmersson-Karlqvist J, Arnlov J, Larsson A. Day-to-day variation of urinary NGAL and 
rational for creatinine correction. Clin Biochem. 2013;46(1-2):70-2. 
388. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-
source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 
2011;12:77. 
389. Furrer MA, Schneider MP, Loffel LM, Burkhard FC, Wuethrich PY. Impact of intra-
operative fluid and noradrenaline administration on early postoperative renal function after 
cystectomy and urinary diversion: A retrospective observational cohort study. Eur J 
Anaesthesiol. 2018;35(9):641-9. 
390. Bickler SN, Weiser TG, Kassebaum N, Higashi H, Chang DC, Barendregt JJ, et al. Global 
Burden of Surgical Conditions. In: Debas HT, Donkor P, Gawande A, Jamison DT, Kruk ME, 
Mock CN, editors. Essential Surgery: Disease Control Priorities, Third Edition (Volume 1). 
Washington (DC)2015. 
391. Joshi GP, Alexander JC, Kehlet H. Large pragmatic randomised controlled trials in 
peri-operative decision making: are they really the gold standard? Anaesthesia. 
2018;73(7):799-803. 
392. Yeung J, Gillies MA, Pearse RM. Pragmatic trials in peri-operative medicine: why, 
when and how? Anaesthesia. 2018;73(7):803-7. 
 
 
 
  
 248   
Appendix 1 Definition of post-operative complications 
All complications should be graded by their severity: 
Mild: Results in only temporary harm and would not usually require specific clinical 
treatment. 
Moderate: More serious complication but which does not usually result in permanent harm 
or functional limitation. Usually requires clinical treatment. 
Severe: Results in significant prolongation of hospital stay and/or permanent functional 
limitation or death. Almost always requires clinical treatment. 
 
 Infective complications 
Infection, source uncertain 
Definition: The Centers for Disease Control defines infection, source uncertain as one where 
there is strong clinical suspicion of infection but the source has not been confirmed because 
clinical information suggests more than one possible site, meeting two or more of the 
following criteria: 
1. Core temperature <36OC or >38OC 
2. White cell count >12 x 109/L or <4 x 109/L 
3. Respiratory rate >20 breaths per minute or PaCO2 <35 mmHg 
4. Pulse rate >90 beats per minute 
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Urinary tract infection 
Definition: A simplified version of the The Center for Disease Control defines a urinary tract 
infection as follows: 
A positive urine culture of ≥105 colony forming units/mL with no more than two species of 
micro-organisms with at least one of the following symptoms or signs: fever (>38 OC), 
urgency, frequency, dysuria, supra-pubic tenderness, costo-vertebral angle pain or 
tenderness with no other recognised cause. 
Guidance: Each of these criteria should be identified within a 24 hour period. 
 
Other infections of the urinary tract (kidney, ureter, bladder, urethra, etc) 
Other infections of the urinary tract must meet at least one of the following criteria: 
i) Patient has organisms isolated from culture of fluid (other than urine) or tissue from 
affected site. 
ii) Patient has an abscess or other evidence of infection seen on direct examination, during a 
surgical operation, or during a histopathologic examination. 
iii) Patient has at least two of the following signs or symptoms with no other recognised 
cause: fever (>38 􀀀C), localised pain, or localised tenderness at the involved site and at least 
one of the following: 
a. purulent drainage from affected site; 
b. organisms cultured from blood that are compatible with suspected site of infection; 
c. radiographic evidence of infection, for example, abnormal ultrasound, computed 
tomography or magnetic resonance imaging; 
d. physician diagnosis of infection of the kidney, ureter, bladder, urethra, or tissues 
surrounding the retroperitoneal or perinephric space; 
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e. physician institutes appropriate therapy for an infection of the kidney, ureter, bladder, 
urethra, or tissues surrounding the retroperitoneal or perinephric space. 
 
Surgical site infection SSI (superficial incisional) 
Definition: The Center for Disease Control defines a superficial incisional surgical site 
infection as open which meets the following criteria: 
1) Infection occurs within 30 days after surgery and 
2) involves only skin and sub-cutaneous tissue of the incision and 
3) The patient has at least one of the following: 
a) purulent drainage from the superficial incision 
b) organisms isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision 
c) at least one of the following symptoms or signs of infection: pain or tenderness, localised 
swelling, redness, or heat, and 
superficial incision is deliberately opened by surgeon and is culture positive or not cultured. 
A culture-negative finding does not meet this criterion. 
d) diagnosis of an incisional surgical site infection by a surgeon or attending physician 
Surgical site infection (deep incisional) 
Definition: The Center for Disease Control defines a deep incisional surgical site infection as 
one which meets the following criteria: 
1) Infection occurs within 30 days after surgery if no implant is left in place or 1 year if 
implant is in place and 
2) Involves deep soft tissues (e.g. fascial and muscle layers) of the incision and 
3) The patient has at least one of the following: 
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a) purulent drainage from the deep incision but not from the organ/space component of the 
surgical site 
b) a deep incision spontaneously dehisces or is deliberately opened by a surgeon and is 
culture-positive or not cultured when the patient has at least one of the following 
symptoms or signs: fever (>38ᵒC), or localised pain or tenderness. A culture-negative finding 
does not meet this criterion. 
c) an abscess or other evidence of infection involving the deep incision is found on direct 
examination, during surgery, or by histopathologic or radiologic examination 
d) diagnosis of an incisional surgical site infection by a surgeon or attending physician 
 
Surgical site infection (organ/space) 
Definition: The Center for Disease Control defines an organ/space surgical site infection as 
one which involves any part of the body excluding the fascia or muscle layers and meets the 
following criteria:(13) 
1) Infection occurs within 30 days after surgery and 
2) The infection appears to be related to the surgical procedure and involves any part of the 
body, excluding the skin incision, fascia, or superficial incision is deliberately opened by 
surgeon and is culture positive or not cultured. A culture-negative finding does not meet this 
criterion. 
d) diagnosis of an incisional surgical site infection by a surgeon or attending physician 
Surgical site infection (deep incisional) 
Definition: The Center for Disease Control defines a deep incisional surgical site infection as 
one which meets the following criteria: 
1) Infection occurs within 30 days after surgery if no implant is left in place or 1 year if 
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implant is in place and 
2) Involves deep soft tissues (e.g. fascial and muscle layers) of the incision and 
3) The patient has at least one of the following: 
a) purulent drainage from the deep incision but not from the organ/space component of the 
surgical site 
b) a deep incision spontaneously dehisces or is deliberately opened by a surgeon and is 
culture-positive or not cultured when the patient has at least one of the following 
symptoms or signs: fever (>38ᵒC), or localised pain or tenderness. A culture-negative finding 
does not meet this criterion. 
c) an abscess or other evidence of infection involving the deep incision is found on direct 
examination, during surgery, or by histopathologic or radiologic examination 
d) diagnosis of an incisional surgical site infection by a surgeon or attending physician 
 
Surgical site infection (organ/space) 
Definition: The Center for Disease Control defines an organ/space surgical site infection as 
one which involves any part of the body excluding the fascia or muscle layers and meets the 
following criteria: 
1) Infection occurs within 30 days after surgery and 
2) The infection appears to be related to the surgical procedure and involves any part of the 
body, excluding the skin incision, fascia, or 
muscle layers, that is opened or manipulated during the operative procedure and 
3) The patient has at least one of the following: 
a) purulent drainage from a drain that is placed through a stab wound into the organ/space 
b) organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/ 
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space 
c) an abscess or other evidence of infection involving the organ/space that is found on direct 
examination, during reoperation, or by histopathologic or radiologic examination 
d) diagnosis of an organ/space surgical site infection by a surgeon or attending  
Laboratory - confirmed bloodstream infection 
Definition: The Center for Disease Control defines laboratory confirmed bloodstream 
infection as one which meets at least one of the following criteria which should not be 
related to infection at another site: 
1) Patient has a recognised pathogen cultured from one or more blood cultures and the 
organism cultured from blood is not related to an infection at another site 
2) Patient has at least one of the following signs or symptoms: fever (>38ÅãC), chills, or 
hypotension and at least one of the following: 
a) common skin contaminant cultured from two or more blood cultures drawn on separate 
occasions 
b) common skin contaminant cultured from at least one blood culture from a patient with 
an intravascular line, and the physician institutes appropriate antimicrobial therapy 
c) positive blood antigen test 
 
Pneumonia 
Definition: The Center for Disease Control defines pneumonia as follows: 
Two or more serial chest radiographs with at least one of the following (one radiograph is 
sufficient for patients with no underlying pulmonary or cardiac disease): 
1) new or progressive and persistent infiltrates 
2) consolidation 
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3) cavitation 
at least one of the following: 
a) fever (>38OC) with no other recognised cause 
b) leukopenia (<4,000 white blood cells/mm3) or leukocytosis (>12,000 white blood 
cells/mm3) 
c) for adults >70 years old, altered mental status with no other recognised cause 
and at least two of the following: 
a) new onset of purulent sputum or change in character of sputum, or increased respiratory 
secretions, or increased suctioning requirements 
b) new onset or worsening cough, or dyspnoea, or tachypnoea 
c) rales or bronchial breath sounds 
d) worsening gas exchange (hypoxia, increased oxygen requirement, increased ventilator 
demand) 
Guidance: The definition may also be used to identify ventilator associated pneumonia. 
 
Cardiac events 
Myocardial infarction 
Definition: Increase in serum cardiac biomarker values (preferably cardiac troponin) with at 
least one value above the 99th percentile upper reference limit and at least one of the 
following criteria: 
Symptoms of ischaemia 
• New or presumed new significant ST-segment or T-wave ECG changes or new left 
bundle branch block 
• Development of pathological Q-waves on ECG 
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• Radiological or echocardiographic evidence of new loss of viable myocardium or new 
regional wall motion abnormality 
• Identification of an intra-coronary thrombus at angiography or autopsy 
Guidance: The definition of post-operative myocardial infarction remains under debate. 
Investigators should consider using either the definition of myocardial injury after 
noncardiac 
surgery (MINS) or myocardial infarction, or both. 
 
Arrhythmia 
Definition: Arrhythmia is defined as electrocardiograph (ECG) evidence of cardiac rhythm 
disturbance. 
Guidance: The use of severity grading for arrhythmia is of particular importance. Variations 
in clinical treatment may introduce bias if this is used as the sole index of severity. 
Cardiac or respiratory arrest 
Clinical criteria according to UK Resuscitation Council Guidelines. 
Cardiogenic pulmonary oedema 
Definition: Cardiogenic pulmonary oedema is defined as evidence of fluid accumulation in 
the alveoli due to poor cardiac function. 
 
Acute kidney injury 
A two-fold increase in serum creatinine or sustained oliguria of < 0.5 ml kg-1 hour-1 for 
twelve hours (consensus definition). 4. Other defined postoperative complications 
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Post-operative haemorrhage 
Definition: The American College of Surgeons National Surgical Quality Improvement 
Program defines post-operative haemorrhage as blood loss within 72 hours after the start of 
surgery which would normally result in transfusion of blood. 
 
Stroke 
Definition: The American College of Surgeons National Surgical Quality Improvement 
Program defines stroke as an embolic, thrombotic, or haemorrhagic cerebral event with 
persistent residual motor, sensory, or cognitive dysfunction (e.g. hemiplegia, hemiparesis, 
aphasia, sensory deficit, impaired memory). 
 
Multi-organ dysfunction syndrome 
A life threatening but potentially reversible physiologic derangement involving failure of two 
or more organ systems not involved in the primary underlying disease process. 
 
Acute psychosis 
Acute episode of severe confusion or personality change which may result in hallucinations 
or delusional beliefs in the absence of a pre-existing diagnosis which may account for the 
clinical symptoms and signs. 
 
Pulmonary embolism 
Definition: A new blood clot or thrombus within the pulmonary arterial system. Appropriate 
diagnostic tests include scintigraphy and CT angiography. Plasma D-dimer measurement is 
not recommended as a diagnostic test in the first three weeks following surgery. 
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Acute respiratory distress syndrome 
Definition: The Berlin Definition of Respiratory Distress Syndrome 
Timing: Within one week of a known clinical insult or new or worsening respiratory 
symptoms 
and 
Chest imaginga: Bilateral opacities not fully explained by effusions, lobar/lung collapse, or 
nodules 
and 
Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload. 
Need objective assessment (e.g. echocardiography) to exclude hydrostatic edema if no risk 
factor present 
and 
Oxygenationb 
o Mild: PaO2:FiO2 between 200 and 300 mmHg with PEEP or CPAP ≥5 cmH2Oc 
o Moderate: PaO2:FiO2 between 100 and 200 mmHg with PEEP ≥5 cmH2O 
o Severe: PaO2:FiO2 ≤100 mmHg with PEEP ≥5 cmH2O 
a Chest radiograph or computed tomography scan. 
b If altitude is higher than 1000 m, a correction factor should be calculated as follows: 
(PaO2:FiO2 x [barometric pressure/760 mmHg]). 
C This may be delivered non-invasively in the mild acute respiratory distress syndrome 
group. 
 
 
 
 258   
Gastro-intestinal bleed 
Definition: Gastro-intestinal bleed is defined as unambiguous clinical or endoscopic 
evidence of blood in the gastro-intestinal tract. Upper gastrointestinal bleeding (or 
haemorrhage) is that originating proximal to the ligament of Treitz, in practice from the 
oesophagus, stomach and duodenum. Lower gastrointestinal bleeding is that originating 
from the small bowel and colon. 
 
Bowel infarction 
Demonstrated at laparotomy. 
Anastamotic breakdown 
Definition: Leak of luminal contents from a surgical connection between two hollow viscera. 
The luminal contents may emerge either through the wound or at the drain site, or they 
may collect near the anastomosis, causing fever, abscess, septicaemia, metabolic 
disturbance and/or multiple-organ failure. The escape of luminal contents from the site of 
the anastomosis into an adjacent localised area, detected by imaging, in the absence of 
clinical symptoms and signs should be recorded as a sub-clinical leak. 
Guidance: There is a lack of consensus regarding the definition of anastomotic leakage. It is 
important to use this definition together with a grading system to measure the impact of 
the anastomotic breakdown on patient outcome. 
Severity grading: 
Mild: Results in only temporary harm and would not usually require specific clinical 
treatment 
Moderate: More serious complication but one which does not usually result in permanent 
harm or functional limitation. Usually requires clinical treatment. 
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Severe: Results in significant prolongation of hospital stay and/or permanent functional 
limitation or death. Almost always requires clinical treatment. 
 
Paralytic ileus 
Definition: Failure to tolerate solid food or defecate for three or more days after surgery 
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Appendix 2 Goal Directed Therapy Algorithm 
 
 
  
 
General haemodynamic measures 
1. Maintenance fluid at 1 ml/kg/hr 
2. Transfuse blood to maintain haemoglobin >80 g/l 
3. Clinician retains discretion to adjust therapy if concerned about risks of 
hypovolaemia or fluid overload 
4. Mean arterial pressure 60-100 mmHg; Sp02 ≥94%; temperature 37°C;  
heart rate <100 bpm 
Administering fluid to a stroke volume end-point 
1. 250ml fluid boluses to achieve a maximal value of stroke volume 
2. Fluid challenges should not be continued in patients who are not fluid 
responsive in terms of a stroke volume increase 
3. Fluid responsiveness is defined as a stroke volume increase ≥10% 
4. If stroke volume decreases further fluid challenge(s) are indicated 
5. Persistent stroke volume responsiveness suggests continued fluid loss 
6. Fluid challenge is not recommended if stroke volume variation is <5% 
Low dose inotrope infusion 
1. Start fixed rate infusion of dobutamine (2.5µg/kg/min) or dopexamine 
(0.5µg/kg/min) after first fluid challenge. 
2. Halve dose if heart rate rises to greater than 100bpm for more than 30 minutes. 
3. Stop infusion if tachycardia persists. 
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Appendix 3: Researcher development training 
 Domain  
A B C D Total 
Conference Attendance (1/2 day) 3 2 0 0 5 
Conference Attendance (1 day) 6 4 0 0 10 
Conference Attendance (2 days) 12 8 0 0 20 
Conference Attendance (3 days) 9 6 0 0 15 
Conference Attendance sub-total 30 20 0 0 50 
Core research knowledge course 6 0 0 0 6 
Health and Safety 0 0 3 0 3 
Clinical governance course 3 0 0 0 3 
Statistics 12 0 0 0 12 
Course/Event Attendance sub-total 21 0 3 0 24 
Fast Track ethical approval 1 0 3 1 5 
Standard ethical approval 3 0 9 3 15 
Ethical approval sub-total 4 0 12 4 20 
External funding application (£2000 - 
£10000) 
0 0 6 3 9 
External funding application sub-total 0 0 6 3 9 
Conference presentation (oral) 9 9 0 12 20 
Internal presentation (>30 mins) 12 6 0 6 24 
External seminar (>30 mins) 6 6 0 8 20 
Journal club/ reading group 3 0 0 3 6 
Giving presentations sub-total 30 21 0 29 70 
Journal club 3 0 0 0 3 
Representing research group  0 0 3 3 6 
Meeting attendance sub-total 3 0 3 3 9 
Mentoring/ supervising of projects 4 2 0 4 10 
Teaching/ demonstrating 0 5 0 5 10 
Teaching sub-total 4 7 0 9 20 
Refereed publications 8 0 0 8 16 
Refereed publications (submissions) 2 0 0 8 10 
Written publications sub-total 10 0 0 16 26 
Total 112 48 24 64 228 
 
Vitae Researcher Development Framework, where one point represents at least 
one hour of training. Knowledge and intellectual abilities (A), Personal 
effectiveness (B), Research governance and organisation (C) and Engagement, 
Influence and Impact (D). 
